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The History of every major Galactic Civilization tends to pass through three distinct
and recognizable phases, those of Survival, Inquiry and Sophistication, otherwise known
as the How, Why and Where phases.
For instance, the first phase is characterized by the question How can we eat? the sec-
ond by the question Why do we eat? and the third by the question Where shall we have
lunch?
Douglas Adams
The Hitchhiker’s Guide to the Galaxy, (1979)
QUEEN MARY, UNIVERSITY OF LONDON
Abstract
Barts and The London, School of Medicine and Dentistry
Wolfson Institute of Preventive Medicine
Doctor of Philosophy
by Valentina Assi
Mammographic density, the amount of radiodense tissue on a mammogram, is a strong
risk factor for breast cancer, with properties that could be an asset in screening and pre-
vention programmes. Its use in risk prediction contexts is currently limited, however,
mainly due to difficulties in measuring and interpreting density.
This research investigates firstly, the properties of density as an independent marker of
breast cancer risk and secondly, how density should be measured.
The first question was addressed by analysing data from a chemoprevention trial, a trial
of hormonal treatment, and a cohort study of women with a family history of breast
cancer . Tamoxifen-induced density reduction was observed to be a good predictor of
breast cancer risk reduction in high-risk unaffected subjects. Density and its changes
did not predict risk or treatment outcome in subjects with a primary invasive breast
tumour. Finally absolute density predicted risk better than percent density and showed
a potential to improve existing risk-prediction models, even in a population at enhanced
familial risk of breast cancer.
The second part of thesis focuses on density measurement and in particular evaluates
two fully-automated volumetric methods, Quantra and Volpara. These two methods
are highly correlated and in both cases absolute density (cm3) discriminated cases from
controls better than percent density. Finally, we evaluated and compared different mea-
surement methods. Our findings suggested good reliability of the Cumulus and visual
assessments. Quantra volumetric estimates appeared negligibly affected by measure-
ment error, but were less variable than visual bi-dimensional ones, affecting their ability
to discriminate cases from controls. Overall, visual assessments showed the strongest
association with breast cancer risk in comparison to computerised methods.
Our research supports the hypothesis that density should have a role in personalis-
ing screening programs and risk management. Volumetric density measuring methods,
though promising, could be improved.
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Chapter 1
Review of breast density issues
and study plan
1.1 Introduction
This chapter first describes the epidemiological and clinical issues in breast density,
then summarises the research for this PhD project. The project itself is in two parts,
evaluation of density as a biomarker of risk in breast cancer, and researching automated
methods of density estimation which can render it usable in population screening.
1.2 Review of issues in breast density
1.2.1 Introduction
Mammographic density is the portion of the breast that appears white on a mammo-
gram (i.e. radiodense) and it identifies the amount of fibroglandular tissue, stroma and
epithelium, in the breast. For a better understanding, Figure 1.1 shows mammograms
from two breasts with different breast composition: (a) is primarily fatty and has low
levels of density, whereas (b) has predominantly dense tissue. As early as 1976, Wolfe
observed that high levels of mammographic density (henceforth referred to simply as
density) were associated with increasing risk of breast cancer [5]. Since then, the mecha-
nisms that account for this association have been investigated, and the association with
risk further quantified. A recent comprehensive review and meta-analysis of the effect of
density on breast cancer risk has been performed by McCormack and dos Santos Silva
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[6], documenting associations of qualitative and quantitative density measures with risk.
The precise mechanism for the effect on risk remains uncertain [7, 8], although recent
hypotheses include increased stromal collagen [9], delayed involution [10] and increased
expression of aromatase [11]. Other aspects of density have been extensively researched,
and it has been found that density is heritable, alterable by weight change or exogenous
hormones and has significant associations with other risk factors for breast cancer [12],
including age, menopausal status, parity, heritability, exogenous hormones (hormone re-
placement therapy and tamoxifen) and body mass index (BMI). The influence of density
on breast cancer risk persists even after adjustment for these factors [13, 14], and high
amounts of fibroglandular tissue were shown to predict higher risk for up to 7-10 years
[15, 16]. In addition to this, recent studies of primary chemoprevention and recurrence-
prevention with tamoxifen [17–20] suggest that a reduction in density reflects a decrease
in breast cancer risk.
In this chapter, the following aspects of density research are reviewed: methods of mea-
suring density, quantification of the independent effect of density on breast cancer risk,
the relationship between density and other breast cancer risk factors, the implication of
density for breast cancer screening, the alterability of density at individual level, and
its potential in monitoring the effects of risk reducing interventions. In addition, some
suggestions for the future applications of density as a breast cancer risk biomarker have
been included.
Figure 1.1: Mammograms of a breast with very low(a) and high density (b)
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1.2.2 Measurement of mammographic density
Methods of assessing breast density have varied over the years, since in 1976 Wolfe pre-
sented his method based on parenchymal patterns [5], and, to date, no ideal method
has been developed. Wolfe was the first to suggest a strong association between the
radiographic appearance of breast tissue and the risk of breast cancer. He identified
four parenchymal patterns and dichotomised these into two main risk categories: pat-
terns N1, predominately fat, and P1, ductal prominence in less than 25% of the breast,
which he suggested indicated low risk, and P2, ductal prominence in at least 25% of the
breast, and DY, extensive dysplasia, which he concluded conferred higher risk. Note
that DY does not necessary imply dysplasia, which is a pathological rather than ra-
diological phenomenon but merely the presence of large uniform areas of density on a
mammogram. Observing that the typical radiological appearance of the premenopausal
breast contained substantial dense areas, Gram et al [21] proposed the Taba`r classifica-
tion which has five patterns, based on anatomic-mammographic correlation: I scalloped
contours and Cooper’s ligaments, evenly scattered terminal ductal lobular units and
oval lucent areas corresponding to fatty replacement; II complete fatty replacement; III
retroareolar prominent duct pattern and fatty involution; IV extensive nodular and lin-
ear densities; and V homogenous fibrosis with convex contour. Tabar patterns II, III, IV
and V correspond approximately to Wolfe’s patterns N1, P1, P2, and DY respectively;
and similarly Tabar patterns IV and V are associated with increased risk [22]. However,
some mammograms which would be P2 or DY in Wolfe’s classification are classified as
Tabar pattern I, since this represents the typical rather dense appearance of the pre-
menopausal breast.
The Taba`r and Wolfe classification methods are categorisations based on both qual-
itative and quantitative observations, but it has been noted that purely quantitative
measures of breast density give better risk prediction [15, 23, 24]. Thus, over time,
these semi-quantitative methods have been replaced by largely quantitative methods,
with percent density most often assessed visually and divided into categories. In the
1990s the American College of Radiology proposed the Breast Imaging Reporting and
Data System (BIRADS ) lexicon that classifies density as: BIRADS-1, almost entirely
fatty breast (“<25 % dense”); BIRADS-2, presence of scattered fibroglandular densi-
ties (“26-50% dense”); BIRADS-3, heterogeneously dense breast (“51-75% dense”); and
BIRADS-4, extremely dense breast (“>75 % dense”). Many researchers have used a 5-
category classification (“<10% dense”, “10% to 25% dense”, “25% to 50% dense”, “50%
to 75% dense” and “>75% dense”), sometimes augmented to six categories by allowing
zero a separate class [25, 26]. Both semi-quantitative methods and BIRADS rely on
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visual assessments, and are relatively quick and easy to perform [27]. However, their
subjective nature constitutes their major weakness, because intra- and inter-observer
variability adversly affects the reproducibility of the results. A standardised lexicon,
such as BIRADS, high-quality mammograms and good training for the raters can un-
doubtedly help to improve reproducibility. In a study on this issue, the inter-observer
agreement for Wolfe’s patterns, as measured by Kappa statistics, ranged from 0.69 to
0.88, and the intra-observer from 0.69 to 0.87, whereas using BIRADS both intra- and
inter-observer agreements were as 0.89 [27].
Visually estimated percent breast density, measured on a 21-point semi-continuous scale
(0, 5%, 10%,. . . 100%), has also been found to predict breast cancer risk [4, 17] but there
is nevertheless much interest in fully automated and computer-assisted methods, firstly
to render the process less labour-intensive and less subjective, and secondly to allow more
comprehensive information (measurements of total breast area, dense area and non-dense
area) to be obtained. Technological progress has generated several computer-assisted or
automated methods, such as planimetry and interactive thresholding (Cumulus) [28].
The former was developed from Wolfe’s expert outlining method where the edge of the
breast and area of dense tissue on a mammogram were marked on an acetate sheet
and quantified using planimetry [29]. For interactive thresholding, instead, an observer
chooses the appropriate threshold level by manipulating an image of the mammogram
on a computer screen so that the dense tissue and edge of the breast are identified,
and the number of pixels in the dense and non-dense areas automatically calculated
[28, 30, 31]. Percent dense area can then be calculated from absolute dense and total
breast area. Hence, interactive thresholding is less subjective than visual assessment,
provides more comprehensive information (measurements of total breast area, dense area
and non-dense area, in addition to a continuous measure of percent dense area) and is
similarly predictive of breast cancer risk [30]. Cumulus is the most widely used inter-
active thresholding tool and is regarded by many as the gold standard. However, this
method is time-consuming, so it is not ideal for density assessment in routine popula-
tion screening (taking an average of two to three minutes per film, whereas purely visual
classification allows performing the assessments of Wolfe patterns, Boyd’s six-category
classification and continuous percent density in less than 1.5 min per mammogram [27]).
There is debate as to whether absolute dense area is a more useful measure than percent
breast density for independent risk prediction [16, 32, 33]. This will be discussed further
in the Breast Density and Breast Cancer Risk section 1.2.3. It is also known that both
percent dense area and absolute dense area tend to be lower when assessed from digital
mammograms rather than films [34], in part due to the processing of the image, but also
to the better delineation of the breast edge on a digital mammogram [35].
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Current methods of measuring density, both visual and semi-automated, have two limi-
tations: (1) they require significant input from the human user, which in turn implies a
need for training and maintains the labour-intensive nature of density measurement; and
(2) they reduce a three-dimensional feature, the breast, to its 2-dimensional projection
obtained on a mammogram. Controlling the reproducibility and reliability of density
measurements (inter- and intra- reader error) is a major challenge, and one to which
there is currently no easy solution as even when there is a high level of agreement on
average, for individual mammograms the disagreement could be as much as 30-35% (for
percent dense area read visually), or more than a category (for Wolfe patterns or Boyd’s
six-category classification)[27].
Methods that assess the volume of dense tissue are currently being developed and will
hopefully give more precise estimates of the amount of fibroglandular tissue within the
breast and therefore be better predictors of breast cancer risk. With the advent of digital
mammography, there is particular interest in fully automated volumetric density estima-
tion. Several automated volumetric approaches have been proposed [36–41], including
some that are undergoing commercial development, but so far the results suggest that
the volumetric methods provide a similar or weaker risk prediction than the area-based
measures. Most recently, Shepherd et al [42] found that the categorical risk classifica-
tion for 20% of women, with or without breast cancer, could be improved by including
fibroglandular volume in the risk assessment model. We shall return to this issue in
section Future Applications 1.2.7.
Magnetic resonance Imaging (MRI)-based analyses has received great attention because
it provides a detailed three dimensional distribution of fibroglandular tissue that is not
subject to the tissue overlap problem in mammography [43]. For this reason, this mea-
sure is anticipated to be the most accurate estimate of the amount of dense tissue in
the breast and several studies have compared it with density measured by mammog-
raphy [43–49] showing that the MRI measure for the volume fibroglandular tissue is
highly correlated to mammographic density, assessed either visually or [44–47] or with a
volumetric fully-automated software [48]. Recently Wang and colleagues [50] compared
three fully-automated volumetric methods based on FFDM, i.e. SXA [42], Quantra [51]
and Volpara [52], to MRI breast density and found them in moderate agreement. Ap-
parently, most cases of disagreement were driven by differences in total breast volume
measured for MRI versus mammography [50]. MRI fibroglandular volume is also often
used ground truth against which mammogram measurements are compared [53], espe-
cially when developing new volumetric methods.
Besides MRI fibroglandular volume, it has also been speculated that another estimates
of breast density from MRI, i.e. background parenchymal enhancement, could provide
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further relevant information on breast cancer risk. Background parenchymal enhance-
ment is the volume and intensity that fibroglandular tissue “enhances” after intravenous
contrast agent administration during MRI, and it appears to have an association with
breast cancer risk as strong as mammographic density and which may be especially
useful evaluating the effectiveness of a treatment, such as tamoxifen [49, 54]. Although
background parenchymal enhancement could promote a better understanding of the re-
lationship between the amount of fibroglandular tissue in the breast and breast cancer
risk, the research in this field is still at an early stage.
Another approach adopted by several research groups is to automate 2-dimensional mea-
surements. In Sweden Li et al. developed Auto Threshold (v1.10) ImageJ plug-in, aim-
ing to mimic Cumulus readings [55]. Results on 1,498 cases and 1,495 controls indicate
a reasonable agreement between fully-automated and computer-assisted thresholding.
Auto Threshold is less labour- and time-consuming, and therefore could be introduced
into clinical practice more easily. Following poor results from the comparisons between
automated volumetric measures and visual assessment, it is believed that, besides the
amount of dense tissue, other aspects of mammographic appearance may be informative
of breast cancer risk [56]. Thus, in Denmark Nielsen and colleagues have developed a
software that extracts textural information from all pixels of segmented breast images,
and recognises texture relating to breast cancer status of women [56]. Their findings
showed that their mammographic texture resemblance (MTR) marker was independent
of mammographic density and more predictive of risk. Likewise Schmidt and colleagues
designed CIRRUS, a fully-automated predictor of breast cancer risk, that tries to iden-
tify the features in a mammographic image that best predict breast cancer risk [57].
Heine et al. adopted a simpler but still effective approach [58]. Their work focused on
the estimation of the ”variation measure”, i.e. the standard deviation of calibrated pixel
values, that appeared to have an association with breast cancer risk at least as strong as
percent density assessed with Cumulus in a case-cohort study (2,311 subjects, including
217 cases) and two case-control studies (1,967 and 762 subjects, including 928 and 246
cases, respectively) [58]. These methods are promising but require further external val-
idation.
Electrical impedance tomography is based on the concept that every different tissue,
and in particular malignant tumours, reacts differently to the same electrical pulse, and
produces reconstructed tomographic 2D or 3D images of the impedance, and therefore of
the tissue composition [59]. Likewise, digital breast tomosynthesis provides 3D images of
breast composition by using multiple low-dose radiographic exposures taken at different
angles [60]. There are high expectations that using these breast imaging methods, it
should be possible to have a more accurate estimate of the amount of breast dense tissue,
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than those based only on two-view 2-dimensional mammograms. Methods for density
estimation from these new 3D breast imaging systems are currently being developed,
however the research on this topic has just started moving its first steps [61].
1.2.3 Breast density and breast cancer risk
Increasing density is associated with an increase in risk of breast cancer regardless of
the type of assessment (qualitative or quantitative)[6], the population (symptomatic
or asymptomatic) [13], whether the density assessment was made on a negative mam-
mogram years prior to the cancer diagnosis (incidence studies) or on the contralateral
mammogram at the time of the breast cancer diagnosis [13]. It should be noted, however,
that the effect is attenuated with increasing time since measurement [6]. Two compre-
hensive meta-analyses, conducted more than a decade apart, both found a strong effect
of density on risk and both observed that quantitative measures gave superior risk pre-
diction to qualitative ones [6, 62]. The RRs for Wolfe’s most dense category (DY)
relative to the least dense (N1) were 3.98 (95% CI (2.53-6.27)) and 2.42 (1.98-2.97),
respectively in incidence and prevalence studies; for BIRADS category “extremely dense
(≥ 75% dense)”, there was a risk of 4.08 (2.96 − 5.63) relative to the lowest category,
“almost entirely fatty (< 25% dense)”; whereas the strength of the association between
percentage density and breast cancer risk was estimated as 4.64 (3.64-5.91) for 75%
density or more compared to less than 5% [6]. Mammographic density is therefore an
important risk predictor for breast cancer, although the mechanisms that account for
this association are currently still unclear and under investigation [7, 8, 63]. Almost 5%
of the female population has extremely dense breasts (dense tissue in 75% or more of
the breast), and these women have a 4- to 6-fold increase in risk compared with those
with primarily fatty breasts (< 10% dense tissue) [6, 26, 64]. It should be remembered,
however, that the mean percent dense area in postmenopausal women is approximately
30% so the relative risk of developing breast cancer for a woman with greater than 75%
density compared to the general population is somewhat lower than that typically re-
ported for comparisons of most and least dense.
The masking bias hypothesis was suggested by Egan and Mosteller [65] to explain the re-
lationship between extensive fibroglandular tissue and subsequent breast cancer risk. It
is based on the fact that density is associated with failure to detect some breast cancers
by mammography [26, 66], since density renders the task of detecting presymptomatic
tumours in the breast more difficult [67]. One supposition is that, in primarily dense
Review of breast density issues and study plan 27
breasts, tumors may be masked because they share the same x-ray attenuation prop-
erties as fibroglandular tissue, therefore an artificially higher incidence of symptomatic
breast cancer is observed in the ensuing years [26, 66, 68]. However, the increased breast
cancer risk in asymptomatic women, and the fact that the risk remains increased after
excluding cancers in the year following negative mammography, indicate that the effect
is not entirely due to masking [6]. Indeed, mammographic density predicts breast cancer
risk up to 10 years thereafter [15, 16]. However, although it is clear that the observed
effect of density on risk is not completely due to masking, the phenomenon is clearly
a potential biasing factor in individual studies. interpretation of results should always
bear in ming the potential of masking to inflate associations with symptomatic cancers
and attenuate the associations with screen -detected.
Breast density has a high attributable fraction compared with other risk factors for
breast cancer [69] and may be reduced by hormonal therapy [17–20] and diet [70]. It is
therefore hoped that by reducing particularly high levels of density a substantial pro-
portion of breast cancers might be prevented. Most breast cancer risk factors account
for a very small percentage of cases, either because the increased risk associated with
the factor is modest or because the prevalence of the factor is very low [71]. Boyd et
al [26] found that 16% of all breast cancers and 26% of breast cancers in women aged
under 56 were attributable to breast densities greater than 50%. This underlines the
potential role of density in breast cancer prevention [17, 72–74].
As noted above, quantitative measures of breast density have been observed to have a
stronger association with risk than qualitative measures. However, this is not universally
observed, so there remains the question as to whether relative or absolute breast density
is a better predictor of risk [8, 16, 33]. Breast density is negatively confounded with two
other risk factors, age and body mass index (BMI). Increases in all three are associated
with increased risk of breast cancer, but percent breast density reduces with both in-
creasing age and BMI [12]. This has a number of implications for risk estimation. First,
the effect of percent density on risk [25], if no adjustment is made for age and BMI, will
be underestimated. Secondly, it should be noted that absolute dense area does not show
this confounding with BMI [75]. Vachon et al [76] found that absolute dense area had
similar risk predictive potential as percent density. Stone et al [33] found similar results
and in addition found that absolute area did not need adjustment for non-dense area (as
a surrogate for BMI) to attain maximum predictive effect, whereas percent density did
require such adjustment. However, Wong et al [75] found that percent density predicted
risk better than absolute dense area, albeit in an Asian population. Thus this remains
an open question.
The influence of mammographic density on breast cancer persists after adjustment for
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other risk factors [14, 76, 77]. This suggests that it can be of use in further improving
individual risk models [1, 73, 74, 78, 79] which in turn will aid in identifying high risk
groups who might benefit from specific preventive or surveillance interventions. See Fu-
ture Applications 1.2.7 for further discussion of this.
1.2.3.1 Breast density and breast cancer outcome
Despite being a strong predictor of breast cancers, higher levels of density do not neces-
sarily imply a worse prognosis, in terms of death or recurrence. Firstly, it was speculated
that an extensive amount of breast density would be associated with more aggressive
tumour characteristics [80], perhaps also because of masking-bias. However, results of a
recent meta-analysis [81] contradicted this hypothesis and concluded that subjects with
denser breasts are more likely to develop breast cancer, regardless of tumour sub-type.
Secondly, two studies [82, 83] comprising women who experienced ductal carcinoma in
situ , observed an association between breast density and subsequent invasive breast
cancer in the contralateral, but not ipsilateral breast, suggesting that dense tissue play
a role in carcinogenesis but not in the further development of the tumour. Finally, a
Danish study [84] involving 48,052 women, aged 50-69 years, screened between 1991
and 2001, reported that breast tumours were more frequent among subjects with denser
breasts, but they were, overall, less severe. The proportion of fatalities was lower than in
women with fattier breasts. Gierach and colleagues had similar findings from a cohort of
9,232 women diagnosed with primary invasive breast carcinoma between 1996 and 2005
[85]. As in the Danish study, the data indicated a lack of association between breast den-
sity and breast cancer mortality, suggesting that following carcinogenesis, other factors
determine how the tumour develops.
1.2.4 Breast density and other breast cancer risk factors
Mammographic density is a representation of the fibroglandular component of breast-
tissue, and, although mammograms do not allow the distinction, the dense area com-
prises both stroma, the connective fibrous tissue, and epithelium, the two layers of
epithelial cells covering it. The complex interactions between these two features may
provide the biological basis for tumorigenesis [7]: although breast cancer tumours arise
mostly from ductal epithelial cells, stroma also plays an important role in the origin and
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development of breast cancer tumours, contributing both instructive and permissive sig-
nals, and represents, therefore, a potential target for cancer-preventing interventions
[86, 87].
1.2.4.1 Age, parity and menopause
Breast density changes throughout a woman’s adult lifetime; the proportion of fibrog-
landular tissue tends to increase until the 3rd decade after menarche (30-40 year old),
then declines progressively with increasing age [88]. Further, more pronounced reduc-
tions occur subsequent to each pregnancy and following the menopause, conferring on
average reductions of 2% and 2.4% in percentage density [89–91]. This suggests a strong
connection between mammographic density and the cumulative exposure to hormones
and growth factors that stimulate cell division in breast stroma and epithelium, sus-
pected to represent an important factor in the age-specific incidence of breast cancer in
the population [92].
1.2.4.2 Confounding with body mass index
The interpretation of mammographic density as a marker of breast cancer risk, particu-
larly when density is measured in relative terms, is complicated by the fact that density
is confounded with BMI. A woman with high BMI tends to have larger breasts than a
woman with low BMI so that 50% dense area might represent very different absolute
amounts of dense breast tissue. Similarly a low amount of relative density may still be
associated with a high risk, because of an extensive dense area, surrounded by an even
larger area of non-dense tissue. Further, when expressing density with percent scores,
its association with breast cancer risk appears weaker in women with larger breasts [93].
Body mass index is an alterable feature. A woman might reduce her BMI with diet and
exercise, for example, and thereby reduce her breast cancer risk, yet if her dense breast
area remains the same (and her breast size decreases) losing weight will mean that her
estimate of risk, based on percent dense area alone, would be increased. A recent review
[94] focusing on mammographic density and physical activity, found no evidence of an
association between them, although results may be influenced by the heterogeneity of
the studies included, in terms of population, definition of physical activity and how this
was reported.
In general, classic anthropometric measures of adiposity (body mass index and waist cir-
cumference) have been shown to be as good as adiposity measures from whole body dual
x-ray absorptiometry and computed tomography for adjusting mammographic density
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for this confounding[95].
1.2.4.3 Confounding with age
As already noted, mammographic density is negatively confounded with age, so that
density decreases and the risk of developing breast cancer increases with increasing age.
This apparent anomaly was first explained by Boyd et al [92] who found that the decline
in percent dense area with age corresponds to the cumulative rate of breast tissue aging
described in Pike’s model [96] and depends more on hormonal history (for example, age
at menarche, age at first birth and age at menopause) than chronological age. McCor-
mack et al [91] further showed that there is a high degree of tracking post age 50 (i.e.
that a woman’s percent density ranking, at age 50, relative to other women in her cohort,
will be the same at age 60) so that a single assessment of a woman’s mammographic
density at age 50 or more might be viewed as a reasonable long-term measure of her
breast cancer risk [91]. As Lokate and colleagues [97] observed in their Dutch cohort,
cases and controls experienced similar age-related declines in mammographic density,
however at all mammographic examinations, density was higher on average for cases
than for controls.
1.2.4.4 Exogenous hormones
The hypothesis of a strong association between mammographic density and exogenous
sex hormones is supported by evidence from a number of studies. A major meta-analysis
[98] showed that oral contraceptives cause a significant increase in breast cancer inci-
dence among current users, relative risk 1.24 (1.15-1.33), and that this effect decreases
with time after stopping use, i.e. it is null after 10 or more years, RR 1.01 (0.96− 1.05).
However, findings relating hormonal contraceptive use and percent mammographic den-
sity are generally negative [76, 99]. In contrast combined hormone replacement therapy
(HRT) with oestrogen and progesterone was found to increase both risk of breast can-
cer [100–102] and mammographic density [101–105]. In particular oestrogen/progestin
combination treatments confer a significant mean increase in density ranging from 3%
to 5% [103, 104, 106]. Sala et al [99] found that while current users of HRT had signifi-
cantly increased density compared to never users, former users did not, which suggests
that exogenous oestrogen has only a short term effect on density. More recently, in a
multi-ethnic study [102] Hou and colleagues observed that the effect of HRT on breast
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cancer risk was modified by mammographic density, BMI and ethnicity. In particular
they observed that underweight/normal weight women with dense breasts were found
to be more sensitive to the detrimental effects of HRT on breast cancer risk, whereas for
black women and overweight/obese women with fatty breasts, HRT use did not affect
their risk of breast cancer.
Treatment with tamoxifen, a selective oestrogen receptor modulator (SERM), causes
a greater density reduction (7.9% (6.9%-8.9%)) than placebo treatments (3.5% (2.7%-
4.3%)), within 18 months [72], and this change seems to reflect a reduction of risk of
breast cancer in a high-risk population [17–20]. It is not yet known whether the same
will be found with other prospective breast cancer prevention therapies. A number of
small studies have looked at the effect of raloxifene, another SERM, on mammographic
density and reported no significant change in density with treatment [107, 108] or a
change of a similar magnitude to that observed in women on placebo [109]. None are
conclusive, however, as they suffer from a number of weaknesses, including a lack of
statistical power. Studies of aromatase inibitors have had negative or inconclusive re-
sults. Two small studies of letrozole in women who had previously undergone 5 years
of tamoxifen treatment [110] and in women with at least 25% mammographic density
(including women with previously treated breast cancer) [111] found no reduction in
density but again are too small to be considered conclusive. A randomised study of
mammographic breast density and exemestane similarly found no significant change in
percent density with treatment [111]. More recently Vachon et al. [112] investigated the
changes in breast composition due to aromatase inhibitors comparing 369 early-stage
postmenopausal patients and 369 matched controls. They found no evidence of signifi-
cant change in percent density due to aromatase inhibitor therapy. However it has been
speculated that breast magnetic resonance imaging (MRI) could be more appropriate
than mammography examination for recording changes in breast dense tissue due to
endocrine treatment [107].
1.2.4.5 Endogenous hormones
Measurements of hormones and growth factors have shown that blood concentrations of
insulin-like growth factor IGF-I and prolactin, respectively in pre- and post-menopausal
women, are associated with mammographic density, both before and after adjustment
for other risk factors [106]. In particular, IGF-I is a known mitogenic agent that strongly
influences epithelial cells of the breast, and is thought to be responsible for a proportion
of breast tumours [113]. It is also hypothesized that pre-menopausal levels of IGF-I may
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be related to risk of post-menopausal breast-cancer [113].
Measurement of hormone levels in ovulating women is complicated by the fact that
levels depend heavily on when in the cycle the blood is taken. Nevertheless studies
aimed at testing the hypothesis that, even in postmenopausal women, breast density
reflects circulating sex hormone levels found no association after adjustment for BMI
[114–116]. Additional support for the hypothesis that mammographic density and post-
menopausal endogenous oestrogen levels are independent lies in the lack of association
between density of the surrounding breast-tissues and the oestrogen receptor status of
a breast cancer [80, 117, 118]. High mammographic density has been observed to in-
crease the risk of both ER-positive and ER-negative breast cancers [81], suggesting that
mammographic density may influence breast cancer risk through oestrogen-independent
pathways [80]. It may also be that endogenous hormone levels are best measured in the
breast tissue itself rather than in the blood because the concentrations of oestrogens
in the tumours of postmenopausal women are significantly higher than that found in
plasma [119]. Furthermore, it has been shown in mice that in situ aromatisation (oe-
strogen production within the breast itself through the action of the enzyme aromatase)
is the key determinant of tumour estradiol levels and tumour growth [120]. Recently
Varghese and colleagues [121] investigated the relationship between mammographic den-
sity and hormone levels on 1,286 women to verify whether the increased risk of breast
cancer caused by endogenous hormones through cell proliferation may be reflected in
mammographic density [122]. They observed no association between density, both in
absolute and percent terms, and estradiol or testosterone levels, after adjusting for BMI.
1.2.4.6 Heritability
Genetic and family history factors are long-established risk factors for breast cancer
[123]. Likewise heritability appears to account for a large proportion of mammographic
density variation, with the odds of a woman having dense breasts (BIRADS category
3 or 4) being 17% (9%-25%) greater for women with a first-degree relative who has
had breast cancer, 19% (10%-29%) greater if the affected relative is a sister, and 22%
(10%-35%) greater if the relative was diagnosed with breast cancer before 50 years of
age [124].
Epidemiologic risk factors associated with mammographic density, e.g. menopausal sta-
tus, age, body mass index (BMI), and number of live births, account for only 20-30%
of variation in the trait [12]; on the other hand the contribution of genetic factors,
to the observed variability in density, has been estimated as between 29% [125] and
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60% [123, 126]. Supporting the hypothesis that genetic factors influence mammographic
density, twin studies demonstrated that the correlation of breast dense tissue between
monozygotic twins was approximately twice as strong as that between dizygotic twins,
0.63 versus 0.27 [123]. Most of the studies suggest considering also an interaction be-
tween genes and environment [123, 127, 128].
Special interest in the genetics lying behind mammographic density arises from the fact
that its strong association with breast cancer risk and its high heritability meet the
criteria for considering it as a potential intermediate phenotype of breast cancer. It is
believed that genes responsible for familial correlation in mammographic density could
also affect the incidence of breast cancer in the population and contribute partially
to the familial aggregation of the disease [123]. Therefore several studies have been
conducted to identify these genes [129–133]. Candidate gene approaches indicated the
presence of an association of both COMT Val158Met and IGF1 rs6220 A<G with pre-
menopausal mammographic density, and of ESR1 (Xbal and Pvull) polymorphisms with
post-menopausal mammographic density [134].The first large genome-wide linkage study
[127] concluded that there may be at least one gene influencing mammographic density
on chromosome 5p. Further recent findings from Dumas and Diorio [135] indicated
that some single nucleotide polymorphisms (SNPs) located in the CYP181, COMT or
HSD1781 genes are associated with mammographic density among nulliparous women,
non-hormone users, those with late menarche or women with high BMI, hence modifying
effects of estrogen-related factors should be considered when evaluating associations of
polymorphisms in estrogen-related genes with premenopausal mammographic density.
Furthermore Tamimi and colleagues [136] conducted a cross-sectional study to investi-
gate the potential association between mammographic density and the 11 SNPs identified
by a multistage genome-wide association study (GWAS) [129], but results were incon-
clusive. However, in 2011 results from another GWAS led by Lindstro¨m and colleagues
[131] reported an association between percent mammographic density and rs10995190
in ZNF365, also known for being associated with susceptibility to breast cancer. In
addition to this, findings from a three-stage GWAS provided additional evidence that
common genetic variation contributes to breast tissue composition and identified a novel
percent mammographic density locus at 12q24, that they suggested should be the focus
of further studies [132]. Recently, Varghese and colleagues [133] investigated the poten-
tial shared genetic basis for mammographic density and breast cancer risk, using two
GWAS: one to identify a set of SNPs that showed the strongest association with mam-
mographic density, and one to examine their association with breast cancer risk. Their
results confirmed Lindstrom findings regarding rs10995190 [131], and then suggested
another SNP (rs10509168) also in the ZNF365 gene. Varghese et al. also evaluated the
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hypothesis of a shared genetic basis between mammographic density and sex-hormone
levels [121] and discarded it, suggesting to consider the two features as two independent
sets of traits. The same study also showed that dense and nondense areas of the breasts
were partly influenced by the same genetic factors, although in opposite directions [63].
There is uncertainty as to whether subjects with known BRCA mutations have higher
density than non-carriers or the general population [137–141].
1.2.4.7 Benign breast disease
It is well established that women who develop benign breast disease (BBD) are at in-
creased risk of developing breast cancer, with the magnitude of the increased risk de-
pending on the degree of epithelial atypia [142, 143] and being particularly high for
women age 45 or less with atypical hyperplasia [144, 145]. Furthermore, Boyd et al.
[146] showed that having high density (> 75%) increased the risk of having hyperpla-
sia without atypia (RR=13.85), and the risk of having atypical hyperplasia or lobular
carcinoma in situ (RR=9.23). Thus, the two features may not be independent factors.
Further investigations by Byrne et al. [142], however, suggest that benign breast disease
histology and mammographic density are independent breast cancer risk factors. Tice
and colleagues addressed this hypothesis on a cohort of 42,818 women with at least one
benign breast biopsy. They found that women with atypical hyperplasia and very high
breast density had the highest risk for breast cancer, however women with almost en-
tirely fatty breasts were at low risk for future breast cancer regardless of the histology
of their breast biopsy [147]. This suggests that there may be synergy between atypia
and density in their effect on subsequent breast cancer risk [147].
1.2.5 Breast density and screening
Mammographic density, appearing as opaque areas on a mammogram, can mask some
radiological features of the breast and thus render it more difficult to detect tumours [70].
As noted in 1.2.3 above, because density influences the detection of cancer, estimates of
the risk of breast cancer associated with mammographic density may be distorted [26].
It has been found that interval cancers occurring within a short period after screening
are more common in women with dense breasts, in particular Boyd and colleagues [26]
observed an increased OR of 17.8 in women with over 75% of breast density, compared
to subjects with primarily fatty (less than 10% dense) breasts in the first 12 months
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after a negative screening, therefore, implying that breast density is associated with a
shorter potential lead time in mammography screening [148]. Nevertheless, in the same
study [26] the association between density and breast cancer risk remained significant,
though weaker, with an OR of 5.7 (2.1-15.5), for cancers detected more than a year after
a negative screening, suggesting that this issue of masking can only partially explain
such an association.
The radiation dose required to penetrate fibroglandular tissue and to compensate for
less effective compression (i.e. greater thickness) is greater in dense breasts, so that cu-
mulative lifetime exposure to radiation due to mammography screening, is also greater
in women with dense breasts [149]. Although this may suggest that mammographic
screening could have a less favourable benefit-harm ratio for women with dense breasts,
particularly younger women, it has been estimated that this exposure has a lifetime
attributable risk of fatal breast cancer of 1.3 per 100,000 women aged 40 at exposure
and <1 case per 1,000,000 women aged 80 at exposure, whereas 292 lives would be saved
as a result of annual screening [150]. Recent results from a major study of adjunct ul-
trasound screening in women with mammographically dense breasts suggest that with
this additional screening modality the interval breast cancer rate in women with at least
50% density could be brought down to a similar level as that currently seen in women
with less than 50% density [151]. Similarly, early results from a non-randomised study
of automated whole breast ultrasound and mammography in asymptomatic women with
BIRADS density 3 or 4 suggest that the breast cancer detection rate could be doubled
for women in these categories with the use of this technology.
As noted previously, MRI is considerably more effective than mammography for the
surveillance of women with high-risk BRCA mutations [152–154], even in BRCA carri-
ers with low mammographic density [155], thus mammographic density does not entirely
explain the difference in performance between these two screening modalities. It should
be remembered that surveillance in such women tends to begin relatively early in adult
life when the breast tissue is denser, which may explain why there is conflicting evidence
as to whether mammographic density is generally greater in BRCA carriers than in non
carriers or the general population [137–140].
MRI is resource intensive, and demands a greater commitment from the screenee than
does mammography. Hand-held ultrasound is labour-intensive and subjective, but there
is now an automated whole-breast ultrasound system (AWBUS) [156–158] that promises
to improve sensitivity, although increasing the numbers of false positives [150, 157, 159].
Hence screening modalities which may mitigate the effect of breast density on sensitiv-
ity and which are more appropriate for high-throughput population screening are digital
mammography and automated ultrasound [150, 156, 158, 160]. Personalised screening
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strategies, according to the level of breast density and other risk factors such as family-
history, have the potential to improve cost-effectiveness of the breast cancer screening
programme.
1.2.6 Breast density and models for predicting breast cancer risk
Currently, there are a number of risk evaluation models available for assessing a woman’s
breast cancer risk based on her risk factors but none have yet been validated in the
general population or have yet incorporated mammographic density into their risk as-
sessment. The majority have been developed and validated in high-risk subgroups of
women. In a study comparing the performance of the Gail [161, 162], Tyrer-Cuzick [1],
Claus [163–165] and Ford [166] models at predicting breast cancer risk in women with a
family history of breast cancer who were attending the Family History Evaluation and
Screening Programme in Manchester, UK, Amir et al. [167] found that the Gail, Claus
and Ford models all significantly underestimated risk and that the Tyrer-Cuzick model
was consistently the better performer, with the ratio of expected to observed numbers
of breast cancers .48 for the Gail model, .56 for Claus, .49 for Ford and .81 for Tyrer-
Cuzick. As regards ability to predict individual cases there was far less difference among
the models, with the area under the ROC curve being .735 for Gail, .716 for Claus,
.737 for Ford and .762 for Tyrer-Cuzick. Thus, it seems that the Tyrer-Cuzick model,
incorporating extensive family history information, endogenous estrogen exposure and
benign breast disease, is the best at predicting the average level of risk of a population,
and therefore the overall number of cases, but has only a slight advantage as regards
individual discrimination and prediction. Other studies have also found that the Gail
model [161] has low discriminatory power (c-statistic = .58) [13] but to some extent this
is due to the fact that the age-specific breast cancer rates on which it is based require
updating [168]. The Tyrer-Cuzick model significantly overpredicts breast cancer risk in
women with atypical hyperplasia [169] whereas the Gail model significantly underpre-
dicts [170]. Both models could therefore be improved by addressing known weaknesses
and adding information on new risk factors, such as genotype and mammographic den-
sity.
Previous attempts [2, 3, 78, 171] to introduce mammographic density into risk predic-
tion models have led to only modest improvements in predictive ability. In 2005, Tice
and colleagues[3, 171] built a model containing only breast density adjusted for age and
ethnicity, which performed as well as the Gail model. Similarly, in 2006 Barlow et al. [2]
used a cohort of 1,007,600 women to develop two models, one for pre-menopausal and
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one for post-menopausal women, that include both traditional risk factors and breast
density. In both cases, breast density, as a single predictor, appeared to be as power-
ful as age, however only a moderate further predictive ability was obtained by adding
this feature to the other factors. During the same year Chen et al. [78] proposed a
model based on age at first live birth, number of biopsies, number of affected relatives,
mammographic density and body weight, as an alternative to the Gail model but the
improvement in discriminatory power, assessed with the c-statistic, was modest (Gail
model: .602 vs Chen model: .664) [162]. It should be noted, however, that in a multi-
variate risk model for breast cancer, most individual risk factors typically account for
only a modest proportion of the predictive power.
These results need validation on independent datasets, and may lead to the conclusion
that major determinants of breast cancer risk remain to be discovered [2]. Nevertheless
measures of mammographic density are likely to make at least a modest contribution.
Given also that all these models used BIRADS [2, 3, 78, 171] as the measure of density
(i.e. a measure with 4 or 5 categories), and it is possible that a more detailed measure
may be more suitable for this context. It may be that continuous measures would lead
to a better prediction. It is also worth noting that there are limitations regarding the
c-statistic, or area under the ROC curve (AUC), as a measure for capturing discrimina-
tion and, therefore, for assessing the usefulness of markers [172, 173].
These issues concerning the predictive power of risk evaluation models are important to
both clinical practice and the current controversy regarding whether or not a woman
should be informed of her mammographic density. Current recommendations in the
US from the American Society of Clinical Oncologists are that if a woman has a 5 year
breast cancer risk of greater than 1.66% by the Gail model then she should be considered
high-risk and offered a risk-reducing intervention such as tamoxifen or raloxifene [174].
However action advocacy groups, in the USA, are pushing for legislation, which would
mandate that women attending screening should be informed regarding their breast
density; thirteen states have already adopted this policy [63]. Similarly, in the UK,
the NICE guidelines [175] recommend a threshold of 8% for the 10 year breast cancer
risk calculated from the Tyrer-Cuzick or a similar model when determining whether a
risk-reducing intervention should be offered. Because mammographic density has not
yet been incorporated into these models, it is still possible for a woman to have high
mammographic density and not satisfy the above criteria. Thus, a woman who is in-
formed of her high mammographic density might have her fears raised but be denied
appropriate counselling and risk-reducing interventions. It is a matter of some urgency,
therefore, that major studies to investigate the complex interrelationship between mam-
mographic density, established breast cancer risk factors and risk of breast cancer, are
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carried out, as the results of these will inform the existing risk evaluation models and
enable them to be further developed. It is of particular importance that we learn how
best to incorporate mammographic density into existing or new models so that the
process of assessing risk becomes more comprehensive and coherent. Work on this is al-
ready underway. The PROCAS (Predicting Risk Of breast Cancer At Screening) study
[176] in the Greater Manchester area of the UK is currently collecting comprehensive
information on women’s breast cancer risk factors (including mammographic density
and SNPs) through the NHS Breast Screening Programme and has already enrolled
about 52,000 women (http://www.uhsm.nhs.uk/research/Pages/PROCASstudy.aspx).
The data collected, together with subsequent follow-up, will provide a valuable resource
for investigating the feasibility and acceptability of assessing breast cancer risk within
a population-based mass screening programme and for the further development and
testing of the statistical models used in the evaluation of individual breast cancer risk.
Specifically, it is intended that the Tyrer-Cuzick model will be updated on the basis of
this study to include two new risk factors, mammographic density and a genetic risk
score based on a number of SNPs. Including information from mammographic density
and SNPs in risk prediction models is the most topical challenge for breast cancer risk
estimation [79]. A similar study, KARMA (http://www.karmastudien.se/) in Sweden
was designed to update the Gail model. So far Darabi et al. recorded a limited but
significant improvement in terms of AUC, including adding percent density, BMI and a
collection of SNPs to the Gail model. It has been suggested that AUC may not be the
most appropriate tool to assess the predictive ability gained adding new information to
the model [173]. However, the current lack of standardisation in breast density assess-
ment is the more important issue to be addressed.
1.2.7 Future applications
The key drawbacks of the established area-based methods of measuring breast density
are that they are subjective (visual assessment, and to a lesser extent computer assisted)
and labour intensive (computer assisted). The intra- and inter-reader error (respectively,
the difference between repeat readings of a single mammogram by the same reader and
the difference between repeat readings of a single mammogram by different readers) can
be as much as 30% and 35%, respectively, for visual assessment [27]. The labour-intensive
nature of density assessment, particularly if measured using interactive threshold meth-
ods, and the subjective decision-making involved in visual assessment, render it difficult
to incorporate into mass screening. For example, it would clearly add an unsustainable
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burden to the UK National Breast Screening programme which screens approximately
two million women per year [177]. However, the advent of digital mammography means
that both these issues may soon be resolved as there are a number of fully-automated
methods of assessing breast density from digital mammography currently being devel-
oped, ranging from bespoke image analysis software designed specifically to work with
particular mammography machines (Quantra [51, 178], Volpara [52, 179]) to stand-alone
generic packages which accept any digital images (Image J), which will assess and record
breast density as the mammogram is being taken.
The potential this technological progress will release is considerable, as major population-
based studies will now become more feasible, and new volumetric and absolute measures
of mammographic density will be readily available, adding little or no labour or time
to population screening. If the automated methods predict risk as effectively as visual
assessment and interactive thresholding, then their use in risk-management could be
incorporated into population screening. Further work is required, however, to validate
these new methods of density assessment for it is not yet known whether they will work
as well as the current methods at determining breast cancer risk.
It should also be noted that the modifiability of breast density may be a major factor in
future applications. As noted above, density has been shown to be modifiable by hor-
monal drugs and by changes in body habitus. The fact that in high-risk women treated
with tamoxifen, only those whose density was reduced after administration showed a
subsequent reduction in breast cancer risk suggests that density can be used not only
to select subjects at risk as candidates for preventive interventions, but also to monitor
the effectiveness of such interventions on an individual basis. [17]
1.2.8 Conclusions
Technological advances suggest that the breast density research community is on the
brink of major progress. Nevertheless, there is currently no fully validated objective
means of assessing mammographic density (see section on Measurement of mammo-
graphic density 1.2.2) and continuing uncertainty as to how to utilise mammographic
density in clinical practice (see sections on interpretation of density and risk 1.2.3 and
future applications 1.2.7). Without this knowledge the current demand in the US for the
introduction of Breast Density Inform Law (for example, Public Act No. 09-41 passed in
the State of Connecticut in 2009) may be premature. Whilst breast density has clearly
been shown to be a powerful factor for predicting the risk of developing breast cancer, its
potential role in assessing hormonal preventive regimes and helping to tailor screening
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algorithms cannot be fully realised until we have density measures which both predict
risk with accuracy and can be used in a population screening context.
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1.3 Aims and objectives
Research plan
1.3.1 Part I: Mammographic density as a biomarker for breast cancer
risk
Mammographic density is recognised as one of the strongest independent risk predictors
for breast cancer risk, but the reasons accounting for this association are not yet fully
understood. Thus it appears to have great potential as a biomarker for risk of this
disease, and great interest lies in investigating its properties.
In this part we analyse studies that have recorded information on density and other risk
factors for breast cancer. It should be underlined that the datasets presented in these
chapters were already existing as part of previous larger studies, and no further data
was collected during the PhD project. However these datasets had not been fully anal-
ysed and exploited for what concerns density and its association to breast cancer risk.
In order to clarify the novelty element of this thesis, Table 1.1 compares the published
results from these studies and the issues that will be addressed in this work. Hence these
data will allow us to investigate the relationship of mammographic density with breast
cancer risk, and with other risk factors. This in turn will clarify the potential of density
as a tool in breast cancer risk management.
The studies involved in the analyses are here described in brief.
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Table 1.1: Main published findings of the studies analysed in part I and new issues
addressed in this thesis
Unreported issues
Study Published Results for analyses Data
in this thesis
IBIS-I Prophylactic tamoxifen reduces the risk Alternative Nested
of breast cancer by about a third. [180] quantification case-control
The risk-reducing effect of tamoxifen of the extent study
persisted for at least 10 years, but most of surrogacy N=1065
side effects of tamoxifen do not continue (123 cases)
after the 5-year treatment period. [181]
The 12- to 18-month change in mammographic
breast density is an excellent predictor
of response to tamoxifen in the
preventive setting. [17]
ATAC Anastrozole showed both short-term and Analyses of Nested
long term superior efficacy than Tamoxifen the relationship dataset
in both improving survival and lessening of density N=601
severe side effects. [182, 183] and its changes (132 cases)
with risk of
recurrence
and first tumour
characteristics
FH01 Annual mammography in women aged 40-49 Assessment of Nested
years at enhanced familial risk is both the strength of case-control
clinically effective in reducing breast the association study
cancer mortality and cost-effective. [184] between density N=298
and risk in (103 cases)
this high-risk
population, with
and without
adjustment for
other risk
factors and
Tyrer-Cuzick
risk estimate
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1.3.1.1 Potential of visually assessed density as a marker of chemopreven-
tive effect: a case-control study within a breast cancer chemopre-
vention trial (IBIS-I), Chapter 2
Data The International Breast cancer Intervention Study (IBIS-I)[17] is 10-year-long
prevention trial, April 1992 to March 2001, that involved 7,152 high-risk subjects from
the UK (60%), Australia or New Zealand (37%) and the rest of Europe (3%), and
investigated the effectiveness of therapy with Tamoxifen, an oestrogen antagonist, in
preventing breast cancer. Women, aged 30-70 years, were considered at high risk if they
had risk factors for breast cancer indicating at least a two-fold relative risk at ages 45-
70 years, a four-fold relative risk at ages 40-44 years or a roughly ten-fold relative risk
at ages 35-39 years. After recruitment one half of the study population was randomly
assigned to a 5-year treatment with Tamoxifen and the other to placebo.
After the main trial results had been reported [181], 123 women who had been diagnosed
with breast cancer and 942 controls were selected and their data analysed to examine
the relationship between changes in breast cancer risk and mammographic density due
to Tamoxifen [17]. The study found that those women treated with tamoxifen where
density decreased most were also the population whose wisk was most reduced. However,
traditional measurement of the extent to which the Prentice criterion for surrogacy was
satisfied were modest [17, 185]. It has been noted in the past that it would be difficult to
find surrogate endpoint which satisfies the Prentice criterion perfectly or nearly perfectly
[186].
This nested case-control data will therefore be used for the following analysis.
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Proposed analysis
• To further examine the recent published result [17] that those whose density de-
creases as a result of treatment, also have corresponding reduced risk.
• To assess an alternative criterion for surrogate endpoints [185] in order to further
clarify the extent to which reductions in density can be considered as a valid
indicator of the success of the treatment.
1.3.1.2 Correlates of density with prognostic markers and outcome in a trial
of treatment of breast cancer (ATAC), Chapter 3
Data The Arimidex (anastrozole), Tamoxifen, Alone or in Combination (ATAC) study
[187] was an international double-blind clinical trial aimed to find a therapy successful in
preventing breast cancer recurrence in post-menopausal women with hormone receptor-
positive tumours. Between July 1996 and 2000 the study enrolled 9,366 postmenopausal
women with localized breast cancer, and randomised them to receive either 5 years of
adjuvant treatment with anastrozole alone, tamoxifen alone or a combination of the two.
The dataset for analysis will comprise 601 women from ATAC, 208 treated with anas-
trozole, 198 with Tamoxifen, and 195 with a combination of the two, including 22% of
cases of recurrence, in each arm respectively 42, 47 and 43.
Proposed analysis
• To analyse the relationship between mammographic density and risk of recurrence
of breast cancer.
• To investigate the interactions of density, treatment and other risk factors.
• To study how density correlates with biomarkers and tumour histochemistry (e.g.
her2 etc.).
• To replicate findings from IBIS-I, that size of density reduction is related to treat-
ment efficacy, here measured by time to recurrence, not prevention like in IBIS-I.
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1.3.1.3 Additional risk information from breast density in a population at
enhanced familial risk of breast cancer (FH01), Chapter 4
Data The Family History (FH01) study [188] was designed to evaluate the effective-
ness of annual mammographic surveillance in young women (50 years old or less) with a
family history of breast cancer. In the UK 6,710 subjects were enrolled because of their
“moderate risk” of developing breast cancer, i.e. their family history was such that they
had a substantially increased of risk of developing breast cancer, but generally not suf-
ficiently strong to suspect a BRCA mutation. These women received annual invitation
to screening and were observed for a minimum of 5 years.
Although mammographic density is well established as a risk factor, its interplay with
other risk factors is less clear. In particular, it is not known whether it adds further
information on risk in a population already known to be at high risk.
At the end of the intervention, a nested case-control study was performed, including 103
cancer cases and 195 matched controls, which investigated how mammographic density
affected risk of developing breast cancer and interacted with familial factors.
The case-control study will be used for the following analysis.
Proposed analysis
• To estimate the additional effect of density on risk, in a population already known
to be at enhanced risk of breast cancer.
• To investigate the association of density and breast cancer risk, adjusted and
unadjusted for other factors in this higher risk population.
• To compare percent and absolute measures of density.
• To study how the relationship between density and breast cancer risk varies ac-
cording to menopausal status.
1.3.2 Part II: Automated volumetric assessments of mammographic
density (Quantra and Volpara)
Fully-automated techniques are expected to be the future of measuring mammographic
density, since they will hopefully provide predictive ability as regards breast cancer risk
and quick assessments, would be possible to implement on a population scale and would
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ensure reproducibility of the results. In addition to this, while repeatability and repro-
ducibility are important in measurement of density, as with measurement of any other
attribute, the crucial feature is the ability to predict breast cancer risk. Therefore a
number of technologies are currently being developed or undergoing validation.
Quantra [51, 178] and Volpara [52, 179] are two of such methods in need of evaluation,
before being recommended in routine screening. In this part of the thesis data from
Princess Grace Hospital, a private facility in central London, are analysed to investigate
the properties of the two new techniques, comparing their predictive ability. In order to
clarify the novelty element of this thesis, Table 1.2 compares the published results from
these studies and the issues that will be addressed in this work.
The studies involved in the analyses are here described in brief.
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Table 1.2: Main published findings of the studies analysed in part II and new issues
addressed in this thesis
Published
Chapter Results Unreported issues for analyses in this thesis Data
Chapter 5 - Analyses of the association between Case-control
breast cancer risk and Quantra absolute study
and relative density measures, also N=400
in comparison to BIRADS visual (200 cases)
assessments.
Evaluation of the impact of age and
area of residence on such association.
Chapter 6 - Assessment of changes in breast Longitudinal
composition as estimated by Quantra, dataset
according to age and area of N=332
residence. (no cases)
Chapter 7 - Analyses of the association between Case-control
breast cancer risk and Volpara absolute study
and relative density measures, also N=366
in comparison to Quantra and BIRADS. (182 cases)
Evaluation of the impact of age and
area of residence on such association.
Chapter 8:
1. IBIS-I see Evaluation of intra- and inter-reader see Table 1.1
Table 1.1 agreement in Cumulus and visual (21
agreement.
2. Chapters 5 - Assessment of potential measurement see above
and 6 error in Quantra density estimates and
its impact on their association with breast
cancer risk.
Evaluating the relationship between
volumetric and area density assessments.
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1.3.2.1 A case-control evaluation of a fully automated volumetric density
measure as a predictor of breast cancer risk (1) (Quantra),
Chapter 5
Data As previously noted, to be practically useful in the context of population screen-
ing and risk management, automatic measurement of density, with little or no call on
manpower, is desirable. In this study details were recorded of 200 cases, female patients
with histopathologically verified breast cancer, and 200 matched controls. For every
subject, mammographic density was assessed both with Quantra volumetric measures
of absolute and relative density and visually with the BIRADS classification. The avail-
able covariates also included age, area of residence and the Quantra measure of total
breast volume.
Proposed analysis
• To compare Quantra measures of absolute and relative volumetric density as re-
gards their ability to discriminate between cases and controls.
• To examine the relationship between mammographic density, as assessed with
Quantra, and the established BIRADS method.
• To assess how the association between density estimates and breast cancer risk
varies according to age and area of residence.
1.3.2.2 Serial volumetric density measures using Quantra, Chapter 6
Data This dataset recorded details of 332 women, (231 younger than 50 years and
101 aged 50 or more years) undergoing two mammographic examinations, typically 18
months apart. Density was assessed with Quantra and we also had information on age
and area of residence.
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Proposed analysis
• To assess changes in breast composition (i.e. amount of dense and fat tissue) over
time, for the combined study group and each age cohort separately.
1.3.2.3 A case-control evaluation of a fully automated volumetric density
measure as a predictor of breast cancer risk (2) (Volpara),
Chapter 7
Data The mammograms of 366 women (182 cases and 184 controls) from the Quantra
case-control study, were reassessed using Volpara[52, 179], another fully-automated vol-
umetric measure.
Proposed analysis
• To examine the relationship between the mammographic density measures pro-
duced with Volpara and the established BIRADS method.
• To compare Volpara measures of absolute and relative volumetric density as re-
gards their ability to discriminate between cases and controls.
• To assess how the association between density estimates and breast cancer risk
varies according to age and area of residence.
• To compare directly Volpara and Quantra assessments.
1.3.2.4 Measuring mammographic density: results, issues and potential im-
plications, Chapter 8
This chapter includes analyses on data described in Chapters 2, 4, 5 and 6 and it focuses
on variability from measurement error and population variation in breast composition.
Proposed analysis
• To evaluate inter- and intra-reader agreement in Cumulus [28] and visual (21-
categories) assessments using data from the IBIS-I study [17], described in Chapter
2.
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• To investigate how measurement error in density assessed with a fully-automated
volumetric method (Quantra) may influence the association between density and
breast cancer risk, observed in Chapter 5.
• To adjust the association between risk and Quantra absolute density estimates
(Chapter 5) for the potential measurement error, using data introduced in Chapter
6 to estimate variability components.
• To study the relationship between two- and three-dimensional density assessments,
and their difference in variability, using data from the longitudinal study presented
in Chapter 6 and CADET1 study [4].
• To compare the propensity for risk prediction of most of the density measures
available for this project (visual 21-category assessment from Chapter 2, Cumulus
from Chapters 2 and 4, Quantra from Chapter 5 and Volpara from Chapter 7)
using standardised odds ratios and the areas under the ROC curve (AUCs).
1.3.3 Implications for practice and for future research
As noted above, the aim of this project is to clarify the role of breast density as a marker
of risk, and to indicate its scope in:
• identification of high-risk individuals for preventive or surveillance interventions,
• monitoring of interventionss to reduce risk at individual level,
• risk and surveillance: management in the context of population screening.
The concluding chapter draws together implications put in terms of what can be imple-
mented in health care now, and which issues remains to be researched.
Part I
Mammographic density as a
biomarker for breast cancer risk
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Chapter 2
Potential of visually assessed
density as a marker of
chemopreventive effect: a
case-control study within a breast
cancer chemoprevention trial
(IBIS-I study)
2.1 Introduction
Studies focusing on cancer incidence as an endpoint within cancer prevention and treat-
ment trials require large numbers of subjects, follow-up over many years, and, conse-
quently, imply great expense. Surrogate markers are measures that can be used as early
indicators of treatment effect because of their ability to predict the outcome of the ther-
apy on this endpoint. They are therefore very attractive for study designers because
of the opportunity they provide to make studies smaller, faster and less expensive. A
surrogate (S) is expected to mediate the effect of the therapy or exposure (Z) on the
true endpoint (T), in other words S should lie on the causal pathway connecting Z to T.
Given the complexity of carcinogenesis, finding an appropriate surrogate marker is not
an easy task [185, 186, 189].
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The appearance of breast tissue on a mammogram varies between subjects due to differ-
ences in breast composition, leading to different levels of risk of developing breast cancer.
In particular, a larger amount of white (dense) areas, i.e. the projection of stroma and
epithelium or fibroglandular tissue, corresponds to higher breast cancer risk [6]. Decades
of research on this topic indicated that this association holds regardless of the tumour-
type [81]. Nevertheless the understanding of the biology underlying the association
between breast cancer risk and mammographic density is still limited [190]. Current hy-
potheses suggest increased stromal collagen, delayed involution and increased expression
of aromatase [63]. One of the most interesting properties of breast density as a risk fac-
tor for breast cancer is that it can be altered and is particularly responsive to hormonal
manipulation. Exposure to hormone replacement therapy, normally progesterone and
oestrogen combined, leads to increases in both breast cancer risk and mammographic
density, although possibly through independent pathways [101, 103, 191]. Tamoxifen
therapy, on the other hand, is associated with a decline in mammographic density as
well as in risk [17–19]. Tamoxifen influences breast cancer risk by blocking oestrogen
stimulation on breast cancer cells, inhibiting both translocation and nuclear binding
of the oestrogen receptor [192]. Recent publications [17–19] showed that subjects who
experienced a considerable reduction (≥10%) in mammographic density, were more re-
sponsive to tamoxifen treatment. This was observed both in a high-risk population in a
cancer-prevention study (IBIS-I) [17] and in the context of reducing risk of recurrence or
death [18, 19]. These findings strengthen the hypotheses that changes in mammographic
density may be a good indicator for the outcome of therapy with tamoxifen.
Previously published findings from the IBIS -I study [17, 181] suggested that: (1) tamox-
ifen (Z) is associated with reduction in breast cancer risk (T), (2) tamoxifen is associated
with reduction in mammographic density (S), and (3) the reduction in mammographic
density is associated with reduction in breast cancer risk. Hence reduction in mammo-
graphic density satisfies three of the four conditions necessary for a surrogate end-point
[185, 193]. The fourth requires that
f(T |S,Z) = f(T |S) (2.1)
where f(T |S,Z) and f(T |S) are the conditional probability distribution of T . In simpler
terms this equation stipulated that the effect of tamoxifen on density should be sufficient
information to infer its effect on breast cancer risk.
The analyses reported in this chapter are based on data from the case-control study
nested in IBIS-I [17] and are aimed at verifying whether this condition holds too, i.e. to
investigate the extent to which mammographic density mediates the effect of tamoxifen
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therapy on breast cancer risk, and thus evaluate the potential of mammographic density
changes as a predictor of the outcome of the treatment.
2.2 Materials and Methods
2.2.1 Study Setting and Population
The IBIS-I chemoprevention study is an international trial designed to evaluate the ef-
fect of tamoxifen on breast cancer risk in high-risk women. It recruited a total of 7,152
women aged 30-70 [180]. A nested case-control study was conducted subsequently to in-
vestigate relationships between treatment, change in mammographic density and known
breast cancer risk factors. It comprised 123 cases from the UK and Finland and 942
British controls, and its results were published in 2011 by Cuzick and colleagues [17].
Detailed breast cancer risk factors were collected at study entry. Of the women in our
subset 507 were treated with tamoxifen and 558 received a placebo treatment, with ran-
dom allocation in the treatment arms [180, 181]. Mammographic density was assessed
visually by one radiologist (R.M.L. Warren) who viewed the film mammograms and
visually estimated the proportion of total breast area that comprised dense tissue (to
the nearest 5%). Baseline films were taken at or up to a year before randomisation, and
follow-up films were taken at least 12 months after randomization, with a median time
between randomization and first follow-up mammogram of 18 months. The assessment
of mammographic density for both cases and controls was based on a composite assess-
ment of both the left and right mediolateral oblique views, with the exception of 13 case
subjects who were diagnosed at the first follow-up mammogram. For these women the
density assessment was made using only the film from the contralateral breast [17].
In this study we only focused on age, body mass index and percent breast density at
baseline as risk factors for breast cancer. Change in breast density between the two
mammograms was classified in four categories as follows: “Increase”, “No change” “Re-
duction 5-10%” and “Reduction ≥10%”.
Further details on the data collection are provided in Cuzick and colleagues’ paper [17].
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2.2.2 Prentice’s criteria and how to quantify the effect of a surrogate
marker
Prentice’s necessary and sufficient condition for a surrogate endpoint [185] is as follows:
a test of the null hypothesis of no relationship of the surrogate to treatment is also a
valid test of no relationship of the true endpoint to treatment.
If T is the clinical outcome or true endpoint, S is the surrogate endpoint, Z is the treat-
ment indicator and f(S|Z), f(S), f(T |Z) and f(T ) are conditional and unconditional
distribution of S and T, this can be expressed as: f(T |S,Z) = f(T |S) where T and Z
are associated to each other and to the surrogate S. Further, Qu distinguished between
surrogate marker and surrogate endpoint, as the former is drug-specific, whereas the
latter is a surrogate for any efficacious treatment [193]. Hence in our case it is more
appropriate to use the term “surrogate marker”, as we tested it only in relation to ta-
moxifen treatment.
Freedman and colleagues [189] proposed the proportion of treatment effect (PTE) ex-
plained by a surrogate marker to quantify the extent to which Prentice’s criterion is
satisfied. PTE is a function of the ratio of the estimated treatment effects, i.e. regres-
sion coefficients γZ and βZ , respectively from a model including both treatment (Z) and
surrogate (S) and one including only treatment (Z) as predictor variable.
PTE = 1− γZ
βZ
. (2.2)
In more familiar terms, γZ is the regression coefficient of the treatment on the true
endpoint adjusted for the surrogate, and βZ is the unadjusted coefficient. The main
drawbacks of this index are that it is unbounded and that results, in particular the
variability of γZ , can easily be affected by a strong collinearity between treatment and
surrogate marker. Because the treatment is generally effective in improving the surro-
gate marker, a strong correlation between treatment and the surrogate marker might be
expected [194]. In this situation the coefficient estimates of the regression model includ-
ing both S and Z may change erratically in response to small changes in the model or the
data [195]; thus making PTE a less reliable estimate of the validity of S as a surrogate
marker, as intended by Prentice [185].
More recently Qu and Case proposed another method, the proportion of information
gain (PIG), to evaluate a surrogate marker [193, 194]. PIG is based on the likelihood
function and is defined as
PIG = LRT (S : 1)/LRT (S,Z : 1) (2.3)
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where LRT(S:1) is the likelihood ratio test statistic comparing the model including in-
tercept and marker S as explanatory variables for outcome and the model only including
the intercept. Likewise LRT(S,Z:1) is the statistic referring to the model including both
surrogate (S) and treatment (Z), along with the intercept, in comparison to the model
based on the intercept only. Simulations showed that PIG overcomes some of the dis-
advantages of PTE [193, 194]. The major conceptual difference between PTE and PIG
is that the former compares the effect of treatment on the true endpoint, adjusted and
unadjusted for the surrogate, whereas the latter compares the effect of the surrogate on
the true endpoint, adjusted and unadjusted for the treatment.
Alonso et al. [196] also developed a method to assess the validity of a potential surrogate
marker according to the Prentice’s criteria, the likelihood reduction factor (LRF). This
method uses the same models necessary to compute PTE and LRF is defined as
LRF (Z, S : Z) = 1− exp{−LRT (Z, S : Z)/n} (2.4)
where LRT(Z, S : Z) is the likelihood ratio test (LRT) based on the models were the true
endpoint is explained by the treatment effect adjusted and unadjusted by the surrogate,
and n is the number of observations. This measure, like PIG, is based on likelihood
function and, as Qu and Case pointed out [194], there is a close relationship between
LRFa, i.e. the adjusted LRF, bounded by [0,1], and PIG,that can be approximated as
follows: 1− LRFA(S,Z : S) ≈ PIG.
2.2.3 Statistical Analyses
The distributions of demographic and other variables at baseline are summarised as
percentages or mean and SDs, as appropriate, both overall and stratified by treatment
arm.
Some results on this dataset have been previously published [17]. These suggested change
in percent density after tamoxifen treatment as a potential predictor of the outcome of
the therapy. Subjects experiencing a reduction in density of at least 10% appeared more
responsive to the therapy in terms of risk reduction.
As noted above, results already published from IBI-I suggest that changes in density
reflect changes in risk. Our aim in this chapter was therefore to assess the extent of den-
sity’s potential as a surrogate for the outcome ofbreast cancer, using alternate formal
measures of this extent. In particular, we assessed the validity of reduction in density as
a surrogate marker for risk reduction using both PTE and PIG methods. Alonso’s LRF
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was considered redundant and not computed because of its close relationship to the PIG
measure. The results of this work apply to an enhanced risk population rather than the
general population. This is appropriate since it is specifically in such a enhanced risk
population that tamoxifen can be used as primary prevention.
Logistic regression models were used to assess the relationship between risk of breast
cancer and both treatment with tamoxifen and reduction in mammographic density. We
used weights to reflect the sampling fraction, since, by study design, the two treatment
arms have different sample size. In particular we weighted the subjects with the inverse
of the probability that the observation is included because of the sampling design, there-
fore subjects in the placebo arm were weighted 532.5/558 and those in the tamoxifen
arm 532.5/507.
All analyses were performed using Stata, version 12.1.
2.3 Results
Baseline characteristics of the 1,065 subjects, overall and by treatment group, are sum-
marised in Table 2.1. More than half of the subjects in both arms had on average
received treatment for at least 5 years. Other characteristics such as age and BMI at
entry in the study were well balanced between the two arms.
The proportion of cases in the two arms are similar, because of the study design, since
the placebo arm here included 558 cases and controls, whereas the tamoxifen arm in-
cluded only 507 subjects, i.e. larger numbers of unaffected subjects were sampled for the
placebo arm. Hence sampling weights were used in the logistic regression. However the
protective effect of tamoxifen against breast cancer has been widely recognised and it
was especially evident in the long-term prospective results from the whole IBIS-I study
[180, 181].
Baseline density levels were similar but differed post-treatment as the two therapies af-
fected mammographic density in different ways. Almost half of the women treated with
tamoxifen (46%) experienced a reduction in the percent density of at least 10%, whereas
only a quarter of the subjects in the placebo arm (25%) showed such a change.
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Table 2.1: Characteristics of the study sample
Overall Tamoxifen Placebo
N=1065 N=507 N=558
Number of cases (%) 123 (11.6) 51 (10.1) 72 (12.9)
Time on treatment
Mean (SD) 4.9 (0.7) 4.9 (0.7) 4.9 (0.7)
Age in years at baseline
Mean (SD) 50.2 (6.2) 50.2 (6.3) 50.1 (6.1)
Body Mass Index at baseline
Mean (SD) 26.7 (4.8) 26.7 (4.9) 26.7 (4.8)
% breast density at baseline, No.(%)
0 % 114 (10.7) 58 (11.4) 56 (10.0)
1-10 % 108 (10.1) 47 (9.3) 61 (10.9)
11-25 % 132 (12.4) 62 (12.2) 70 (12.5)
26-50 % 252 (23.7) 129 (25.4) 123 (22.0)
51-75 % 240 (22.5) 109 (21.5) 131 (23.5)
76-100 % 219 (20.6) 102 (20.1) 117 (21.0)
Mean(SD) 44.5 (30.2) 44.1 (30.0) 44.8 (30.4)
Change in breast density categories after 12 months, No. (%)
Increase 86 (8.1) 20 (3.9) 66 (11.8)
No change 394 (37.0) 161 (31.8) 233 (41.8)
Reduction 5-10% 213 (20.0) 94 (18.5) 119 (21.3)
Reduction ≥10% 372 (34.9) 232 (45.8) 140 (25.1)
It is clear from Table 2.2 that the numbers and the percentages of events varied according
to the change in density that the patients experienced, therefore this is a strong risk
factor. Likewise tamoxifen reduced the number of breast cancer events. Table 2.3 shows
the estimates required for computing both Freedman’s and Qu’s methods [189, 193, 194]
for surrogate markers.
We fitted the models with and without treatment (Z) and our potential surrogate marker
(S), Table 2.3. Freedman’s PTE was then obtained as:
PTE = 1− −0.18−0.28 = .37. (2.5)
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Table 2.2: Change in density and breast cancer incidence according to randomised
treatment group (P=placebo, T=tamoxifen)
Change in density Nr. patients at risk/events Percent of events
after 12-month treatment P T P T
Increase 66/9 20/4 13.6 20.0
no change 233/27 161/20 11.6 12.4
Reduction >5% 119/21 94/12 17.6 12.8
Reduction ≥10% 140/15 232/15 10.7 6.5
Table 2.3: Intermediate endpoint validation analysis
Model βz SE(βZ) LR (χ
2) df
ln(p/1− p) = β0 + βZZ + βSS -.18 .21 9.85 4
ln(p/1− p) = β0 + βZZ -.28 .19 2.09 1
ln(p/1− p) = β0 + βSS - - 8.77 3
ln(p/1− p) = β0 - - 0 0
Qu’s PIG instead is computed as:
PIG =
LRT (S : 1)
LRT (S,Z : 1)
∗ 100 = 8.77
9.85
∗ 100 = 89%. (2.6)
This low PTE may be due to collinearity between S and Z. This hypothesis is supported
by the significant association between treatment arm and density reduction observed in
Table 2.2 (χ2 test: p<.01). Qu and Case observed similar disagreement between PTE
and PIG in their example based on the MORE (Multiple Outcome of Raloxifene Eval-
uation) study [194]. This issue will be further discussed in the next section.
2.4 Discussion
Reduction in mammographic density is a potential surrogate marker in trials with ta-
moxifen, since there is a very high proportion of information gain (PIG) [193, 194],
89%. Conversely, Freedman’s proportion of treatment effect (PTE) explained by a sur-
rogate marker [189] appeared modest, (.37). A similar disagreement between the two
methods was observed also by Qu and Case [194] in their example using data from the
MORE study [197]. They felt this was an illustration of the limitations of PTE: this
measure is unbounded and susceptible to collinearity between treatment and surrogate
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marker. As a matter of fact the standard error for PTE in their simulation was quite
high, especially in comparison with the other measures. This is supporting evidence
of the collinearity existent between the surrogate and the treatment, as it would make
parameter estimates, in the regression model including both factors, more susceptible
to small changes in the data [195]. Another disadvantage of Freedman’s PTE is that it
does not consider whether the coefficient of the treatment remain significant after the
surrogate marker is introduced to the model. It would be difficult to observe a PTE
equal to 1 as it would require that the adjustment for the surrogate marker nullifies the
coefficient of the treatment. This rarely happens but the significance of the effect of the
treatment may be more strongly influenced, in other words: even if the introduction of
the surrogate marker decreases only slightly the coefficient of the treatment, the latter
may no longer be significant.
PIG on the other hand addresses significance , and therefore consistency, of effects rather
than their size, being based on likelihood ratio test statistics of the models, which also
makes it robust to collinearity. This method is based on the concept that the treatment
will not contribute much information to the clinical outcome, once the surrogate mark-
ers are available, if these are truly effective surrogates [194]. The disadvantage of this
method is that there is no established cut-off point for PIG above which the surrogate
marker is deemed to be valid. However 89% appears high enough to consider reduction
of at least 10% in mammographic density as a good predictor of the efficacy of treatment
with tamoxifen.
There is also the difference noted that PTE and PIG are not measuring exactly the
same phenomenon. PTE measures the attenuation of the magnitude of the treatment
effect by adjusting for the surrogate; PIG measures the additional information provided
by the treatment effect in addition to that provided by the surrogate. Also, as noted
above, the PIG is more related to consistency rather than magnitude of effect.
Density as a surrogate may not apply to treatment with other therapies though, as
different treatments may act through different causal pathways. Risk-reduction strate-
gies using raloxifene, aspirin or aromatase inhibitors have not led to larger changes in
mammographic density compared to the placebo arms [107, 111, 112, 198–200], despite
being more successful in reducing risk of breast cancer. The fibroglandular tissue may
be related to potential oestrogen binding sites in the breast but not to the amount of
bioavailable estradiol, so that mammographic density is not an appropriate surrogate
marker for the effect of aromatase inhibitors in reducing the risk of breast cancer [200].
It is also possible that mammographic appearance is not the right tool for assessing
changes in breast composition due to aromatase inhibitors and thus alternative tech-
niques, such as MRI or ultrasound tomography may need to be evaluated [200]. To
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support this theory, Eng-Wong and colleagues [107] assessed the change in breast den-
sity in high-risk premenopausal women from both mammograms and breast magnetic
resonance imaging (MRI) and observed that the breast MRI volume (MRIV) declined
significantly after use of raloxifene, whereas mammographic density did not. It should
be observed that because of the limited size of the sample (N=27) this result would
require validation on a larger dataset. Cigler and colleagues [111] found that letrozole
does not significantly affect breast density, however it should be noted that their subjects
were previously treated with tamoxifen and therefore this may have already achieved
maximal density-lowering effects. Vachon et al. deduced similar conclusions from their
study on the impact of letrozole in women completing 5 years of tamoxifen [110]. A
more recent study [112] enrolled 369 early-stage breast-cancer postmenopausal patients
and 269 matched healthy controls to study the efficacy of aromatase inhibitors, anas-
trazole and exemestane. In this case as well, no therapy induced reduction in density
was reported, other than the natural decline observed also in the controls. Raloxifene is
a selective oestrogen receptor modular (SERM) with similar mechanisms to tamoxifen,
but a review on raloxifene trials [198] found no treatment-induced change in density, in
contrast to the IBIS-I study [17]. This could be due to a difference in the population:
IBIS-I included healthy pre- and post-menopausal women at high risk of developing
breast cancer whereas the studies on raloxifene included in the review were performed
mostly on healthy post-menopausal women not at high risk. Hence subjects in these
studies had lower baseline breast density, which may have made reductions in breast
density less evident [198].
Even though change in mammographic density appears promising as a surrogate for
tamoxifen treatment, it is not ready to be used as such, because the assessment of mam-
mographic density has yet to be standardised [28, 201]. Currently the most popular
density classification method is BIRADS, which uses four wide categories and therefore
may not be sensitive enough to reflect change in density at the required level of de-
tail. The IBIS-I case-control study [17] used visually assessed density in 21 categories,
and found that a reduction in density of at least 10% was a good indicator for a suc-
cessful outcome of the treatment. Kim and colleagues [18] observed similar results in
preventing recurrence using interactive thresholding to estimate density. In Sweden Li
et al. assessed mammographic density, at baseline and follow-up, using an automated
thresholding method [55], and in their data a reduction in dense area of at least 20%
corresponded to a decrease in mortality of 50%, in comparison to little or no change.
Finally in a recent Korean study [20] mammographic density reduction was defined di-
chotomously comparing baseline and follow-up mammograms classified using BIRADS
categories. In this study patients who showed a reduction in breast density according to
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BI-RADS classification after an average of 19 months of adjuvant tamoxifen treatment
had a 65% lower risk of recurrence than patients who did not show such reduction. Other
density assessment methods, e.g. volumetric methods such as Quantra or Volpara, may
need different cut-off points in density reduction. A standardisation of breast density
assessment with general accepatibility to patients and practitioners is necessary for its
use in risk-prediction of breast cancer in routine mammography screening. Likewise the
use of breast density reduction as a surrogate marker is limited without standardised
measurements.
In conclusion, this study found that mammographic density reduction could be a valid
surrogate for a positive outcome with tamoxifen treatment in high-risk women. How-
ever, it is not clear whether it could be also used for other therapies for reducing risk
of breast cancer. Alternative imaging methods, for example MRI or tomosonography,
may be better than mammography in detecting the relevant changes in breast composi-
tion. In any case, mammographic density reduction requires an established standardised
method of measurement in order to be used as a surrogate. The potential for automated
methods to fill this role is further investigated in the second part of this thesis.
Chapter 3
Mammographic density, risk of
breast cancer recurrence and
characteristics of the tumour
(ATAC study)
3.1 Introduction
Despite advances in therapy a substantial number of breast cancer patients remain at
risk for late recurrences. In particular almost one in five breast cancer survivors after
5 years of adjuvant therapy suffers a recurrence within 10 years after treatment [202].
Being able to identify subjects more likely to develop a recurrence would be crucial to
design focused and more effective disease control strategies. Mammographic density,
i.e. the amount of radiodense tissue in a mammogram, is a strong and independent
risk-predictor for breast cancer, but it is unclear if it could be helpful in a prognostic
setting. A British study, including 759 screened women with an invasive breast cancer
[203], reported that mammographic density and prognosis, subsequent to diagnosis and
treatment, were unrelated. Later results on a Danish cohort [84], by contrast, indicated
that breast tumours arising within mixed or dense breasts were less aggressive than
tumours detected in primarily fatty breasts. Finally, in 2009 a study comprising 335
women, who underwent breast-conserving surgery for invasive breast cancer [204], sug-
gested that mammographic density could provide a good indicator of risk of local breast
cancer recurrence. However, these results were limited to subjects who did not receive
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breast irradiation.
The ATAC trial [182, 183] was designed to evaluate anastrazole and tamoxifen as adju-
vant treatments for prevention of breast cancer recurrence. Therapy with anastrazole,
and other aromatase inhibitors, has not been observed to have a significant effect on
density [112, 205], whereas tamoxifen is known to affect the breast composition of the
subjects, substantially decreasing density [17–20]. Recent evidence suggests that reduc-
tion in density of at least 10%, following tamoxifen therapy, in unaffected women at
moderate to high-risk of breast cancer, might lead to a risk reduction of 63% [17]. Like-
wise Kim and colleagues [18] suggested that patients, with ER-positive breast cancer,
who did not experience a reduction of at least 10% in density after a year of tamoxifen
therapy, were twice as likely to have a recurrence than those who did experience such a
reduction. Similar results were reported on a cohort of Swedish post-menopausal breast
cancer patients [19] and in Korea on a group of premenopausal women with ER-positive
breast cancers [20]. Hence, reduction in the amount of fibroglandular tissue could pro-
vide an indicator of the effectiveness of the treatment [17–20]. This background suggests
two hypotheses: that density might be employed as a risk predictor also for recurrence;
and that targeting density reduction could be a successful strategy for dynamic therapy
decisions to prevent breast cancer recurrences.
Breast cancer is a heterogenous disease; not only have different pathological subtypes
of breast cancer distinct clinico-morphological features and require different treatment
strategies, but they are also associated with distinct risk factors, suggesting an etiologic
heterogeneity [80, 206]. For this reason the relationship between density and breast
tumour subtypes has been subject of several investigations that have reported contra-
dicting results [80, 207–211]. A recent meta-analysis [81] concluded that mammographic
density should be recognised as an important and strong marker of overall and of sub-
type specific risk.
The analyses reported here are on a subset of subjects from the ATAC trial, thus post-
menopausal women with histologically proven operable invasive breast cancer and ran-
domly assigned to treatment with anastrazole, tamozifen or a combination of the two,
after completing primary surgery, chemotherapy and, often, radiotherapy. The data
included details on tumour characteristics, as well as information on the cell prolifera-
tion marker Ki-67. Mammographic density was assessed retrospectively on baseline and
subsequent yearly mammograms.
This gave us the opportunity to investigate: the role of mammographic density in asso-
ciation to risk of recurrence, both as an indicator of higher risk and as a target for more
effective treatment; and how mammographic density and its changes interact with the
tumour characteristics, including (Ki-67), both overall and within the treatment arms.
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3.2 Materials and Methods
3.2.1 Study setting and population
The Arimidex (anastrazole), Tamoxifen, Alone or in Combination (ATAC) trial has been
described in detail previously [182, 183]. In brief it was designed to compare the effi-
cacy and safety of anastrazole and tamoxifen to prevent breast cancer recurrence, during
a 5-year treatment and a 10-year follow-up. The trial enrolled 9,366 postmenopausal
women with localised breast cancer, and randomly assigned (1:1:1) them to one of the
three treatment arms, anastrazole, tamoxifen and a combination of the two.
This chapter presents analyses on a subset of these women, that comprises 601 sub-
jects from centres in England and Wales, including 132 that experienced breast cancer
recurrences (20-24% in each arm). The dataset recorded information about age and
Body Mass Index (BMI) at entry in the study. Characteristics of the first tumour, such
as histological grade, tumour size, nodal and ER status, were collected through CRF
pathological reports from each centre. Moreover, information on HER2 (human epider-
mal growth factor receptor 2) status and Ki-67, a cellular marker for proliferation, was
available for a subset of the subjects. HER2 status was determined using the Dako Her-
cepTest (k5207; Dako Cytomation, Carpinteria, CA) followed by the Vysis fluorescence
in situ hybridization (FISH; Downers Grove, IL) test for tumors [212]. Ki67 was scored
as the percentage of positively stained cells among 1,000 malignant cells [213].
Data included details regarding time to recurrence, to death or exit from the study.
Please note that in these analyses “recurrence events” refers to local and distant recur-
rences, but also death before recurrence if deemed a consequence of the primary breast
tumour.
Mammographic density was assessed visually (to the nearest 5%) using the MLO view
on the contralateral breast from scanned film mammograms taken at baseline and ide-
ally yearly thereafter. Our analyses focused on density at baseline and its changes after
one, two and five years of treatment.
After the initial analysis at 33 months of follow-up [182], the combination group was
stopped because no benefit compared with tamoxifen alone was seen, in terms of either
efficacy or tolerability, and follow-up data were not subsequently collected. However,
the mammograms were collected retrospectively, after randomising on the sample firstly
enrolled in ATAC, and blinded to the treatment arm. Thus we had details on density
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also for women in the combination arm even after its termination.
3.2.2 Statistical Analyses
The distributions of demographic and other variables at baseline are summarised as
percentages or mean and SDs, as appropriate, both overall and stratified by treatment
arm.
Percent density distribution was presented using both categories, following Boyd’s clas-
sification (”0 %”, ”1-10 %”, ”11 - 25%”, ”26-50%”, ”50-75%” and ”>75%”) [28], and
mean and SDs, again both overall and stratified by treatment arm. Likewise changes in
density after 12, 24 and 60 months were summarised with mean and SDs, highlighting
the distribution of changes after two years of treatment categorised as follow: ”> −5%”,
”−5−−10%”, ”≤ −10%” and ”Unknown”.
Associations between risk of breast cancer recurrence and risk factors, such as age and
body mass index (BMI) at baseline and the first breast tumour characteristics were eval-
uated using univariate logistic regression models. Univariate and multivariable logistic
regression models were run to analyse the association between mammographic density at
baseline and its changes after 12, 24 and 60 months and risk of breast cancer recurrence.
These analyses were repeated after adjusting for the available risk factors (age and BMI
at baseline and first breast tumour characteristics). Multivariable Cox regression models
evaluated how mammographic density and its changes over time affected the time free
from recurrences.
We illustrated the relationship between the characteristics of the first breast tumour and
mammographic density at baseline and its changes over time, both overall and accord-
ing to treatment arm, using means, SDs, and box-plots. Significance testing was done
using non-parametric test for trend [214] or Wilcoxon rank-sum test, for dichotomous
variables. Repeated measures of density at baseline and after 1, 2 and 5 years were
also analysed graphically and with linear regression models over time, adjusting for age
and BMI, in order to investigate potential different trends according to tumour charac-
teristics. The regression models took into account the potential correlation of repeated
measures on the same subjects.
Results from the two tests on HER2 status were defined as “Positive” or “Negative”.
This was available only for a limited number of subjects (N=268), none of whom were
in the combination group.
The cell proliferation marker Ki-67 was first log-transformed, because of the approximate
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lognormal distribution of the data [215], then scatter plots and Pearson’s correlation co-
efficients allowed an evaluation of the relationship between the quantitative Ki-67 level
and mammographic density and its changes over time, both overall and according to
treatment arm. Note that, similarly to HER2, there were no data on Ki-67 for the sub-
jects in the combination group so only the anastrazole and tamoxifen arm are compared.
3.3 Results
As noted above, this study comprised 601 post-menopausal women, diagnosed with
breast cancer and enrolled in the ATAC trial from centres around England and Wales.
Median follow-up for this analysis was 102 months (range 3-127), including a total of
4650 women-years (1640 women-years for anastrazole, 1557 for tamoxifen and 1453 for
the combination arm).
A similar number of recurrences (20-24 %) occurred in these subsets of the three study
arms though they differed in time to recurrence (Table 3.1). As reported previously
[183] disease-free survival was significantly better in the anastrazole group compared to
the tamoxifen arm. The distributions of baseline age and BMI appeared similar across
the groups (Kruscal-Wallis non-parametric ANOVA p-values: .69 and .31 respectively),
whereas mammographic density was similar in the tamoxifen and anastrazole arms, but
appeared higher in the combined group. However this difference was not statistically
significant, according to ANOVA analysis (p=.27). Likewise for the change in density,
the combination group, two and five years in the study, showed a higher, although not
significantly higher, reduction, probably due to a regression to the mean phenomenon
related to the higher initial level of density.
The analyses of the association between the risk of breast cancer recurrence and the avail-
able risk factors and first tumour characteristics revealed that age, histological grade,
nodal status and tumour size were strongly and positively associated with risk of recur-
rence (Table 3.2). However in the multivariable logistic regression model, only age at
diagnosis and tumour size remained significant. In other words women diagnosed with a
larger tumour (>2 cm) and who entered the ATAC study at an older age were especially
prone to recurrence.
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Table 3.1: Characteristics of the study samples in the three treatment arm
Treatment Arm
Anastrazole Tamoxifen Combined Total
(N=208) (N=198) (N=195) (N=601)
Number of recurrences (%) 42 (20.2) 47 (23.7) 43 (22.1) 132 (22.0)
Time at recurrences, No.(%)*
0-12 months 0 (0.0) 3 (6.4) 1 (2.3) 4 (3.0)
12-24 months 3 (7.1) 7 (14.9) 3 (7.0) 13 (9.8)
24-60 months 17 (40.5) 12 (25.5) 18 (41.9) 47 (35.6)
>60 months 22 (52.4) 25 (53.2) 21 (48.8) 68 (51.5)
Age in years at baseline
Mean (SD) 63.2 (7.7) 63.3 (8.4) 63.9 (8.7) 63.5 (8.2)
Body Mass Index in kg/m2 at baseline
Mean (SD) 27.3 (5.0) 27.1 (4.6) 26.7 (4.8) 27.0 (4.8)
% breast density at baseline, No.(%)
0% 17 (8.2) 15 (7.6) 8 (4.1) 40 (6.7)
1-10% 37 (17.8) 26 (13.1) 31 (15.9) 94 (15.6)
11-25% 44 (21.2) 53 (26.8) 44 (22.6) 141 (23.5)
26-50% 59 (28.4) 52 (26.3) 48 (24.6) 159 (26.5)
51-75% 39 (18.8) 46 (23.2) 53 (27.2) 138 (23.0)
76-100% 12 (5.8) 6 (3.0) 11 (5.6) 29 (4.8)
Mean(SD) 33.6 (24.9) 34.2 (24.6) 37.4 (25.3) 35.0 (25.0)
Median (IQR) 30 (40) 30 (40) 35 (45) 30 (40)
Change in breast density, mean (SD)
after 12 months (N=464) -3.8 (10.0) -3.3 (10.7) -3.6 (11.6) -3.6 (10.7)
after 24 months (N=525) -4.9 (10.0) -4.3 (11.3) -5.5 (12.4) -4.9 (11.2)
after 60 months (N=506) -6.8 (11.6) -7.1 (12.9) -8.5 (14.2) -7.4 (12.8)
Change in breast density categories after 24 months, No. (%)
> −5% 88 (42.3) 85 (42.9) 75 (38.5) 248 (41.3)
−5−−10% 48 (23.1) 34 (17.2) 38 (19.5) 120 (20.0)
≤ −10% 49 (23.6) 52 (26.3) 56 (28.7) 157 (26.1)
Unknown 23 (11.1) 27 (13.6) 26 (13.3) 76 (12.6)
Note: (*) percent values refer to the amount of recurrences
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Table 3.2: Odds ratios (ORs) for the risk of recurrence of breast cancer from univariate
logistic models
case subjects controls subjects Univariate
Variable (N=132) (N=469) OR [95% Conf. Interval]
Age at baseline in y, No. (%)
≤59 33 (36.3) 185 (39.5) 1.00 (referent)
60-69 51 (4.1) 190 (4.5) 1.50 .93 2.44
≥70 48 (23.6) 94 (2.0) 2.86 1.72 4.76
Ptrend <.01
Body mass index in kg/m2, No. (%)
≤23 23 (17.4) 83 (17.7) 1.00 (referent)
24-25 19 (14.4) 83 (17.7) .83 .42 1.63
26-30 52 (39.4) 178 (38.0) 1.05 .60 1.84
>30 26 (19.7) 101 (21.5) .93 .49 1.75
Unknown 12 (9.1) 24 (5.1) -
Ptrend .93
Histological grade, No. (%)
(1) Well 24 (18.2) 113 (24.1) 1.00 (referent)
(2) Moderate 66 (5.0) 233 (49.7) 1.33 .79 2.24
(3) Poor/Undiff 36 (27.3) 93 (19.8) 1.82 1.02 3.27
Unknown 6 (4.5) 30 (6.4) -
Ptrend .04
Nodal status, No. (%)
Negative 67 (5.8) 324 (69.1) 1.00 (referent)
Positive 58 (43.9) 125 (26.7) 2.24 1.49 3.37
Unknown 7 (5.3) 20 (4.3) -
Ptrend <.01
Tumour size, No. (%)
≤2cm 71 (53.8) 328 (69.9) 1.00 (referent)
>2cm 61 (46.2) 140 (29.9) 2.01 1.36 2.99
Unknown 0 (0.0) 1 (0.2) -
Ptrend <.01
ER status, No. (%)
Positive 94 (71.2) 361 (77.0) 1.00 (referent)
Negative 21 (15.9) 48 (1.2) 1.68 .96 2.94
Unknown 17 (12.9) 60 (12.8) 1.09 .61 1.95
Ptrend .40
Note: Subjects classified as “Unknown” were excluded when testing for trend.
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Table 3.3: ORs for risk of breast cancer recurrence from univariate and multivariable
logistic regression models using mammographic density and its change over time
Variable category obs OR [95% Conf. Interval] P>z
% breast density at baseline per 10% 601 .96 .89 1.04 .349
% breast density at baseline per 10% 464 .95 .87 1.05 .314
12-month change in density per 10% reduction .94 .76 1.17 .599
% breast density at baseline per 10% 525 .97 .89 1.07 .576
24-month change in density per 10% reduction .91 .73 1.12 .370
% breast density at baseline per 10% 506 .96 .87 1.07 .490
60-month change in density per 10% reduction .97 .78 1.20 .754
In univariate and multivariate analyses (Table 3.3), mammographic density and its
changes were not significantly related to the risk of breast cancer recurrence nor to
the probability of remain recurrence free for the whole follow-up.
Table 3.4: ORs for risk of breast cancer recurrence from multivariable logistic regres-
sion models using mammographic density and its change over time adjusted for other
risk-factors*
Variable category obs OR [95% Conf. Interval] P>z
% breast density at baseline per 10% 531 .98 .89 1.08 .627
% breast density at baseline per 10% 398 .96 .85 1.07 .443
12-month change in density per 10% reduction .95 .73 1.23 .689
% breast density at baseline per 10% 466 .96 .86 1.08 .542
24-month change in density per 10% reduction 1.05 .82 1.34 .714
% breast density at baseline per 10% 447 .94 .82 1.08 .374
60-month change in density per 10% reduction 1.11 .87 1.42 .408
Note: (*) age and BMI at baseline, tumour size, hystological grade, nodal and ER status
After adjusting for age, BMI and first breast tumour characteristics (Table 3.4), the
results were not materially different.
We repeated the multivariable logistic regression analyses, adjusted for the other risk
factors and tumour characteristics, in the three treatment arms separately (Table 3.5).
Once again mammographic density and its changes over time appeared ineffective in
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Table 3.5: ORs for risk of breast cancer recurrence from multivariable logistic re-
gression models using mammographic density and its change over time stratified by
treatment arms adjusted for other risk-factors*
Variable category obs OR [95% Conf. Interval] P>z
Anastrazole
% breast density at baseline per 10% 183 .88 .73 1.05 .163
% breast density at baseline per 10% 134 .87 .68 1.12 .286
12-month change in density per 10% reduction 1.08 .58 1.98 .814
% breast density at baseline per 10% 164 .84 .66 1.05 .126
24-month change in density per 10% reduction 1.12 .66 1.91 .623
% breast density at baseline per 10% 167 .83 .64 1.07 .149
60-month change in density per 10% reduction 1.11 .67 1.85 .675
Tamoxifen
% breast density at baseline per 10% 175 1.05 .89 1.25 .558
% breast density at baseline per 10% 130 .94 .77 1.15 .564
12-month change in density per 10% reduction 1.07 .69 1.65 .774
% breast density at baseline per 10% 151 1.14 .93 1.39 .224
24-month change in density per 10% reduction .97 .62 1.50 .881
% breast density at baseline per 10% 140 1.04 .82 1.33 .738
60-month change in density per 10% reduction 1.20 .79 1.84 .394
Combination
% breast density at baseline per 10% 173 .97 .82 1.15 .734
% breast density at baseline per 10% 134 .97 .80 1.17 .727
12-month change in density per 10% reduction .75 .48 1.20 .230
% breast density at baseline per 10% 151 .91 .74 1.11 .340
24-month change in density per 10% reduction 1.08 .74 1.58 .685
% breast density at baseline per 10% 140 .94 .75 1.18 .609
60-month change in density per 10% reduction 1.00 .66 1.51 .994
Note: (*) age and BMI at baseline, tumour size, hystological grade, nodal and ER status
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discriminating subjects who experienced a second tumour event and those who did not,
in every treatment arm.
Table 3.6: HRs for risk of breast cancer recurrence from multivariable Cox survival
regression models using mammographic density and its change over time adjusted for
other risk-factors*
Variable obs HR [95% Conf. Interval] P>z
% breast density at baseline 531 1.00 .99 1.01 .545
% breast density at baseline 398 1.00 .99 1.01 .419
12-month change in density 1.00 .98 1.03 .732
% breast density at baseline 466 1.00 .99 1.01 .553
24-month change in density 1.00 .98 1.02 .825
% breast density at baseline 447 1.00 .98 1.01 .437
60-month change in density .99 .97 1.01 .488
Note: (*) age and BMI at baseline, tumour size, hystological grade, nodal and ER status
Results from the Cox regression analyses (Table 3.6) confirmed those observed with lo-
gistic regression models, and the hazard ratios related to mammographic density and
how it changed after 12, 24 and 60 months were all not significant.
We repeated the analyses reported in Tables 3.3, 3.4, 3.5 and 3.6 without adjusting for
baseline density, and results were not affected: odds ratios and hazard ratios related to
changes in density remained not significant (results not shown).
In Table 3.7 the distributions of mammographic density and its changes over time are
summarised with means and SDs according to histological grade (“(1) well differenti-
ated”, “(2) moderately differentiated” and “(3) poorly differentiated”). Overall mam-
mographic density at baseline appeared lower for subjects who were classified as “(3)
Poor/Undiff.”. These subjects appeared also the least responsive to the treatment in
terms of breast density reduction. In particular after one year of treatment we registered
a trend across the three histological categories, however after 2 and 5 years the women
classified as “(2) Moderate” experienced a reduction similar to the subjects whose cells
were differentiating “(1) Well”, and even the differences between these two groups and
the “(3) Poor/Undiff.” group are no longer significant when assessed with Wilcoxon
rank-sum test (p=.10 and p=.40 for 24 and 60 months respectively). These are further
illustrated in Figure 3.1, that also suggests a similar decreasing trend for each of the
histological grade, but a lower baseline density for subjects with poorly differentiated
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tumours, although not significantly lower, as confirmed in the linear regression analyses
adjusted for age and BMI (Linear regression coefficient for “(3) poorly differentiated”: -
1.3, p=.64). These results did not differ according to treatment arm (results not shown).
Table 3.7: Distribution of mammographic density at baseline and its change after 12,
24 and 60 months according to histological grade
(1) Well (2) Moderate (3) Poor/Undiff
N=137 N=299 N=129
Variable mean (SD) mean (SD) mean (SD) Ptrend
% density at baseline 35.2 (25.6) 35.7 (25.2) 32.6 (23.2) .490
12-month change in density -4.8 (10.3) -3.8 (11.1) -1.4 (8.9) .029
24-month change in density -5.5 (10.4) -5.3 (12.4) -3.8 (9.1) .069
60-month change in density -8.6 (13.6) -7.6 (13.5) -6.0 (9.4) .325
Figure 3.1: Mammographic density over time according to histological grade
Overall results regarding the relationship between nodal status and mammographic den-
sity (Table 3.8) reported nothing significant. Mammographic density and its changes
at the different time-points were similar in subjects whose nodal status was classified
as ”Negative” or ”Positive/Unknown”, suggesting similar decreasing patterns in den-
sity for both groups. There was a baseline significant difference at 24 months, with
the node negative group showing greater changes. This appears evident in Figure 3.2,
where, after the second year of treatment, density in the two groups decline in similar
magnitude although values in the node negative group are consistently lower. Linear
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regression analysis of density over time, adjusted for age and BMI, confirmed this re-
sult. No substantial difference according to nodal status, instead, was observed in the
analyses stratified by treatment arm (results not shown).
Table 3.8: Distribution of mammographic density at baseline and its change after 12,
24 and 60 months according to nodal status
Positive or Unknown Negative
N=210 N=391
Variable mean (SD) mean (SD) PWilcoxon
% density at baseline 35.6 (25.5) 34.7 (24.7) .697
12-month change in density -3.9 (11.0) -3.4 (10.6) .808
24-month change in density -3.7 (12.0) -5.4 (10.8) .086
60-month change in density -6.6 (13.3) -7.9 (12.6) .126
Figure 3.2: Mammographic density over time according to nodal status
Table 3.9 and Figures 3.3-3.4 illustrate how tumour size and mammographic density and
its changes over time interact. Overall no significant difference was recorded in density or
density reductions between subjects who had a first tumour larger than 2 cm and those
who had a smaller tumour. Only after 2 years of treatment the difference is borderline
significant, indicating that women who had a larger first tumour were less responsive
to treatment in terms of density reduction. This result is further supported by Figure
3.3 and by the linear regression analysis of density over time. Average density levels in
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Table 3.9: Distribution of mammographic density at baseline and its change after 12,
24 and 60 months according to tumour size
≤ 2cm >2cm
N=399 N=201
Variable mean (SD) mean (SD) PWilcoxon
% density at baseline 34.7 (25.1) 35.6 (24.7) .605
12-month change in density -3.7 (11.1) -3.3 (10.0) .551
24-month change in density -5.5 (11.5) -3.7 (10.5) .064
60-month change in density -8.0 (13.3) -6.2 (11.8) .173
subjects who had larger primary tumours were consinstently higher (+6%, p<.01). This
difference between the two tumour size groups appeared stronger in the tamoxifen arm
(Figure 3.4.b). However after 5 years of treatment this difference was less notable, even
in the tamoxifen arm (Wilcoxon rank-sum test: p=.10).
Figure 3.3: Mammographic density over time according to tumour size
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Figure 3.4: Distribution of changes in mammographic density after 12 and 24 months
according to tumour size and treatment arm
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Table 3.10: Distribution of mammographic density at baseline and its change after
12, 24 and 60 months according to ER status
Positive Negative
N=455 N=69
Variable mean (SD) mean (SD) PWilcoxon
% density at baseline 35.3 (25.0) 36.2 (25.0) .785
12-month change in density -3.9 (10.5) -5.8 (13.6) .806
24-month change in density -5.0 (11.2) -6.8 (12.9) .884
60-month change in density -7.7 (12.9) -9.0 (14.2) .999
Most of the subjects in our study had a first breast tumour which was oestrogen receptor
positive (455/524). Table 3.10 and Figures 3.5-3.6 display the results of the analyses of
the relationship between ER status and density, both overall and according to treatment
arm. Overall, contrary to expectations, the mean reductions at 12, 24 and 60 months
were consistently larger in the ”Negative” group, however these differences were not
significant. The linear regression analysis of density over time confirmed these results.
The stratified analyses on changes after 24 months highlighted that in the anastrazole
and in the tamoxifen arms the reduction were larger, though not significantly, in the
subjects who had ER positive tumours, as one would expect. In the combination group,
instead, we observe a significant trend in the opposite direction. This is likely due to
the limited number of subjects in the combination arm who had an ER negative tumour
(N=22).
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Figure 3.5: Mmmographic density over time according to ER status
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Figure 3.6: Distribution of changes in mammographic density after 12 and 24 months
according to ER status and treatment arm
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Table 3.11: Distribution of mammographic density at baseline and its change after
12, 24 and 60 months according to HER2 status
Positive Negative
N=26 N=242
Variable mean (SD) mean (SD) PWilcoxon
% density at baseline 33.9 (24.5) 36.7 (27.1) .666
12-month change in density -3.8 (10.1) -2.5 (8.0) .617
24-month change in density -4.8 (10.8) -5.2 (9.8) .889
60-month change in density -7.6 (12.8) -6.6 (10.8) .661
Analyses of the interaction between mammographic density and HER2 status were lim-
ited by the small number of HER2 positive subjects (N=26). Results showed no substan-
tial difference in density and its changes between the two groups (Table 3.11). However,
this observation is qualified by the small proportion of HER2 positive subjects.
Figure 3.7: Association between the amount of protein ki67 and (a) mammographic
density at baseline and its change after (b) 12, (c) 24 and (d) 60 months
Mammographic density and risk of breast cancer recurrence (ATAC study) 81
Figure 3.8: Association between the amount of protein ki67 and the changes in mam-
mographic density after (a,b)12, (c,d) 24 and (e,f) 60 months according to treatment
arm
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Results on density and cellular proliferation, indicated by levels of the protein Ki-67,
are reported in Figures 3.7 and 3.8. They revealed a significant negative relationship
between density and Ki-67, which means that the higher the density the lower the levels
of Ki-67 and vice versa. However, the lower the level of KI-67 at baseline, the larger the
reduction in density for each of the time-points. In other words breasts with a lower level
of cellular proliferation were more likely to experience a higher reduction in the amount
of fibroglandular tissue. This was evident also in both treatment groups, although the
relationship between the level of Ki-67 and the changes in density after 12, 24 and 60
months was stronger in the tamoxifen arm (Figure 3.8).
3.4 Discussion
Mammographic density at baseline appeared unrelated to risk of recurrence, and larger
reductions in density did not necessarily lead to a lower risk of recurrence. Our find-
ings support Porter and colleagues’ previous study [203], reporting a lack of association
between primarily dense breast composition and breast cancer prognosis, whereas they
contradict Cil et al.’s [204] conclusions, that suggested that denser breasts were more
likely to experience a recurrence. In comparison with both these studies, ours had the
advantage of considering density assessed in greater quantitative detail (21 visual cate-
gories), whereas Porter and colleagues had it classified according to the four BIRADS
categories and Cil’s study used a variation of Wolfe’s parenchymal patterns [89]. On the
other hand, in both Porter’s and Cil’s data, mammographic density was assessed on the
contralateral breast on a diagnostic pretreatment mammogram, whereas our study used
as baseline mammograms those taken at enrollment in the ATAC trial. Since entry in
the trial was after the subjects underwent chemotherapy and, often (65% of subjects in
our subset), radiotherapy treatment, density may be affected by these. Chemotherapy
is known to affect mammographic appearance [216], whereas the relationship between
density and radiotherapy has not been established.
Similar changes in density were reported across the treatment arms (Table 3.1), and
unlike previous findings [18–20] a reduction in dense tissue of 10% or higher did not
suggest better outcomes.
Despite being a strong predictor of primary breast cancer, higher levels of density do
not increase risk of death or recurrence. This result is consistent with Gierach and col-
leagues’ findings on a cohort of 9,232 women diagnosed with primary invasive breast
carcinoma [85], that reported that BIRADS density was not related to breast cancer
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death, especially after adjusting for tumour characteristics and risk factors. Likewise,
results from a Danish study [84] indicated that subjects with denser breasts had a higher
incidence of breast tumours, but the proportion of breast cancer deaths among them was
lower than among women with fattier breasts. Thus, risk factors for the development of
breast cancer may not necessarily be the same as factors influencing the risk of death
after developing a breast cancer [84, 85]. Our findings suggest that the same may be
applied to risk of recurrence.
Our analyses did not suggest an association between mammographic density and risk of
more aggressive tumours, as previous studies suggested [80, 211]. However it is known
that dense breasts decrease mammographic sensitivity, resulting in delayed detection
and corresponding to larger and more advanced tumours [207]; and this could explain
why those studies observed such a relationship. A recent meta-analysis on mammo-
graphic density and tumour subtypes [81] suggested that denser breast tissue increases
the risk of developing a breast tumour overall, no matter what the sub-type is.
Our results suggest a modest association of histological grade with changes in density,
consistent with the effect of grade on response to treatment. Good or moderate differ-
entiation in the tumour was associated with a significantly larger reduction in density,
at least for the first two years of treatment. Density appeared affected by nodal status
after the second year of treatment, and the “Negative-node” group experienced higher
reductions in the amount of fibroglandular tissue after 24 months. Our analyses sug-
gested similar findings regarding ER and HER2 status, however the small number of ER
Negative (N=69) and HER2 Positive (N=26) subjects prevented a proper comparison.
In our data, tumour size appeared not influenced by mammographic density, although,
after two years, subjects with smaller tumours experienced significantly greater reduc-
tions in breast dense tissue, especially in the tamoxifen arm (p=.04). This effect was
temporary and after 5 years the difference in reduction between the two groups (≤ 2 cm
and > 2cm) was no longer significant. However studying the trend in density over time
according to tumour size, it was more evident that density was consistently higher and
less likely to reduce in women with larger primary tumours.
It is worth reminding also that for all histological grade, nodal status and tumour size,
there was a borderline significant difference 24 months into the study, always showing
the larger reduction in the category with the better prognosis, i.e. histological grade 1
(“well differentiated”), negative nodal status and smaller primary tumour.
Levels of the proliferation marker Ki-67 were significantly lower in those with higher
density at baseline in this study. In contrast to our findings, Harvey and colleagues
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[217] observed that increased breast density was significantly associated with Ki-67 ac-
tivity in the ducts. However their analyses considered only 56 women and focused on the
effect of the use of hormone replacement therapy and the histologic changes it caused,
whereas our sample comprised 268 subjects. Another study of 55 tamoxifen users [218]
reported no correlation between breast density and cell proliferation. These findings
may also be due to the limited sample size. Furthermore, in our data, a lower baseline
level of Ki-67 corresponded to a larger reduction in fibroglandular tissue. This may
be partly due to the initial higher levels of density in those with low Ki-67, however
we observed also a stronger association between Ki-67 and reduction in density in the
tamoxifen arm. Since this phenomenon is affected by treatment given, this suggestes
that it does indeed reflect a biological association. The higher the levels of proliferation
at baseline, the higher the chance that subjects would experience no change or even
an increase in density over the years of treatment, particularly in the tamoxifen arm.
There is extensive clinical evidence that tamoxifen decreases cell-proliferation in breast
tissue [218]. In 2005 Dowsett et al. compared the effect on levels of Ki-67 of treatment
with anastrazole and tamoxifen, alone or combined [215]. Results showed significantly
greater suppression of the proliferation marker within the anastrazole arm, which could
explain the weaker correlation between Ki-67 and density changes we observed in that
treatment group. Unfortunately we only had data on Ki-67 levels at baseline, so we
could not compare the changes in both suppression of proliferation and breast density
during treatment. Nevertheless, we can hypothesize that increased cell proliferation
would limit reductions in density, and therefore the higher the level of Ki-67, the lesser
the resulting decrease of breast density. If anastrazole is more effective than tamoxifen
in suppressing proliferation, but not in decreasing density, than the relationship between
changes in fibroglandular tissue and baseline level of Ki-67 would be weaker in this arm,
as we observed. Further investigations on this relationship are needed, as levels of Ki-67
could be crucial to understanding how aromatase inhibitors and tamoxifen affect breast
cancer risk and the tissue composition of the breast.
This study had limitations. Firstly, because therapy with aromatase inhibitors was a
major focus, it comprised only post-menopausal women, thus our findings may not apply
to premenopausal breast cancer patients. Secondly, as we noted above, mammographic
density was assessed after chemotherapy and, in most subjects (65%), radiotherapy,
which may have affected not only the breast composition but also how this tissue re-
sponds to treatment, as well as the relationship between density and Ki-67. Moreover,
our sample included relatively few cases of ER negative or HER2 positive tumours.
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Figure 3.9: Comparison of percent density assessments using images scanned with
VIDAR (old scanner) and ARRAY (new scanner)
Hence our results regarding the relationship between density and these two tumour cat-
egories, as well as their response to treatment, are not conclusive. Larger studies focusing
on these two tumour subtypes and non-hormonal treatments may be needed. Finally, it
may be hypothesised that results might have been influenced by a possible sub-optimal
quality of the images, because of the scanner used (VIDAR). To verify if this was the
case, a batch of mammograms (N=103) were re-scanned with a new machine (Array
2905HD Laser Film Digizer) and we compared density assessments using both images
for each mammogram (Figure 3.9). Results showed a good agreement between the two
scanners (Pearson’s correlation coefficient: 86.4%) and reassured usabout the reliability
of the findings we reported in this chapter (Intraclass correlation coefficient: 76%, 95%
CI (67.8%, 84.2%)).
In conclusion, mammographic density at baseline did not predict risk of recurrence and
greater reductions in the proportion of dense tissue were not necessarily suggesting bet-
ter outcomes of the treatment. However, subjects with primary invasive tumour of poor
histological grade experienced smaller reductions in breast density. After two years in
the study, the differences in density were more evident also between subjects with differ-
ent nodal status and size of the primary tumour, with larger reductions in the negative
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node and smaller tumour groups. Further, women with a higher baseline level of cell
proliferation were less likely to experience changes in breast composition. Thus, we can-
not yet assign a role for density in management of such patients. Further studies are
needed to determine the role mammographic density plays in the pathways of adjuvant
treatments, histologic factors and improved survival, as well as the effect of radiotherapy
on breast tissue composition.
Chapter 4
Mammographic density and
breast cancer risk in a young
population at enhanced familial
risk (FH01 study)
4.1 Introduction
In UK the NHS Breast Screening Programme (NHSBSP) invites women aged 50 to 70
for mammographic screening every 3 years, and the age range is currently being ex-
tended from 47 to 73. The majority of women in their 40s are, therefore, not included
because it has been observed that screening in women aged 40 to 49 has lower sensitivity
and, due to the lower incidence in this age group, fewer lives are saved in return for the
financial and human costs [219]. However, there is evidence that targeted screening in
this age group could lower breast cancer mortality in women at higher than average risk
by detecting tumours at an earlier stage [13, 73, 188, 220]. Since family history of breast
cancer is a well-established indicator of risk of developing the disease [1, 221], in the UK,
many women under 50, i.e. not yet eligible for the national screening programme, are
offered early mammographic screening when found to be at moderate or high familial
risk.
High breast density reduces screening sensitivity as well as increasing risk of developing
a breast tumour [2, 74]. As noted in the previous chapters, mammographic density is
a reflection of the amount of connective and epithelial tissue in the breast [222] and
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declines with age [88]. More precisely the proportion of epithelial tissue increases until
age 30-40 years, then declines progressively [88], and between the ages of 40 and 49
years the majority of women have high- or very high- density breasts, respectively 57%
and 17% of the subjects, according to BIRADS classification [223]. However, because
of its strong independent association to breast cancer risk, it has been suggested that
density should also be considered when deciding the appropriate surveillance regimen
for a high-risk patient [73].
An important question to be clarified before such a strategy could be adopted as policy
is whether density adds further information on risk in a population already defined as at
enhanced risk, even after adjustment for other risk factors. FH01 is a study recruiting
precisely such a population. It is a longitudinal, single arm study of five years of mam-
mographic surveillance in 6,710 women aged 40-49, at moderate familial risk of breast
cancer [188, 224].
The present investigations were run on a case-control study nested within FH01 [188,
224]. Our primary objective was to evaluate mammographic density as a risk factor for
breast cancer, investigating its ability to discriminate between cases and controls in this
population, that have not only been classified as high risk because of their family history
[188, 224], but also have a predominant proportion of high density subjects because of
the age range [223]. Secondly, we examined the interactions between density and other
breast cancer risk factors, e.g. age at menarche and parity, and how these affected the
association between density and risk of breast cancer. Finally, we studied the additional
effect of density adjusted for a 10-year risk of breast cancer established from multiple
familial and non familial risk factors [1]. The results of the work in this chapter neces-
sarily pertain only yo a younger population at enhanced familial risk. However, there
is a need to clarify the role of mammographic density in further risk delineation in this
risk group. The effect of density in such risk groups is considerably less well researched
than in the general population.
4.2 Materials and Methods
4.2.1 Study setting and population
The FH01 study [188, 224] was designed to evaluate the effectiveness of annual mam-
mographic screening in women younger than 50 years who have a clinically significant
family history of breast cancer. Across the UK, a total of 6,710 women, aged 40-49
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years, were enrolled between 2003 and 2007 because of their moderate familial risk of
developing breast cancer. The intervention offered every subject annual mammography
over 5 years and the study was concluded in 2009 [188, 224].
Here we report on a case-control study nested within FH01, with 103 breast cancer
cases, each matched by age and time in the study, until diagnosis, to either one or two
controls free from breast cancer. There were a total of 195 controls.
Mammographic density was assessed on the last mammogram prior to diagnosis for the
cases, and for the controls density was assessed on the image closest to this in time.
Density measures were estimated, by trained radiologists (Professor R.M.L. Warren, I.
Warsi, Dr. M. Kataoka), using the semi-automatic computerised interactive threshold-
ing programme (Cumulus) [28]. This method provides estimates of total breast area
and absolute density (cm2), allowing percent density and non-dense breast area to be
computed.
The dataset included other risk factors for breast cancer: age at menarche, parity, age
at first live birth, use of hormone replacement therapy and menopausal status. We also
had absolute risk estimates using the Tyrer-Cuzick model. The Tyrer-Cuzick model
provides 10 year risk estimates for developing breast cancer based on extensive family
history information, multiple other breast cancer risk factors mainly representing expo-
sure to endogenous oestrogen, and benign breast disease [1].
4.2.2 Statistical Analyses
The distributions of demographic and other variables at the first examination are sum-
marised as percentages for discrete variables, or means and SDs for continuous variables.
Percent density was categorised following Boyd’s classification (“< 5%”, “5 − 10%”,
“10 − 25%”, “25 − 50%”, “50 − 75%” and “> 75%”) [28] and then reduced to five
and four categories, collating first “< 5%” with “5 − 10%” and then “50 − 75%” with
“> 75%”, in order to have more than five subjects for each level of density, both in cases
and controls.
The relationship between breast cancer risk and density, both percent and absolute,
was assessed using odds ratios obtained from conditional logistic regression, taking into
account the matching of the study design. The relationship between density estimates
and other variables was investigated both graphically and using the Pearson’s corre-
lation coefficient, the Wilcoxon rank-sum test and the non-parametric test for trend
[214], as appropriate. Multivariable conditional logistic regression was used to adjust
for other risk factors. In order to include nulliparous subjects in the conditional logistic
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regression model with age at first pregnancy, we created a new discrete variable age
at first pregnancy * with the three following categories “Under 30”, “30 or more” and
“Nulliparous”. The relationship between breast cancer risk and density was also studied
adjusted for the Tyrer-Cuzick estimate of 10-year risk of breast cancer. However, since
these estimates are based on age, besides age at menarche, parity, menopausal status
and family history, conditional logistic would have led to adjusting for age twice (both
in the model and in the matching). Thus standard unconditional logistic was performed
instead for this analysis.
Secondary analyses, including only premenopausal subjects, the majority of this popu-
lation (75%), were also performed.
All analyses were performed with STATA software version 11.
4.3 Results
The characteristics of the 103 case subjects and 195 control subjects are shown in Table
4.1. On average the subjects underwent the mammographic examination used for the
density assessment 3 months after their 44th birthday and had about 2-years follow-
up in the study at that time. They experienced their first period aged 12 years and
8 months and gave birth for the first time when they were 26. The modal number of
children was two (41%), only 14 % had been prescribed hormone replacement therapy
and the majority (75%) were premenopausal.
Percent density and non-dense area had similar mean values and standard deviations
in the two groups. Conversely, absolute density and, consequently, total breast area
had substantial differences in distribution, both mean and SD, between case and control
subjects.
Mammographic density and breast cancer risk in a young population (FH01 study) 91
Table 4.1: Characteristics of the study sample
cases controls
N=103 N=195
Age at mammogram in years
mean (SD) 44.38 (2.33) 44.21 (2.18)
Years of follow-up
mean (SD) 2.32 (1.63) 2.09 (1.49)
Menopausal status (%)
Pre-menopausal 86 (83.50) 148 (75.90)
Post-menopausal 5 (4.85) 17 (8.72)
Unknown 12 (11.65) 30 (15.38)
Age at menarche in years
mean (SD) 12.84 (1.60) 12.63 (1.43)
Number of live births (%)
0 19 (19.79) 34 (18.48)
1 16 (16.67) 28 (15.22)
2 39 (40.63) 83 (45.11)
3 20 (20.83) 26 (14.13)
≥4 2 (2.08) 13 (7.07)
Unknown 7 - 11 -
Age at first live birth in years
mean (SD) 26.70 (5.79) 25.58 (5.23)
Hormone replacement therapy or HRT (%)
Users 13 (13.54) 28 (15.82)
Tyrer-Cuzick 10-years estimate of risk, mean (SD)
Absolute risk .068 (.041) .057 (.039)
Relative risk 3.71 (2.48) 3.06 (2.23)
Breast composition,mean (SD)
Absolute density (cm2) 56.86 (41.38) 47.80 (31.74)
Percent density (%) 36.71 (19.29) 34.55 (19.21)
Non-dense area (cm2) 105.38 (65.61) 100.54 (62.48)
Total breast area (cm2) 162.24 (73.77) 148.34 (61.88)
Mammographic density and breast cancer risk in a young population (FH01 study) 92
Figure 4.1: Distribution of (a) absolute and (b) percent density among cases and
controls
Figure 4.1 and Table 4.2 show in more detail how the distribution of absolute and per-
cent density varies between cases and controls. In both it is seen that the median for
absolute density in the cases is higher than that for the controls, although the Wilcoxon
rank-sum test found this difference to be weakly significant (p=.09). On the other hand
percent density appeared to be distributed similarly in the two groups.
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Table 4.2: Distribution of cases and controls in density categories based on quintiles
of the controls distribution
cases (%) controls (%) Total (%)
Absolute density
0-20.77 cm2 13 (12.62) 38 (19.49) 51 (17.11)
20.77-32.41 cm2 13 (12.62) 39 (20.00) 52 (17.45)
32.41-49.93 cm2 24 (23.30) 39 (20.00) 63 (21.14)
49.93-77.02 cm2 32 (31.07) 39 (20.00) 71 (23.83)
≥77.02 cm2 21 (20.39) 40 (20.51) 61 (20.47)
Total 103 (100.00) 195 (100.00) 298 (100.00)
Percent density
0-14.58 % 14 (13.59) 38 (19.49) 52 (17.45)
14.58-29.93 % 26 (25.24) 39 (20.00) 65 (21.81)
29.93-40.86 % 20 (19.42) 39 (20.00) 59 (19.80)
40.86-52.44 % 18 (17.48) 39 (20.00) 57 (19.13)
52.44-100 % 25 (24.27) 40 (20.51) 65 (21.81)
Total 103 (100.00) 195 (100.00) 298 (100.00)
4.3.1 Mammographic density and breast cancer risk
Table 4.3 shows how mammographic density, assessed in percent and absolute terms, re-
lates to breast cancer risk, using both control quintiles and a continuous effect expressed
per 10-unit increase, and adjusting for non-dense area, which has been suggested as a
proxy for BMI [33, 225, 226]. Categorisation by quintiles of the distribution among con-
trols did not seem able to discriminate between cases and controls, as was also the case
in Table 4.2. However, we observed a significant continuous effect of absolute density,
in discriminating cases and controls, especially after adjusting for non-dense area. This
may be related to the fact that among cases, absolute density has a skewed distribution,
with a longer tail for extreme values (Figure 4.1.a).
We also categorised percent density using Boyd’s cut-off points (Table 4.4), and condi-
tional logistic regression led to significantly and steadily increasing ORs (p=.034), after
adjusting for non-dense area (Table 4.5). To be more specific, subjects with percent
density between 10 and 25 % were three (3.1) times more likely to have breast cancer
than women with a breast density of less than 10%, when they have similar non-dense
area. This difference in risk increases with the categories with up to a 12.6 (95% CI
(1.40,114.06)) OR between the two extreme density groups, i.e. “< 10% dense” and
“> 75% dense” (Table 4.5).
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Table 4.3: ORs for risk of developing breast cancer from conditional logistic regression
models using mammographic density
Factor category obs OR [95% Conf. Interval] P>z
absolute density 0- 20.77 cm2 292 1.00 - - .099
20.77-32.41 cm2 1.11 0.44 2.79
32.41-49.93 cm2 2.13 0.87 5.20
49.93-77.02 cm2 2.75 1.18 6.42
> 77.02 cm2 1.57 0.67 3.72
absolute density per 10cm2 292 1.06 0.99 1.14 .064
percent density 0- 14.58% 292 1.00 - - .614
14.58-29.93% 1.84 0.82 4.11
29.93-40.86% 1.41 0.63 3.15
40.86-52.44% 1.19 0.53 2.67
52.44-100% 1.63 0.74 3.59
percent density per 10% 292 1.05 0.93 1.19 .449
absolute density per 10cm2 292 1.07 1.00 1.15 .040
non-dense area per 10cm2 1.02 0.98 1.07 .257
percent density per 10% 292 1.15 0.97 1.37 .105
non-dense area per 10cm2 1.04 0.99 1.10 .111
These results could have been influenced by the scarcity of subjects in the highest cat-
egory (Table 4.4), so we repeated the conditional logistic analyses combining the two
highest categories in “> 50% dense” (Table 4.6). Here again we observed a significant
and steady increase in the ORs across Boyd’s categories (p=.048), and the odds ratio
between the two extreme density groups was 4.43 (1.26,15.58).
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Table 4.4: Distribution of percent density, categorised using Boyd’s cut-off points (5
categories)
Categories controls (%) cases (%) Total (%)
<10% 27 (6.93) 7 (13.99) 34 (11.56)
10-25% 38 (21.78) 22 (19.69) 60 (20.41)
25-50% 79 (44.55) 45 (40.93) 124 (42.18)
50-75% 47 (23.76) 24 (24.35) 71 (24.15)
>75% 2 (2.97) 3 (1.04) 5 (1.70)
Total 193 (100.00) 101 (100.00) 294 (100.00)
Table 4.5: ORs for risk of developing breast cancer from conditional logistic regression
models using mammographic percent density classified in Boyd’s density categories (5)
and adjusted for amount of non-dense tissue, n=292
Factor category OR [95% Conf. Interval] P>z
percent density <10% dense 1.00 - - .231
10-25% dense 2.24 .83 6.05
25-50% dense 2.10 .84 5.23
50-75% dense 2.00 .76 5.23
>75% dense 5.19 .71 37.70
percent density <10% dense 1.00 - - .034
10-25% dense 3.09 1.04 9.23
25-50% dense 3.81 1.22 11.86
>50% dense 4.25 1.20 15.07
>75% dense 12.62 1.40 114.06
non-dense area per 10 cm2 1.06 1.00 1.12 .046
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Table 4.6: ORs for risk of developing breast cancer from conditional logistic regression
models using mammographic percent density classified in Boyd’s density categories and
adjusted for amount of non-dense tissue, n=292
Factor category OR [95% Conf. Interval] P>z
percent density <10% dense 1.00 - - .279
10-25% dense 2.26 .84 6.09
25-50% dense 2.08 .84 5.17
>50% dense 2.13 .82 5.52
percent density <10% dense 1.00 - - .048
10-25% dense 3.08 1.04 9.17
25-50% dense 3.69 1.19 11.42
>50% dense 4.43 1.26 15.58
non-dense area per 10 cm2 1.06 1.00 1.11 .070
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4.3.2 Mammographic density and other risk factors
Figure 4.2 shows the relationship between age and mammographic density, both in ab-
solute and percent terms. Absolute density did not appear to be correlated with age
(p=.88) whereas percent density did, but only weakly (p=.08). However, it is reason-
able to believe that we observed this because of the design of the study, that included a
limited age-range.
Figure 4.2: Association between age at mammogram and mammographic density
measures, (a) absolute and (b) percent
The associations between density measures and risk factors for breast cancer (use of
HRT, age at menarche, age at first live pregnancy and number of live pregnancies)
are shown in Figures 4.3 and 4.4. The unexpected significantly negative association
between the use of HRT and both percent and absolute density (Figures 4.3.a and
4.4.a) was possibly due to the strong confounding effect of menopause. Apart from this,
absolute density appeared unrelated to the other risk factors for breast cancer (Figure
4.3). On the other hand, percent density was significantly negatively related to parity
and positively related to age at first birth (Figures 4.4.c and .d).
We repeated these analyses using only controls (results not shown), and the results were
similar to those using the whole dataset.
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Figure 4.3: Association between absolute density (cm2) and risk factors for breast
cancer
Figure 4.4: Association between percent density (%) and risk factors for breast cancer
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The risk factors available were included in multivariable conditional logistic regression
models, along with density measures, to study their impact on the association between
density and breast cancer risk. Results are shown in Tables 4.7, 4.8 and 4.9. Absolute
density was more strongly associated with breast cancer risk than percent density, after
adjustment for other risk factors for breast cancer. Moreover, the association between
absolute density and breast cancer risk appeared independent of other risk factors. The
ORs were consistently significant at about 1.08 per 10 cm2, increasing slightly to 1.10
per 10 cm2 after adjusting for age at first pregnancy (Table 4.9), possibly related to the
exclusion of nulliparous subjects in the analysis (N=174). This hypothesis is supported
by the fact that when nulliparous women were included in the model (Table 4.10) the
OR per 10 cm2 of dense tissue was again 1.07 (1.00,1.15), after adjusting for non-dense
area, consistent with the results obtained from the analyses with the other risk factors.
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Table 4.7: ORs for risk of developing breast cancer from conditional logistic regression
models using mammographic density measures adjusted for use of hormone replacement
therapy and age at menarche
Factor category obs OR [95% Conf. Interval] P>z
absolute density per 10cm2 261 1.07 1.00 1.15 .044
hrt Never 1.00 - - .977
Currently or previous 0.99 0.44 2.21
percent density per 10% 261 1.11 0.96 1.27 .155
hrt Never 1.00 - - .989
Currently or previous 1.01 0.44 2.28
absolute density per 10cm2 261 1.08 1.00 1.16 .039
non-dense area per 10cm2 1.01 0.97 1.06 .648
hrt Never 1.00 - - .910
Currently or previous 0.95 0.42 2.17
percent density per 10% 261 1.19 0.99 1.43 .063
non-dense area per 10cm2 1.04 0.98 1.10 .223
hrt Never 1.00 - - .957
Currently or previous 0.98 0.43 2.22
absolute density per 10cm2 240 1.08 1.01 1.16 .033
age at menarche per year 1.10 0.92 1.31 .295
percent density per 10% 240 1.11 0.97 1.28 .122
age at menarche per year 1.08 0.91 1.28 .400
absolute density per 10cm2 240 1.09 1.01 1.17 .026
non-dense area per 10cm2 1.02 0.97 1.06 .509
age at menarche per year 1.11 0.93 1.33 .247
percent density per 10% 240 1.23 1.02 1.50 .032
non-dense area per 10cm2 1.05 0.99 1.11 .125
age at menarche per year 1.11 0.93 1.32 .264
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Table 4.8: ORs for risk of developing breast cancer from conditional logistic regression
models using mammographic density measures adjusted for parity
Factor category obs OR [95% Conf. Interval] P>z
absolute density per 10cm2 259 1.07 1.00 1.15 .050
parity 0 1.00 - - .677
1 0.98 0.39 2.47
2 0.80 0.41 1.55
3 1.36 0.61 3.03
≥4 0.33 0.07 1.70
percent density per 10% 259 1.08 0.94 1.24 .286
parity 0 1.00 - - .666
1 0.99 0.40 2.48
2 0.84 0.43 1.63
3 1.31 0.59 2.90
≥4 0.32 0.06 1.63
absolute density per 10cm2 259 1.08 1.00 1.16 .040
non-dense area per 10cm2 1.01 0.97 1.06 .534
parity 0 1.00 - - .701
1 0.96 0.38 2.42
2 0.79 0.41 1.54
3 1.38 0.62 3.08
≥4 0.34 0.07 1.73
percent density per 10% 259 1.16 0.96 1.40 .128
non-dense area per 10cm2 1.03 0.97 1.10 .269
parity 0 1.00 - - .773
1 0.97 0.39 2.45
2 0.84 0.43 1.63
3 1.37 0.61 3.07
≥4 0.36 0.07 1.84
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Table 4.9: ORs for risk of developing breast cancer from conditional logistic regression
models using mammographic density measures adjusted for age at first live pregnancy
Factor category obs OR [95% Conf. Interval] P>z
absolute density per 10cm2 174 1.10 1.01 1.19 .025
age at 1st pregnancy per year 1.03 0.97 1.09 .308
percent density per 10% 174 1.14 0.97 1.34 .104
age at 1st pregnancy per year 1.03 0.97 1.09 .397
absolute density per 10cm2 174 1.10 1.01 1.19 .029
non-dense area per 10cm2 1.00 0.95 1.06 .974
age at 1st pregnancy per year 1.03 0.97 1.09 .310
percent density per 10% 174 1.20 0.97 1.49 .094
non-dense area per 10cm2 1.03 0.96 1.10 .479
age at 1st pregnancy per year 1.03 0.97 1.09 .412
Table 4.10: ORs for risk of developing breast cancer from conditional logistic re-
gression models using mammographic density measures adjusted for age at first live
pregnancy, including nulliparous women
Factor category obs OR [95% Conf. Interval] P>z
absolute density per 10cm2 292 1.06 .99 1.13 .076
age at 1st pregnancy* Under 30 1.00 - - .414
30 or more 1.60 .84 3.08
Nulliparous 1.22 .69 2.16
percent density per 10% 292 1.04 .92 1.18 .534
age at 1st pregnancy* Under 30 1.00 - - .415
30 or more 1.62 .85 3.10
Nulliparous 1.22 .68 2.17
absolute density per 10cm2 292 1.07 1.00 1.15 .048
non-dense area per 10cm2 1.02 .98 1.07 .271
age at 1st pregnancy* Under 30 1.00 - - .370
30 or more 1.58 .82 3.03
Nulliparous 1.25 .70 2.22
percent density per 10% 292 1.14 .96 1.35 .149
non-dense area per 10cm2 1.04 .99 1.10 .143
age at 1st pregnancy* Under 30 1.00 - - .432
30 or more 1.55 .81 2.98
Nulliparous 1.21 .68 2.16
Mammographic density and breast cancer risk in a young population (FH01 study) 103
Table 4.11: ORs for risk of developing breast cancer from conditional logistic regres-
sion models using mammographic density measures adjusted for the other available risk
factors
Factor category obs OR [95% Conf. Interval] P>z
absolute density per 10 cm2 143 1.11 1.01 1.21 .025
non-dense area per 10 cm2 1.00 .94 1.07 .982
hrt Never 1.00 - - .301
Current or previous .47 .12 1.95
age at menarche per year 1.06 .82 1.36 .665
age at 1st pregnancy per year 1.04 .96 1.12 .304
parity per pregnancy 1.06 .64 1.76 .823
Table 4.12: ORs for risk of developing breast cancer from conditional logistic regres-
sion models using mammographic density measures adjusted for the other available risk
factors, including nulliparous women
Factor category obs OR [95% Conf. Interval] P>z
absolute density per 10 cm2 216 1.08 1.00 1.16 .056
non-dense area per 10 cm2 1.01 .96 1.06 .660
hrt Never 1.00 - - .180
Current or previous .47 .16 1.42
age at menarche per year 1.09 .91 1.31 .360
age at 1st pregnancy* Under 30 1.00 - - .958
30 or more 1.39 .65 2.95
Nulliparous .74 .23 2.41
parity per pregnancy .77 .50 1.20 .252
The inclusion of all risk factors in a conditional logistic regression model (Table 4.11)
reduced the number of observations to 143, mostly because of missing values, but also
because 83 subjects were dropped by the conditional analyses due to all positive or all
negative outcomes. Nevertheless absolute density appeared strongly and significantly
associated with breast cancer risk after adjusting for the other available risk factors
(non-dense area, use of HRT, age at menarche, age at first pregnancy and number of
live births), with an OR of 1.11 (1.01,1.21) per 10 cm2 of dense tissue. This analysis
was repeated including the nulliparous women and results are displayed in Table 4.12.
The number of observations increased to 216 and the OR per 10 cm2 of dense tissue
was 1.08 (1.00,1.17), in agreement with the previous results of independence between
absolute density and the other risk factors, except for non-dense area.
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4.3.3 Mammographic density and Tyrer-Cuzick 10-year risk estimate
Figure 4.5: Association between mammographic density measures, (a) absolute and
(b) percent, and the Tyrer-Cuzick 10-year personal risk [1]
The relationship between mammographic density measures and Tyrer-Cuzick 10-year
personal risk estimates is displayed in Figure 4.5. In both cases there is a negligible and
non-significant association.
After adjusting for the Tyrer-Cuzick 10-year relative risk of developing breast cancer
(Tables 4.13 and 4.14), the association between absolute density and breast cancer risk
was not altered, in that the OR per 10 cm2 of dense tissue was 1.08 (1.00,1.16) without
adjusting for non-dense area and 1.09 (1.01,1.17) after adjustment. This indicates that
absolute density added risk information to the Tyrer-Cuzick risk estimates and could
potentially improve risk stratification and delineation of high-risk groups.
In the analysis using percent density classified in Boyd density categories, Table 4.14,
the association between density and breast cancer risk was slightly weakened by adjust-
ment for Tyrer-Cuzick risk: the ORs ranged between 2.61 and 3.90, and, overall, lost
significance.
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Table 4.13: ORs for risk of developing breast cancer from unconditional logistic
regression models using mammographic density measures adjusted for non dense area
and Tyrer-Cuzick estimates for 10-year personal risk [1]
Factor category obs OR [95% Conf. Interval] P>z
absolute density per 10cm2 292 1.08 1.00 1.16 .038
personal risk <.06 risk 1.00 - - <.001
≥.06 risk 2.95 1.75 4.98
percent density per 10% 292 1.06 .93 1.21 .375
personal risk <.06 risk 1.00 - - <.001
≥.06 risk 2.93 1.74 4.92
absolute density per 10cm2 292 1.09 1.01 1.17 .024
non-dense area per 10cm2 1.02 .98 1.07 .240
personal risk <.06 risk 1.00 - - <.001
≥.06 risk 3.01 1.78 5.10
percent density per 10% 292 1.19 .99 1.42 .062
non-dense area per 10cm2 1.05 1.00 1.11 .068
personal risk <.06 risk 1.00 - - <.001
≥.06 risk 3.01 1.78 5.08
Table 4.14: ORs for risk of developing breast cancer from unconditional logistic
regression models using mammographic percent density classified in Boyd’s density
categories and adjusted for amount of non-dense tissue and Tyrer-Cuzick estimates for
10-year personal risk [1], N=294
Factor category OR [95% Conf. Interval] P>z
percent density <10% dense 1.00 - - .079
10-25% dense 2.61 .87 7.86
25-50% dense 3.27 1.01 10.56
>50% dense 3.90 1.05 14.52
non-dense area per 10 cm2 1.05 1.00 1.11 .068
personal risk < .06 risk 1.00 - - <.001
≥ .06 risk 2.79 1.65 4.71
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4.3.4 Results for premenopausal women
As noted above, the majority of women were premenopausal, but there was a minority
of postmenopausal women, which appeared to introduce confounding to the relationship
between HRT and density, and may have other unforeseen confounding effects.
Logistic regression analyses were therefore repeated on the premenopausal subset (78.5%)
of the sample. In the univariate analyses, every additional 10 cm2 of dense tissue was
associated with a 12% increase in odds of breast cancer (OR: 1.12 (1.03,1.22)), Table
4.15. Even after adjusting for other risk factors (Table 4.16), results remained strongly
significant and the OR ranged between 1.12 and 1.14.
Among premenopausal women, percent density also had a significant association with
breast cancer risk, after adjustment for non-dense area or other risk factors (Tables 4.15
and 4.16). However, it appears that adjusting percent density for non-dense breast area
gives similar information as we would obtain from absolute density.
Table 4.15: ORs for risk of developing breast cancer from conditional logistic results
for density in premenopausal women
Factor category obs OR [95% Conf. Interval] P>z
absolute density 0- 20.77 cm2 200 1.00 - - .026
20.77-32.41 cm2 1.59 .51 5.00
32.41-49.93 cm2 2.62 .85 8.10
49.93-77.02 cm2 3.54 1.21 10.36
> 77.02 cm2 2.47 .85 7.18
absolute density per 10cm2 200 1.12 1.03 1.22 .008
percent density 0- 14.58% 200 1.00 - - .194
14.58-29.93% 1.97 .72 5.41
29.93-40.86% 1.72 .63 4.67
40.86-52.44% 1.16 .44 3.04
52.44-100% 2.53 .99 6.49
percent density per 10% 200 1.13 0.97 1.31 .108
absolute density per 10cm2 200 1.14 1.04 1.24 .005
non-dense area per 10cm2 1.03 0.98 1.08 .228
percent density per 10% 200 1.34 1.07 1.67 .009
non-dense area per 10cm2 1.08 1.01 1.15 .033
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Table 4.16: ORs for risk of developing breast cancer from conditional logistic regres-
sion models using mammographic density measures adjusted for other risk factors for
breast cancer, in premenopausal women
Density measure adjusted for obs OR [95% Conf. Interval] P>z
Absolute density hrt 183 1.13 1.03 1.23 .007
per 10 cm2
hrt 183 1.14 1.04 1.25 .005
non-dense area
age at menarche 180 1.12 1.03 1.22 .009
age at menarche 180 1.14 1.04 1.25 .005
non-dense area
parity 185 1.12 1.03 1.22 .008
parity 185 1.14 1.04 1.25 .005
non-dense area
age at 1st pregnancy 119 1.16 1.04 1.28 .007
age at 1st pregnancy 119 1.15 1.03 1.29 .011
non-dense area
Percent density hrt 183 1.20 1.02 1.41 .030
per 10 %
hrt 183 1.42 1.12 1.79 .003
non-dense area
age at menarche 180 1.15 0.98 1.34 .078
age at menarche 180 1.37 1.09 1.73 .008
non-dense area
parity 185 1.13 0.96 1.32 .137
parity 185 1.32 1.05 1.66 .018
non-dense area
age at 1st pregnancy 119 1.26 1.04 1.53 .020
age at 1st pregnancy 119 1.37 1.04 1.79 .024
non-dense area
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On this premenopausal subset, absolute density also added significant risk information
to the Tyrer-Cuzick personal risk estimates, with or without adjustment for non-dense
area, Table 4.17. The ORs were smaller than those obtained in the previous conditional
logistic regression analyses, possibly because of use of standard unconditional analyses.
After adjustment for Tyrer-Cuzick risk estimates, percent density had a significant effect
only after adjusting for non-dense area which was also significantly associated with risk
in this model. This is not surprising, since percent density and non-dense breast area
together give information similar to absolute density on its own.
Table 4.17: ORs for risk of developing breast cancer from unconditional logistic results
for density adjusted for Tyrer-Cuzick estimates for risk [1], in premenopausal women
Factor category obs OR [95% Conf. Interval] P>z
absolute density per 10cm2 232 1.09 1.01 1.18 .027
personal risk <.06 risk 1.00 - - .002
≥.06 risk 2.50 1.40 4.47
percent density per 10% 232 1.10 .95 1.28 .189
personal risk <.06 risk 1.00 - - .002
≥.06 risk 2.51 1.41 4.46
absolute density per 10cm2 232 1.10 1.02 1.19 .019
non-dense area per 10cm2 1.02 .98 1.07 .288
personal risk <.06 risk 1.00 - - .002
≥.06 risk 2.55 1.42 4.58
percent density per 10% 232 1.29 1.05 1.59 .017
non-dense area per 10cm2 1.07 1.01 1.13 .032
personal risk <.06 risk 1.00 - - .001
≥.06 risk 2.61 1.45 4.68
4.4 Discussion
In these analyses with 298 subjects, including 103 breast cancer cases, at enhanced fa-
milial risk of breast cancer [188], an association between mammographic density and
breast cancer risk was evident, especially when expressing density continuously and in
absolute terms (cm2). This result is consistent with other studies, on the general popu-
lation, where it has been observed that an absolute measure of density is more predictive
of risk than percent density [32, 33, 225–227] [Chapters 5 and 7], possibly because it is
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a closer estimate of the amount of stromal and fibroglandular tissue and is less affected
by confounding with BMI.
Although adjustment of percent density estimates for non-dense area has been consid-
ered a reasonable substitute for adjusting for BMI, interpretation is problematic. Firstly,
the structural negative collinearity of percent density and non-dense area may lead to
instability of estimates. Secondly, empirically we observed that risk prediction using
absolute density unadjusted was similar to that using percent density with adjustment
for non-dense areas, both in terms of effect size and information as measured by log-
likelihood differences.
A 10 cm2 increase in dense tissue corresponded to an increase in the odds of about 8%,
when having a similar amount of non-dense tissue, and this result was not altered by
adjusting for other risk factors. This independence of the association of density and
breast cancer risk from other risk factors is consistent with observations in other studies
[13, 16, 92].
Another of our results was that, in our high or moderate familial risk population, the risk
association was more evident in the premenopausal majority. A possible explanation is
the fact that some high risk women experienced a premature menopause because of a hys-
terectomy and/or oophorectomy, and therefore the menopausal status for these subjects
was unclear and thus sometimes classified as “unknown”. To support this hypothesis
we repeated the conditional logistic regression analyses excluding only the subjects with
“unknown” menopausal status. On the remaining 232 subjects, we observed an OR of
1.11 (1.02,1.20) per 10 cm2 of dense tissue after adjusting for non-dense breast area.
The reduction of the sample, from 298 to 232, could help explain this change. Never-
theless, further investigations on larger samples of these under 50, high-risk women with
postmenopausal or unclear menopausal status, could provide a clearer explanation.
In our study, age at mammogram did not appear to have an effect on either absolute
or percent density, unlike most of the previous literature [91, 228]. This is most likely
to be due to the limited age range available in our study, rather than to the enhanced
familial risk that characterised the subjects in FH01. However, in another study with
volumetric assessment of density [Chapter 6], we observed that absolute density did not
vary with increasing age, whereas the percent density did, because of a steady increase
with age in non-dense breast volume.
Despite HRT being known to increase mammographic density [101, 103–105], we ob-
served a significant negative association between these two features. This is most likely
to be explained by a confounding effect of menopausal status, as HRT is normally pre-
scribed to postmenopausal women and menopause is known to lead to a significant
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decrease in density [90, 91]. Also, the age range of the women in this study meant that
they were mainly premenopausal.
In this data, age at menarche appeared unrelated either to absolute or percent density.
These results are consistent with the weak or null association between density and age at
menarche observed in other studies [12, 226, 229, 230]. De Stavola and colleagues [229]
observed in a cohort of 5,104 women a significant tendency for later age of menarche
to be associated with a denser Wolfe pattern, however this association was only signif-
icant among postmenopausal women once adjusted for other risk factors, such as BMI.
Likewise, Vachon et al. [12] in 2000 conducted a study with 1,900 subjects reaching a
similar conclusion, that late age at menarche was associated with increased density, but
the magnitude and statistical significance were attenuated in multivariate analyses. If
this assumption is real, it is an interesting example of negative confounding. However, a
case-control study, comprising 607 cases and 667 controls, from a multi-ethnic popula-
tion [230] concluded that mammographic density was not related to age at menarche, in
agreement with our results. More recently, Haars and colleagues [226] investigated the
relationship between density expressed in both absolute and percent terms and other
risk factors on a population of 418 postmenopausal women, and observed, as in in our
study, no significant tendency of increasing density at increasing age at menarche.
Reproductive factors (age at first birth and parity) were strongly related to percent
breast density. This is in agreement with previous literature and consistent with biolog-
ical mechanisms, since parity leads to changes in breast morphology and biochemistry
and it is known that some of these changes are reflected by a reduction in mammographic
density [231]. Hence, it is generally observed that late age of first pregnancy is associ-
ated with higher breast density, as well as the fact that breast density decreases with
increasing number of births [12, 89, 226, 232, 233]. However, mammographic density
expressed in absolute rather than percent terms did not appear to be related to these
reproductive factors in our data. It is interesting to compare this result with the study
from Haars et al. [226], as in both cases there is a comparison between proportional and
absolute amount of density in association with other factors. In their study, both mea-
sures showed an association between density and parity, and both were unrelated to age
at first childbirth, unlike in our data. The populations of the two studies differed consid-
erably: theirs comprised only postmenopausal subjects, aged 49.2-65.8 years, whereas
ours were under 50, mostly premenopausal women at enhanced familial risk. More re-
cently, Woolcott and colleagues obtained data from four case-control studies (1,699 cases
and 2,422 controls) in order to investigate if the association between density, assessed
with Cumulus in both absolute and percent terms, and breast cancer risk was modified
by reproductive factors [231]. As in Haars’s study, analyses showed that percent density
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was lower among women with greater parity and did not vary by age at first birth, and
results for absolute dense area followed a similar pattern.
One of the goals of this study was to evaluate the ability of breast density to further dis-
criminate cases from controls, after adjusting for Tyrer-Cuzick 10-year risk estimates [1].
Both density measures were found independent from Tyrer-Cuzick 10-year risk-estimates
of developing breast tumours. Absolute density, in particular, appeared to add discrim-
inatory ability to the model, both on its own and after adjusting for non-dense breast
area. These results further highlight the potential of density in risk management and
surveillance policy, and support the suggestion of using it to identify high-risk subjects
and to design personalised screening programmes [73].
The cases included in the study were primarily screen detected (80%). Thus, the effect
of density on risk may be artificially reduced in this study due to masking, particularly
as this is a relatively young population with denser breast tissue than is typical in the
National Screening Programme. However, the effect of density is consistently observed
in this dataset. When data were restricted to screen-detected cases, the OR we obtained
(1.06 (.98-1.14) per 10 cm2 of dense tissue) did not vary substantially from the original
results but it was no longer significant, possibly because of the loss of statistical power
due to the sample reduction, from 292 to 239 subjects.
The main weakness of this study is the small number of cases. However, it has the
strength of allowing the analyses to focus on this selected high- and moderate-risk pop-
ulation, that, because of their relatively young age, could benefit the most from individ-
ually tailored surveillance.
In summary, absolute density aided discrimination between cases and controls even in
this population at enhanced familial risk for breast cancer. Moreover, our study pro-
vides further evidence that absolute density should be preferred over percent density.
Not only was absolute dense area more predictive than percent density, it was not associ-
ated with most of the risk factors that percent dense area was, thus making it a simpler
risk-predictor and less affected by confounding factors. In addition, absolute density
appeared able to improve significantly the risk-prediction provided by Tyrer-Cuzick 10-
year risk estimates. Further and larger studies are needed to validate these results and
to have a better understanding of how density should be used to provide more effective
screening programmes.
Part II
Automated volumetric
assessments of mammographic
density (Quantra and Volpara)
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Chapter 5
A case-control evaluation of a
fully automated volumetric
density measure (Quantra) as a
predictor of breast cancer risk
5.1 Introduction
As noted in Chapter 1, area based breast density assessments measure the amount
of breast stromal and epithelial, or dense, tissue that appears white in a mammo-
gram. There are currently two main approaches for measuring density: computer-
assisted, e.g. interactive thresholding (Cumulus) [30], and visual, e.g. Boyd’s six-
category classification (SCC) [25, 26] and Breast Imaging Reporting and Data System
(BIRADS )[234, 235]. The latter was developed in the 1990s by the American College
of Radiology, and is a standardized lexicon that classifies density into four categories
according to the proportion of dense tissue in the mammogram. It is widely employed
because of its ease of use in routine screening, and its reasonably high inter- and intra-
observer agreement rates [27]. In addition to this, it has been shown to be a successful
risk predictor [2, 3]. Tice and colleagues [3] observed, within a cohort of 81,777 women
(5.1 average years of follow-up, 955 cases), that a model based on BIRADS alone, ad-
justed for age and ethnicity, could predict breast cancer risk as accurately as the Gail
model [161, 162], a multivariable statistical model commonly implemented for this pur-
pose. Similarly, the results of Barlow et al. [2] suggested that, as a single predictor,
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BIRADS is almost as powerful as age. However, the dense area on the mammogram is a
two-dimensional representation of a three-dimensional feature, the volume of fibroglan-
dular tissue in the breast; hence, in principle, a volumetric measure is preferable. Dense
volume is expected to be more directly related to risk and to capture more accurately
the underlying biological processes that lead to breast cancer, since it is believed to be
a more precise estimate of the amount of fibroglandular tissue in the breast [30].
It has long been thought that the introduction of a calibration object, beside the breast
during imaging, would allow the projected dense area to be directly related to the thick-
ness and the composition of the breast tissue, and thereby provide an estimate of the
fibroglandular volume [30, 236]. Recent fully-automated volumetric approaches have
used X-ray attenuation at each pixel to estimate the amount of fibroglandular tissue it
represents, and hence estimate both the overall and the dense volume [38]. One example
is Quantra, a software package that analyses raw images from full-field digital mammo-
grams (FFDM) to quantify dense tissue. This method appears promising according to
the results presented at conferences [38, 48, 237–244], and recent publications [51, 178],
partially in terms of reproducibility, but there is no certainty that this will be the case
in a risk-prediction context.
Disappointingly, other automated volumetric approaches proposed so far [8, 36, 245]
seem to provide similar or weaker risk prediction than area-based measures. Ding and
colleagues [245] compared the standard mammography form (SMF), a software tool for
volumetric assessment, to Wolfe’s parenchymal patterns, visual percent density (21-point
scale) and interactive thresholding. Their data suggested that the volumetric measure-
ments had a lesser association with breast cancer risk than interactive thresholding, the
current gold standard [28]. The predictive ability of SMF was also investigated by Aitken
et al. [36] within a case-control study comprising 969 subjects (355 cases), that led to
similar discouraging results. Likewise, findings from Boyd and colleagues’s comparison
of area-based Cumulus with the new volumetric version (Cumulus V ) [8] indicated that
the volumetric measure provided similar risk information to that of the area method.
These results highlighted the need to develop new techniques or to refine current algo-
rithms, and to validate the novel approaches using larger datasets. The pursuit of a
fully automated density measurement continues, as density could only be used for risk
management at a population level if it could be measured automatically.
In this study, we examine the relationship between Quantra and BIRADS and evaluate
their performance in predicting risk of breast cancer, and also compare Quantra absolute
and percent measurements of dense volume.
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5.2 Material and Methods
5.2.1 Data collection
We conducted a case-control study, whose participants were women attending the Princess
Grace Hospital, an independent hospital in central London, who had full-field digital
mammographic examinations in 2005-2009. Two hundred symptomatic cases were ran-
domly selected from patients with histopathologically verified breast cancer, and each
case was matched with a healthy control by date of birth, age at examination and lat-
erality of mammogram used for density determination.
All mammograms were high quality two-view images, soft copy reported on high reso-
lution monitors. Image quality was not a factor in case selection before randomization,
and because all images were adequate, none were rejected during the density estima-
tion. Among cases, density was assessed on the last mammogram of the contralateral
breast before cancer detection; for controls, density was estimated on the same side as
the matched case, using mammograms dating as close as possible to the matched case
diagnosis. Both views were used for assessing density, as it is known that the craniocau-
dal view tends to give higher density estimates than the mediolateral oblique view [4].
The area-based density was estimated by two experienced radiologists (Dr. Nick Perry
and Dr. Katja Pinker-Domenig) using the standard density grades according to the
American College of Radiology Breast Imaging Reporting and Data System (BIRADS)
[234]. This system classifies density into four categories: (A) < 25% dense (almost en-
tirely fatty); (B) 25− 50% dense (scattered fibroglandular density); (C) 51− 75% dense
(hetereogeneously dense); (D) > 75% dense (extremely dense) [246].
Breast density was also assessed using an integral automated volumetric breast density
measurement system (Hologic, Quantra). Further details of Quantra are provided in the
next section.
As previous results suggested higher density in women resident in London [246], we also
recorded data on area of residence. Area of residence was classified as London, any other
region in the UK (based on the post-code of residence), or outside the UK, referred to
as “abroad” for brevity. In addition to age, area of residence, and density assessed with
both Quantra and BIRADS, no other data on breast cancer risk factors was available.
Complete information was collected for every variable in the study (breast density and
total volume estimates, age and area of residence) thus there were no missing values.
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5.2.2 Quantra
Quantra is a software application that quantifies the total volume of the breast, its
fibroglandular, dense, component (absolute density) in cm3, and proportional breast
density as a ratio of the two (percent density).
Quantra accepts and evaluates raw image data, produced by Full-Field Digital Mam-
mography (FFDM). It evaluates density from even just a single view and can use either
cranio-caudal or mediolateral oblique images. If both views are available the software
estimates density as an average from both images. In our study the two views of the
contralateral breast were taken into account for each case, and the same side was chosen
for the matched control.
The algorithm is based on a physical model of the X-ray imaging chain that relates
breast tissue X-ray attenuation to the digital mammography images provided. It esti-
mates the amount of fibroglandular tissue that an X-ray must have penetrated in order
to deposit a measured amount of energy at the detector. Thus Quantra provides a re-
sult in centimetres of fibroglandular tissue penetrated (Hfg) at each pixel of the image
(Figure 5.1.a). After completing the analysis of every pixel, all the Hfg are aggregated
into the volume of fibroglandular tissue (absolute density), given in cm3.
Figure 5.1: Quantra volumetric assessment of fibroglandular tissue (a) and total
breast volume (b)
Source: Understanding R2 Quantra 1.3, Hologic
Likewise, for the total volume, Quantra considers the entire outline of the imaged breast,
compensating for the decrease in thickness in the uncompressed portions (Hu), Figure
5.1.b. The percent density is then computed as a ratio.
For further information on Quantra algorithm:
http://www.hologic.com/en/breast-screening/volumetric-assessment/
A case control evaluation of Quantra 117
5.2.3 Statistical analyses
Demographic and other variables are summarised using percentages for categorical vari-
ables or medians and IQRs for continuous variables. We had data on age, area of
residence classified as “London”, “Other UK regions” and “abroad”, total breast vol-
ume, dense volume, non-dense volume and BIRADS classification. Total breast volume
and non-dense volume were used as potential indirect indicators of BMI, which was not
available, and age under 50 versus greater than or equal to 50 was used as a surrogate
for menopausal status.
Conditional logistic regression was used to calculate odds ratios (OR) for risk of breast
cancer after adjustment for potential confounding factors. This analysis was repeated
after log-transformation of Quantra estimates. Secondary analyses were also performed
stratified by area of residence (London vs Other UK), and age.
The relationship between BIRADS and Quantra was investigated graphically and non-
parametric tests [214] were used to test for differences for trend across ordered groups.
All analyses were performed using STATA, version 12.1.
5.3 Results
Characteristics of the 200 cases and 200 controls are summarised in Table 5.1. The
matching algorithm, based on date of birth, age at examination and laterality of mam-
mogram used for density determination, was successful as the distribution of these factors
was the same for each group. There was no difference between cases and controls in the
proportions of women from London, from other British regions, and from abroad. The
distribution of total breast volume, dense volume (absolute density) and percent density
were compared between the case and control groups using the Wilcoxon rank-sum test.
Results indicated that there was no significant difference between cases and controls in
both total breast volume and percent density, p = .15 and p = .40 respectively, whereas
cases seemed to have systematically greater dense volume in terms of cm3 (p = .01).
Figure 5.2 supports this result, as controls tended to group at lower levels than cases for
absolute density, whereas this trend was less evident for percent density.
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Table 5.1: Characteristics of the study samples
Cases Controls Total
N=200 N=200 N=400
Age at mammogram, No.(%)
< 45 35 (17.5) 35 (17.5) 70 (17.5)
45-54 63 (31.5) 63 (31.5) 126 (31.5)
55-64 53 (26.5) 52 (26.0) 105 (26.2)
≥ 65 49 (24.5) 50 (25.0) 99 (24.8)
Area of residence, No. (%)
London 102 (51.0) 107 (53.5) 209 (52.2)
Other UK 81 (40.5) 78 (39.0) 159 (39.8)
Abroad 15 (7.5) 17 (8.5) 32 (8.0)
Measures of mammographic breast density assessed by Quantra, Median (IQR)
Percent breast density, in % 20 (14.0) 19.5 (13.0) 20 (13.5)
Absolute breast density, in cm3 91 (76.5) 75.5 (60.5) 82 (73.5)
Total breast volume, in cm3 441.5 (399.5) 407.5 (347.0) 422.5 (392.5)
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Figure 5.2: Distribution of (a) percent and (b) absolute breast density in cases and
controls
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Figure 5.3: Distribution of BIRADS dense categories in cases and controls, (a) overall
and (b) stratified by age
Figure 5.3 depicts the distribution of BIRADS classification between cases and controls.
It shows a pattern of a smaller proportion of cases in the lowest density category, and
a greater proportion in the highest. This was more pronounced in women aged 50 or
more (Figure 5.3.b).
We also investigated the association of percent and absolute density, assessed using
Quantra, with the risk of breast cancer (Tables 5.2 and 5.3). The odds ratios related to
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absolute density and non-dense volume are expressed per 10 cubic centimetre increase,
whereas those regarding percent density are given per 10% increase. Comparing the
performance of risk prediction of the two variables derived by the Quantra system (Tables
5.2 and 5.3), the outcomes suggest that only absolute breast density had a significant
univariate main effect (p=.03), and that an increase of 10 cm3 1 in fibroglandular volume
would lead to a 4% increase in risk of breast cancer. The introduction of the other risk
factors (non-dense volume and area of residence) to the model did not substantially alter
these results, whereas the observed effect of Quantra percent density was strengthened
by adjustment for these factors, OR 1.47 (95% CI (1.09, 1.98)) per 10% density (Table
5.2). In both cases, likelihood ratio tests indicated that the fit of the model did not
improve significantly from the inclusion of other risk factors.
The introduction of area of residence in the model caused a reduction in sample size for
two reasons: (a) 32 women from abroad were excluded from the analysis in order to study
the urban effect of London against other areas in the UK; (b) a further 28 observation
were dropped by the analyses because of all positive or all negative outcomes.
Table 5.2: ORs for developing breast cancer from conditional logistic regression mod-
els using Quantra percent density
Factor category obs OR [95% Conf. Interval] P>z
univariate
% density per 10% 400 1.15 .92 1.44 .211
adjusted for non-dense volume
% density per 10% 400 1.29 1.00 1.66 .050
non-dense volume per 10 cm3 1.01 1.00 1.02 .055
adjusted for London residence
% density per 10% 340 1.31 1.01 1.70 .040
residence Other UK 1.00 - - .660
London .90 .56 1.44
adjusted for non-dense volume and London residence
% density per 10% 340 1.47 1.09 1.98 .011
non-dense volume per 10 cm3 1.01 1.00 1.02 .081
residence Other UK 1.00 - - .864
London .96 .60 1.54
1The average absolute density is 97.31 cm3.
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Table 5.3: ORs for developing breast cancer from conditional logistic regression mod-
els using Quantra absolute density
Factor category obs OR [95% Conf. Interval] P>z
univariate
absolute density per 10 cm3 400 1.04 1.00 1.08 .030
adjusted for non-dense volume
absolute density per 10 cm3 400 1.04 1.00 1.09 .063
non-dense volume per 10 cm3 .99 .99 1.01 .719
adjusted for London residence
absolute density per 10 cm3 340 1.04 1.00 1.08 .062
residence Other UK 1.00 - - .956
London .99 .62 1.58
adjusted for non-dense volume and London residence
absolute density per 10 cm3 340 1.05 1.00 1.10 .063
non-dense volume per 10 cm3 1.00 .99 1.01 .480
residence Other UK 1.00 - - .869
London .96 .60 1.54
Table 5.4 shows the ORs associated with quintiles of absolute dense volume, based on
the control distribution, in order to further understand the linear association between
Quantra absolute density and risk of developing breast cancer. According to these re-
sults, the presence of at least 125 cm3 of dense tissue in the breast would correspond
to a 77% increase in breast cancer relative risk, compared to subjects with less than 47
cm3 of dense tissue. The effect on breast cancer risk of absolute density categorised in
this way was significant (p=.02).
Table 5.4: ORs for developing breast cancer from a conditional logistic regression
model using the quintiles of Quantra absolute density among controls
Quintile OR [95% Conf. Interval] P>z
1st quintile (< 47 cm3) 1.00 - - .020
2nd quintile (47− 65 cm3) .78 .39 1.55
3rd quintile (66− 87 cm3) 1.08 .56 2.06
4th quintile (88− 124 cm3) 1.26 .68 2.35
5th quintile (≥ 125 cm3) 1.77 .95 3.29
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Results of the analyses using Quantra measures after log-transformation are summarised
in Table 5.5. The evidence sustaining the association between breast cancer risk and
absolute density appears stronger in comparison with the results obtained using the
original measures. However, they led to similar conclusions to those of Tables 5.2 and
5.3, and we therefore returned the original measures for the following analyses, this
also facilitates the interpretation of the results. Nevertheless, in the analysis based on
the log-transformed densities, the chi-square statistics demonstrate that adjustment of
the percent density effect for total breast volume is returning the same information as
absolute density but at the cost of adding a degree of freedom.
Table 5.5: ORs for developing breast cancer risk from conditional logistic regression
models using Quantra log-transformed measures
Factor obs OR [95% Conf. Interval] P>z modelχ2 df
univariate
log-absolute density 400 1.50 1.07 2.11 .020 5.62 1
adjusted for log-non-dense volume
log-absolute density 400 1.76 1.08 2.85 .022 6.47 2
log-non-dense volume .83 .56 1.24 .358
adjusted for log-total volume
log-absolute density 400 1.83 1.03 3.25 .038 6.38 2
log-total volume .79 .47 1.34 .386
univariate
log-% density 400 1.35 .82 2.24 .236 1.42 1
adjusted for log-non-dense volume
log-% density 400 1.86 1.02 3.40 .044 5.20 2
log-non-dense volume 1.39 .99 1.94 .055
adjusted for log-total volume
log-% density 400 1.73 .98 3.03 .057 5.66 2
log- total volume 1.43 1.01 2.01 .042
Table 5.6 reports the results from the analyses on the association between risk of devel-
oping a tumour in the breast and percent breast density classified according to BIRADS
categories. The relationship between BIRADS density and risk is a non-linear one, nev-
ertheless the risk of developing breast cancer in subjects classified as “extremely dense”
(D) is more than two-fold higher than women defined “almost entirely fatty” (A). The
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univariate OR is estimated to be 2.26 (1.01, 5.05), and the effect is stronger when ad-
justing for area of residence (OR 2.72 (1.12, 6.62)).
BIRADS and absolute Quantra measures assess breast density in different ways: the first
gives a subjective evaluation of the dense tissue area in terms of 25% intervals, whereas
the second is an automatic system that estimates the volume of fibroglandular tissue in
cm3. Bearing this in mind, a comparison between the risk-predictive performances of
the two variables must be tentative (Tables 5.3 and 5.6).
Table 5.6: ORs for developing breast cancer from conditional logistic regression mod-
els using BIRADS classification
Factor category obs OR [95% Conf. Interval] P>z
univariate
BIRADS (A) <25% dense 400 1.00 - - .161
(B) 25-50% dense 1.57 .90 2.73
(C) 50-75% dense 1.24 .66 2.35
(D) ≥75% dense 2.26 1.01 5.05
adjusted for non-dense volume
BIRADS (A) <25% dense 400 1.00 - - .188
(B) 25-50% dense 1.57 .90 2.73
(C) 50-75% dense 1.24 .65 2.34
(D) ≥75% dense 2.18 .97 4.88
non-dense volume per 10 cm3 1.00 1.00 1.01 .276
adjusted for London residence
BIRADS (A) <25% dense 340 1.00 - - .057
(B) 25-50% dense 1.56 .86 2.84
(C) 50-75% dense 1.42 .71 2.84
(D) ≥75% dense 2.78 1.15 6.74
residence Other UK 1.00 - - .825
London .96 .59 1.54
adjusted for non-dense volume and London residence
BIRADS (A) <25% dense 340 1.00 - - .065
(B) 25-50% dense 1.57 .86 2.85
(C) 50-75% dense 1.42 .71 2.84
(D) ≥75% dense 2.72 1.12 6.62
non-dense volume per 10 cm3 1.00 .99 1.01 .594
residence Other UK 1.00 - - .902
London .98 .60 1.60
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Conditional logistic regression analyses were repeated in women aged under 50 years
and 50 or more separately (Tables 5.7,5.8 and 5.9). Quantra percent density was signif-
icant in discriminating cases from controls in the younger group, particularly when the
model took non-dense volume into account, with an OR per 10% density of 1.61 (1.05,
2.48) (Table 5.7). Conversely, Quantra absolute density was not significant in the model
based only on women aged under 50 (OR per 10 cm3: 1.02 (.97, 1.07)), but there was a
considerate loss of power as the sample size reduced from 400 to 154 (Table 5.8). This
result is partly explained by the dependency of percent density on non-dense volume,
as Figure 5.4 illustrates. At younger ages, cases tend to have a higher percent density
not because of a greater absolute volume of dense tissue, but due to a generally smaller
amount of non-dense tissue than controls. Furthermore, among women aged under 50,
there was no substantial difference in breast cancer risk in subjects belonging to the
two extreme categories of BIRADS classification, i.e. “almost entirely fatty” (A) and
“extremely dense” (D). At older ages, on the other hand, breasts classified as “extremely
dense” have 4.12 (1.41, 12.07) times higher odds of cancer than those classified as “al-
most entirely fatty” (Table 5.9).
Table 5.7: ORs for developing breast cancer from conditional logistic regression mod-
els using Quantra percent density, stratified by age
Factor category obs OR [95 Conf. Interval] P>z
univariate
Under 50
% density per 10% 154 1.46 1.01 2.10 .045
50 or more
% density per 10% 246 .97 .72 1.31 .850
adjusted for non-dense volume
Under 50
% density per 10% 154 1.61 1.05 2.48 .029
non-dense volume per 10 cm3 1.01 .99 1.02 .336
50 or more
% density per 10% 246 1.09 .78 1.52 .607
non-dense volume per 10 cm3 1.01 1.00 1.02 .107
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Figure 5.4: Comparison of medians and inter-quartile ranges of Quantra (a) percent
density, (b) non-dense volume and (c) absolute density by age group, between cases
and controls
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Table 5.8: ORs for developing breast cancer from conditional logistic regression mod-
els using Quantra absolute density, stratified by age
Factor category obs OR [95 Conf. Interval] P>z
univariate
Under 50
absolute density per 10 cm3 154 1.02 .97 1.07 .493
50 or more
absolute density per 10 cm3 246 1.06 1.01 1.11 .022
adjusted for non-dense volume
Under 50
absolute density per 10 cm3 154 1.04 .97 1.11 .279
non-dense volume per 10 cm3 .99 .98 1.01 .384
50 or more
absolute density per 10 cm3 246 1.06 .99 1.13 .083
non-dense volume per 10 cm3 1.00 .99 1.01 .984
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Table 5.9: ORs for developing breast cancer from conditional logistic regression mod-
els using BIRADS classification, stratified by age
Factor category obs OR [95 Conf. Interval] P>z
univariate
Under 50
BIRADS (A) <25% dense 154 1.00 - - .692
(B) 25-50% dense .89 .34 2.36
(C) 50-75% dense 1.51 .48 4.74
(D) ≥75% dense .88 .24 3.29
50 or more
BIRADS (A) <25% dense 246 1.00 - - .148
(B) 25-50% dense 2.24 1.11 4.54
(C) 50-75% dense 1.10 .50 2.44
(D) ≥75% dense 4.12 1.41 12.07
adjusted for non-dense volume
Under 50
BIRADS (A) <25% dense 154 1.00 - - .707
(B) 25-50% dense .87 .32 2.35
(C) 50-75% dense 1.48 .47 4.70
(D) ≥75% dense .86 .23 3.27
non-dense volume per 10 cm3 1.00 .99 1.01 .891
50 or more
BIRADS (A) <25% dense 246 1.00 - - .233
(B) 25-50% dense 2.16 1.06 4.39
(C) 50-75% dense 1.05 .47 2.34
(D) ≥75% dense 3.67 1.24 10.89
non-dense volume per 10 cm3 1.01 1.00 1.02 .188
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Table 5.10: ORs for developing breast cancer from conditional logistic regression
models using Quantra percent density, stratified by UK location of residence
Factor category obs OR [95 Conf. Interval] P>z
univariate
London
% density per 10% 124 1.25 .83 1.86 .283
Other UK
% density per 10% 72 1.49 .91 2.44 .112
adjusted for non-dense volume
London
% density per 10% 124 1.41 .89 2.23 .146
non-dense volume per 10 cm3 1.01 .99 1.02 .236
Other UK
% density per 10% 72 2.02 1.07 3.82 .030
non-dense volume per 10 cm3 1.03 1.00 1.06 .046
Table 5.11: ORs for developing breast cancer from conditional logistic regression
models using Quantra absolute density, stratified by UK location of residence
Factor category obs OR [95 Conf. Interval] P>z
univariate
London
absolute density per 10 cm3 124 1.03 .98 1.09 .231
Other UK
absolute density per 10 cm3 72 1.11 1.00 1.22 .050
adjusted for non-dense volume
London
absolute density per 10 cm3 124 1.04 .97 1.12 .291
non-dense volume per 10 cm3 1.00 .98 1.02 .824
Other UK
absolute density per 10 cm3 72 1.10 .98 1.24 .121
non-dense volume per 10 cm3 1.00 .98 1.03 .890
In the analyses stratified by area of residence (Tables 5.10, 5.11 and 5.12), 32 women
living abroad were excluded in order to focus on within-UK differences. A further 172
observations, 85 in the “London” group and 87 in the “Other UK” group, did not con-
tribute to the matched statistical analysis due to all positive or all negative outcomes.
Therefore the reduced sample sizes affect the precision of the results. However, Quantra
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Table 5.12: ORs for developing breast cancer from conditional logistic regression
models using BIRADS classification, stratified by UK location of residence
Factor category obs OR [95 Conf. Interval] P>z
univariate
London
BIRADS (A) <25% dense 124 1.00 - - .025
(B) 25-50% dense 4.18 1.54 11.34
(C) 50-75% dense 1.61 .50 5.25
(D) ≥75% dense 12.14 2.06 71.38
Other UK
BIRADS (A) <25% dense 72 1.00 - - .896
(B) 25-50% dense .40 .07 2.20
(C) 50-75% dense .40 .07 2.37
(D) ≥75% dense .70 .09 5.46
adjusted for non-dense volume
London
BIRADS (A) <25% dense 124 1.00 - - .023
(B) 25-50% dense 4.21 1.54 11.50
(C) 50-75% dense 1.64 .50 5.35
(D) ≥75% dense 12.19 2.07 71.72
non-dense volume per 10 cm3 1.00 .99 1.02 .484
Other UK
BIRADS (A) <25% dense 72 1.00 - - .915
(B) 25-50% dense .35 .06 2.13
(C) 50-75% dense .29 .04 1.90
(D) ≥75% dense .57 .07 4.92
non-dense volume per 10 cm3 1.01 .99 1.04 .175
densities, both absolute and percent (the latter after adjustment for non-dense breast
volume) seemed to be able to discriminate better cases from controls in British women
not living in London (Tables 5.10 and 5.11), whereas BIRADS density registered strongly
increasing ORs in London residents (Table 5.12).
We repeated these stratified analyses using unmatched logistic models adjusted for age,
in order to preserve a larger portion of the sample (Tables 5.13, 5.14 and 5.15). These
unconditional analyses relating to Quantra density estimates confirmed the previous
results. In the models with BIRADS, on the other hand, the larger sample, 368 subjects
instead of 196, led to less extreme results, especially among London residents, i.e. the OR
for the most dense breasts in comparison to the primarily fatty ones (“<25% dense”) was
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3.5 (1.3, 9.6) instead of 12.1 (2.1, 71.4), as observed in the conditional logistic analyses.
Table 5.13: ORs for developing breast cancer from unconditional logistic regression
models using Quantra percent density adjusted for age, stratified by UK area of resi-
dence
Factor category obs OR [95 Conf. Interval] P>z
adjusted for age
London
% density per 10% 209 1.07 .80 1.44 .632
age per year 1.01 .99 1.04 .386
Other UK
% density per 10% 159 1.46 1.00 2.14 .050
age per year 1.00 .97 1.03 .792
adjusted for non-dense volume and age
London
% density per 10% 209 1.17 .84 1.63 .366
non-dense volume per 10 cm3 1.01 .99 1.02 .301
age per year 1.01 .99 1.04 .343
Other UK
% density per 10% 159 1.59 1.05 2.40 .027
non-dense volume per 10 cm3 1.01 1.00 1.02 .270
age per year 1.00 .96 1.03 .763
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Table 5.14: ORs for developing breast cancer from unconditional logistic regression
models using Quantra absolute density adjusted for age, stratified by UK area of resi-
dence
Factor category obs OR [95 Conf. Interval] P>z
adjusted for age
London
absolute density per 10 cm3 209 1.09 .99 1.08 .177
age per year 1.01 .99 1.04 .361
Other UK
absolute density per 10 cm3 159 1.04 .98 1.10 .181
age per year .99 .96 1.01 .318
adjusted for non-dense volume and age
London
absolute density per 10 cm3 209 1.04 .98 1.10 .236
non-dense volume per 10 cm3 1.00 .98 1.01 .803
age per year 1.01 .99 1.04 .346
Other UK
absolute density per 10 cm3 159 1.06 .98 1.15 .117
non-dense volume per 10 cm3 .99 .98 1.01 .370
age per year .99 .96 1.02 .511
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Table 5.15: ORs for developing breast cancer from unconditional logistic regression
models using BIRADS classification adjusted for age, stratified by UK area of residence
Factor category obs OR [95 Conf. Interval] P>z
adjusted for age
London
BIRADS (A) <25% dense 209 1.00 - - .056
(B) 25-50% dense 2.43 1.16 5.10
(C) 50-75% dense 1.67 .70 4.00
(D) >75% dense 3.46 1.25 9.56
age per year 1.01 .99 1.04 .378
Other UK
BIRADS (A) <25% dense 159 1.00 - - .726
(B) 25-50% dense .80 .30 2.13
(C) 50-75% dense .95 .31 2.85
(D) >75% dense 1.13 .28 4.51
age per year .98 .96 1.01 .264
adjusted for non-dense volume and age
London
BIRADS (A) <25% dense 209 1.00 - - .059
(B) 25-50% dense 2.40 1.14 5.05
(C) 50-75% dense 1.66 .69 3.99
(D) >75% dense 3.41 1.23 9.46
non-dense volume per 10 cm3 1.00 .99 1.01 .524
age per year 1.01 .99 1.04 .402
Other UK
BIRADS (A) <25% dense 159 1.00 - - .748
(B) 25-50% dense .80 .30 2.13
(C) 50-75% dense .94 .31 2.84
(D) >75% dense 1.11 .28 4.45
non-dense volume per 10 cm3 1.00 .99 1.01 .764
age per year .98 .95 1.01 .249
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Figure 5.5 compares medians of Quantra measures by case-control status and age group,
stratified by area of residence and may help to explain such result. In London residents,
case and control lines are relatively close, especially for median percent density, imply-
ing poor discrimination. Moreover, comparing the controls from London and other UK
regions, subjects from the capital appear to have a higher percent density, even pre-
senting similar absolute density estimates, because they have lower non-dense volume.
The Wilcoxon rank-sum test comparing non-dense breast volume among women living
in London or elsewhere in the UK supports this result (p=.03). This may mean that
London women have lower percent density because they are thinner than women resi-
dent in other UK regions.
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Figure 5.5: Comparison of medians and inter-quartile ranges of Quantra (a) percent
density, (b) non-dense volume and (c) absolute density by age group, between UK
residents from London or other British regions, stratified by case-control status
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Figure 5.6 shows the relationship between BIRADS and Quantra (a) percent and (b)
absolute density. The boxplots represent the distribution of percent and absolute breast
density in each BIRADS category. Ideally, with increasing BIRADS category, one would
expect to observe an increasing trend among the boxes, as evidence of a positive asso-
ciation between density measured by the two methods. Overall results from tests for
trend suggest the absence of association between BIRADS and Quantra percent density
among controls (p=.35). However, focusing only on cases, the two measures appear
significantly but inversely related (p<.01). There appears to be no association between
BIRADS classification and Quantra absolute density, and tests for trend are consistent
with this (cases: p=.38; controls: p=.76).
Figure 5.6: Boxplots of (a) percent and (b) absolute breast density stratified by
BIRADS categories and case-control status
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Analyses of the other measures estimated by Quantra, i.e. (a) non-dense and (b) to-
tal breast volume (Figure 5.7), yielded similar results. Among controls, tests for trend
showed no significant association between BIRADS and Quantra non-dense and total
breast volume (respectively p=.35 and p=.38). In contrast, among cases, tests for trend
showed a significant and positive association with BIRADS categories for both non-dense
(p<.01) and total breast volume (p=.01). This indicates that the result for percent den-
sity in cases is due mainly to the non-dense volume.
Figure 5.7: Boxplots of (a) non-dense and (b) total breast volume stratified by BI-
RADS categories and case-control status
Because of the lack of association observed between the two measures, we performed
a conditional logistic regression adjusting Quantra absolute density for BIRADS, with
results shown in Table 5.16. These results provide further evidence that there is no
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Table 5.16: ORs for developing breast cancer risk from conditional logistic regression
models using Quantra absolute density and adjusting for BIRADS categories
Factor category obs OR [95% Conf. Interval] P>z
absolute density per 10 cm3 400 1.04 1.00 1.07 .035
BIRADS (A) <25% dense 1.00 - - .191
(B) 25-50% dense 1.58 .90 2.78
(C) 50-75% dense 1.23 .65 2.35
(D) ≥75% dense 2.19 .97 4.93
relationship between BIRADS classification and Quantra absolute density, as the values
do not substantially vary from those reported in previous Tables 5.3 and 5.6. The two
measures appeared to have independent effects on risk. This suggests that they may be
measuring different aspects of breast density.
5.4 Discussion
Our data seem to support the hypothesis that absolute volume of dense tissue, is a better
predictor of breast cancer risk than percent density, possibly because it gives a closer es-
timate of the number of cells at risk of suffering a malignant transformation. However it
should be noted that the OR for the highest quintile compared to the lowest is only 1.77
(Table 5.4); in other words, the observed difference in the number of cases and controls
between high and low amounts of dense volume is modest. In order to validate and give
further support to our findings, it would be interesting to compare the performances of
Quantra dense volume and interactive thresholding, the current gold standard. Previ-
ously, other volumetric estimates [8, 36, 245] failed to be more informative in similar
comparisons. It should be noted that our study population is on average younger than
the target population for screening in the UK, and is likely yo be of higher socioeconomic
status than the general population, since it is made up of users of a private healthcare
facility. Also, the cases are symptomatic. It is feasible that the levels of breast density
may differ from the general population. However, the comparison between cases and
controls would be expected to be valid.
In our data, the lack of association between Quantra and BIRADS is surprising and
raises questions about the validity of both measures. Moreover the association between
breast cancer risk and BIRADS classification here appears weaker than one would ex-
pect. As McCormack and dos Santos Silva’s meta-analysis [6] reported BIRADS category
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“extremely dense (≥ 75% dense)” typically presents a risk of 4.08 (2.96, 5.63) relative
to the lowest category, “almost entirely fat (≤ 25% dense)”, whereas in this study it
was 2.26 (1.01, 5.05). A first suggestion could be to repeat these analyses on further
and larger datasets for validation. If these results were confirmed we should start in-
vestigating what Quantra is actually measuring, since it seems to be strongly related
to breast cancer risk. In particular, the significant inverse positive association between
BIRADS and Quantra non-dense breast volume, among cases is surprising. It could
indicate that part of the visually assessed dense tissue is detected as fat by Quantra. It
should be mentioned that, recently, Ciatto and colleagues compared Quantra estimates
and BIRADS readings by 11 expert radiologists on 418 digital mammograms [51] and
their findings suggested that, despite Quantra estimates being consistently lower than
visual classification, there was a good agreement between automated and visual density
assessments. This is in opposition to what we observed, thus further analyses on a larger
dataset are needed to clarify this issue.
Figure 5.8: Percent distribution of BIRADS in the present study compared to Barlow
2006 [2]
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Table 5.17: Distribution (%) of BIRADS in Tice et al. 2005 [3], Barlow et al. 2006
[2] and the present study
BIRADS dense categories Tice et al. 2005 Barlow et al. 2006 present study
controls cases
(%) (%) (%) (%)
(A) <25% dense 7,890 (9.7) 142,660 (8.6) 42 (21.0) 30 (15.0)
(B) 25-50% dense 36,543 (44.7) 744,080 (45.2) 97 (48.5) 106 (53.0)
(C) 50-75% dense 31,282 (38.2) 633,954 (38.5) 45 (22.5) 39 (19.5)
(D) ≥75% dense 6,062 (7.4) 126,680 (7.7) 16 (8.0) 25 (12.5)
Total 81,777 (100.0) 1,647,374 (100.0) 200 (100.0) 200 (100.0)
Supplementary investigation of the distribution of BIRADS, stratified by menopausal
status (Figure 5.8), revealed that our data differ significantly from those observed in
larger studies [2, 3]. Barlow’s dataset was chosen for the comparison because the high
number of women (N=1,647,374) assessed with BIRADS and the similarity of propor-
tions in the categories found in Tice’s analysis on 81,777 subjects [3] make it a good
estimate of the general population. Table 5.17 shows the distributions of BIRADS cate-
gories in the cases and controls in the present study and in the larger studies of Tice et
al. [3] and Barlow et al. [2]. In our sample women, both cases and controls, seem to be
more likely to have less dense breasts (BIRADS categories A or B) than in the the other
two studies, with a corresponding deficit in category C. The cases in our study do have
a higher proportion in category D, as one would expect. The differences between the
distributions in the controls here and in the Barlow population were significant overall,
and in pre- and post-menopausal women separately (p<.01 in every comparison). Thus
it may be that our sample is not representative of the general population; and the fact
that the data were collected in a private medical facility could have introduced selection
bias. Also, of course, the controls are not a population sample, but are age-related to
cases.
Another possibility is that the visual classification of density on processed, full-field
digital images is not reliable. The image-digitization process is not designed to assess
breast density but to help detect tumours. The processing algorithm is developed to
remove image errors and to attenuate areas of whiteness (dense tissue) within the raw
images, so that tumours are more visible. Consequently, breasts are classified as less
dense as they would be if the assessment were based on film mammograms. This fact
might explain not only the differences in distribution between our sample and Barlow’s
but also the poor performance and small ORs of a well-established method, (BIRADS)
in the present case-control study. Based on our findings, one would have to conclude
that visual estimation from digital mammograms is a less reliable measure. However,
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a previous study [34] compared density measures, using both Wolfe’s patterns and the
Boyd’s six category classification (SCC), assessed from film and digital mammograms,
and found substantial agreement. More recently Harvey et al. [247] found no difference
in reported BIRADS breast density categories according to acquisition method, i.e. film
or digital images. Thus, it is by no means clear that visual assessment by BIRADS or
other systems is not reliable with digital mammography.
There have been studies [48, 50, 248] that compared Quantra volumetric assessments to
MRI breast density [47] that should help evaluate what Quantra is actually measuring.
Although the total breast volume appeared to be estimated with a good agreement, the
fibroglandular tissue volume, or absolute density, was poorer (squared Pearson’s correla-
tion coefficient: .36), leading also to low correlation regarding percent density (squared
Pearson’s correlation coefficient: .51) [50, 248]. Nevertheless Wang and colleagues [50]
concluded that the observed lack of agreement between mammographic density and MRI
density was most likely driven by differences in total breast volume. Kontos et al. [48],
instead, observed that MRI estimates of absolute density were significantly lower than
Quantra estimates for women with very low density breasts. This finding suggests that
Quantra may consider as dense some fatty tissue, one may speculate that it could be
due to the compression applied during the mammographic exam. Nevertheless Kontos
and colleagues were using a limited sample (N=32), thus their results require validation
from a larger dataset.
Non-dense breast volume is utilised as a proxy measure for BMI, though it also allows
absolute density to be adjusted to become percent density and vice versa. Interestingly,
the association between breast cancer risk and percent density increases in strength af-
ter adjusting for non-dense volume, so it seems that there is independent information in
each measure. It is also probable that this finding is due to the fact that percent density
and non-dense breast volume together allow the computation of the amount of dense
breast volume in terms of cm3 and thus are just as informative as absolute density on
its own. The structural collinearity of non-dense volume and percent density, however,
make the adjusted estimates difficult to interpret. This may be distinct from the issue
of confounding with BMI, which could be effectively answered in a study including BMI
data on the subjects. Clearly, non-dense volume is at best a partial substitute for BMI.
Case subjects included in this study were symptomatic, and this may have affected our
findings due to masking, i.e. symptomatic subjects are likely to have denser breasts
that can hide tumours and lead to negative screening. Thus, masking should reduce
observed associations of density with risk of screen-detected cases and exaggerate asso-
ciations with post-screening, symptomatic cancers. However, if this was the case, we
would have expected a much stronger association between density and risk.
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The results with respect to area of residence suggest that the higher percent density
in London women is largely due to lower non-dense breast volume. This is consistent
with our previous finding, and with the observation that women residing in London
are thinner than women living outside the capital [246, 249]. The differing results by
“menopausal” groups (age below and above 50) may be chance findings and need con-
firmating by further studies, with explicit data on menopausal status.
These findings need to be validated using a larger dataset with richer data on other
risk factors in order to be confirmed and to help explain the apparent lack of association
between Quantra density measures and BIRADS categories. Our main finding that,
overall, absolute dense volume is a better predictor of risk than percent, is consistent
with our own previous findings [Chapter 4]. Quantra volumetric method requires further
validation as well, but it suggests that this is a hopeful direction for research and for
risk management in practice.
Chapter 6
Serial volumetric density
measures using Quantra: changes
with time and age
6.1 Introduction
Mammographic density has been consistently found to be lower in older women than
in younger women [92], and the relationship between mammographic density and time
has been investigated in several studies [16, 88, 91]. Better understanding of how breast
composition varies with age, how density increases with age up to age 40 and then de-
creases [88], could give us a wider insight into the association of density with risk, and
improve breast screening and breast cancer prevention programmes.
As a woman ages the mammographic appearance of her breasts changes because of an
involution process, i.e. there is a reduction in glandular tissue, and a simultaneous in-
crease in fat and connective tissue [16]. In particular Hutson and colleagues [88] analysed
breast samples, collected at necropsy, from subjects aged 10 to 80, and concluded that
the proportion of the breast comprised of epithelial tissue increases in the first decades
after menarche (approx. age 10 to 40), and then declines progressively until menopause.
In post-menopausal subjects this proportion remained fairly constant [88].
In 2010 McCormack et al. focused on the relationship between breast composition and
age in 645 women aged 50 to 65, studying the screening mammograms available in a
3- to 12-year interval [91]. Their findings suggest a non-linear relationship between age
and mammographic density, both percent and absolute dense area, with a greater drop
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in the first years after the 50th birthday, intuitively due to the beginning of menopause,
and then a gradual stabilization by age 65. The proportion of non-dense tissue in
the mammograms correspondingly increased but the rate of change was almost double
that of dense area. However, it is hoped that volumetric methods of assessment for
mammographic density should provide more precise measures of the changes in breast
composition [91].
The current study comprised 331 women without breast cancer, whose density was as-
sessed on two occasions using Quantra, a fully-automated volumetric method [51]. These
data allow investigations of the change in breast composition over time within subjects,
and how the rate of change varies according to age. In addition, we performed a cross-
sectional analysis on the association between age and the amount of dense and non-dense
breast tissue at baseline. The potential presence of an “urban effect” [246] was also a
subject of investigation.
6.2 Materials and methods
6.2.1 Data collection
Between 2002 and 2008, 413 women attending for mammography screening at the
Princess Grace Hospital, a private facility in central London, were randomly selected
to enter a cohort study of volumetric changes in breast composition. Cohort members
were aged 34 to 81 and had no diagnosis of breast cancer before or during the study.
These women underwent two digital mammographic examinations, on average 18 months
apart. Due to misrecording and missing values, the final dataset included complete de-
tails on 332 women (231 younger than 50 years and 101 aged 50 or more years at entry).
The younger group included one subject whose exact age was not known, but was known
to be under 50.
Density was assessed with Quantra, an automated volumetric method. This technique
is described in the previous chapter [Chapter 5]. It provides estimates of the total and
dense volumes in cm3, and the percent density, which is a ratio of the two. We also
computed the volume of fatty tissue (non-dense volume), as the difference between total
and dense volumes.
As previous results suggested higher density in women resident in London, data on area
of residence was also recorded. This was classified as London, any other region in the
UK (based on the post-code of residence), or overseas.
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Aside from residence, age, breast composition assessed by Quantra and screening his-
tory, no other personal data was available.
6.2.2 Statistical analysis
The distributions of demographic and other variables at the first examination were sum-
marised as percentages for discrete variables, or means and SDs for continuous variables.
Total breast volume and non-dense volume were used as a proxy for BMI, and the sub-
division between women aged under 50 and those aged 50 or over, at the first screening,
provided an approximate indicator of menopausal status.
Changes in breast composition between the two mammogaphic examinations were the
main subject of investigation, and were first summarised with means and SDs. The null
hypothesis of “no change” was assessed using the non-parametric Wilcoxon matched-
pairs signed-ranks test. The relationship between age at baseline and the changes in ab-
solute and percent density, non-dense and total breast volume, was studied graphically
and through linear regression analyses. The hypothesis that the rate of change in breast
composition is time/age-dependent was investigated using boxplots, non-parametric
tests for trend across ordered groups and linear regression. Note that the differences in
mammographic measures between screens were computed as follows: screen2−screen1,
so that the change is positive if the measure has increased over time, and negative if it
has decreased.
The relationship between age and breast composition at baseline was investigated using
linear regression and Pearson’s correlation coefficients.
Secondary analyses, stratified by age at baseline and by area of residence (London or
elsewhere in the UK), were also performed.
All analyses were performed with STATA software version 11.
6.3 Results
The sample recruited in the study comprised 332 women, resident mainly in London
(64%) and on average aged 47 (Table 6.1). The age distribution varied significantly ac-
cording to area of residence (χ2 test: p=.02), because women living outside the capital
tended to be more often in the extreme age classes, “under 45” and “65 or more” (Fig.
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6.1).
Figure 6.1: Distribution of age at baseline and area of residence (London: N=213,
Other UK: N=83)
Overall, breast composition at baseline, shown in Table 6.1, was as one would expect: at
older ages women had, on average, significantly lower percent density (Wilcoxon rank-
sum test: p<.01) and higher amounts of fatty and total volume (p<.01 for both), whereas
absolute breast density did not, on average, change significantly with age (p=.78).
Serial volumetric density measures using Quantra 147
Table 6.1: Characteristics of the study samples at baseline
Age groups
under 50 50 or more Total
N=231 N=101 N=332
Age at baseline
mean (sd) 42.1 (3.4) 58.4 (6.8) 47.1 (8.9)
Area of residence (%)
London 154 (66.7) 59 (58.4) 213 (64.2)
Other UK 58 (25.1) 25 (24.8) 83 (25.0)
Abroad 19 (8.2) 17 (16.8) 36 (10.8)
Measures of mammographic breast density assessed by Quantra at baseline
mean (sd)
Percent breast density (%) 26.9 (11.4) 20.0 (9.4) 24.8 (11.3)
Absolute breast density (cm3) 102.9 (72.1) 96.5 (52.0) 101.0 (66.6)
Non-dense volume (cm3) 321.0 (250.8) 446.9 (277.5) 359.3 (265.2)
Total breast volume (cm3) 423.9 (303.3) 543.4 (309.8) 460.2 (309.7)
Figure 6.2: Distribution of the time interval (in years) between screenings and age at
baseline
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For the group aged 50 or more mammography screening was repeated after one year in
81% of cases, most other cases after 2 years, whereas 49% of younger women (49.4%)
had their second mammogram 2 to 5 years after (Figure 6.2). In all women considered,
we observed a significant decrease of percent density between the first and second mam-
mogram (-.3%, p=.03), a stronger effect among older women (-.8%, p<.01). This was
due to the fact that both groups experienced a substantial increase in volume of fatty
tissue (under 50: +8.6 cm3, p<.01; 50 or more: +10 cm3, p<.05). Absolute density did
not change substantially between screens (Table 6.2).
Table 6.2: Breast composition measures at first and second screen
screen 1 screen 2
Variable Mean (SD) Mean (SD) p
Under 50, N=231
Percent breast density (%) 26.9 (11.4) 26.9 (12.0) .39
Absolute breast density (cm3) 102.9 (72.1) 103.6 (74.7) .31
Non-dense breast volume (cm3) 321.0 (250.8) 329.5 (262.3) <.01
Total breast volume (cm3) 423.9 (303.3) 433.1 (313.4) <.01
50 or more, N=101
Percent breast density (%) 20.0 (9.4) 19.3 (9.1) <.01
Absolute breast density (cm3) 96.5 (52.0) 94.5 (48.9) .80
Non-dense breast volume (cm3) 446.9 (277.5) 456.9 (268.8) .05
Total breast volume (cm3) 543.4 (309.8) 551.3 (296.6) .11
Total, N=332
Percent breast density (%) 24.8 (11.3) 24.6 (11.7) .03
Absolute breast density (cm3) 101.0 (66.6) 100.8 (68.0) .46
Non-dense breast volume (cm3) 359.3 (265.2) 368.3 (270.3) <.01
Total breast volume (cm3) 460.2 (309.7) 469.1 (312.7) <.01
Figure 6.3 depicts the changes in (a) percent density, (b) absolute density, (c) non-dense
volume and (d) total volume between the two screens according to age of the subjects; it
shows also the fitted linear slope with related 95% confidence interval (area in grey). In
every case the distribution was a funnel-shaped pattern, with a broader range of values
for change in density between screens at earlier ages and a narrower distribution at later.
The intervals around the fitted lines are narrower at younger ages because of a higher
number of subjects. The linear trend described by these slopes was not significantly
different from zero, and in particular in the charts regarding the change in density, both
percent and absolute, the lines are almost exactly parallel to the X-axis (coefficient for
percent density: -.02, p=.6; coefficient for absolute density: -.08, p=.7). Interestingly,
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between 40% and 50% of young women experienced an increase in breast density (both
percent and absolute) between the first and the second mammogram.
Figure 6.3: Changes in breast composition between subsequent mammograms accord-
ing to age at baseline (years)
The fact that at younger ages the interval between screens was wider and therefore
subject to a higher variability could also explain the funnel shape. Thus, we repeated
this analysis considering only the subjects screened a year or less apart (Figure 6.4).
However results did not differ substantially from the previous ones.
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Figure 6.4: Changes in breast composition between subsequent mammograms ac-
cording to age at baseline (years), with maximum one-year interval between screens
Investigating if and how changes in breast composition depend on time between mea-
surements (Figures 6.5 and 6.6), the results suggested that changes in non-dense and
total breast volume increased with time between mammograms. This is consistent with
the findings above that in the younger women, the percent and absolute density did not
change significantly between screens, and that the significant change in percent density
in all ages combined was driven by an increase in non-dense volume (Table 6.2).
The relationship between change in density and time between screens was investigated
only overall and in the young group, because women aged 50 or more underwent their
second screen mostly (98%) only one or two years after the first (Figure 6.2). Thus,
there was insufficient variation in time interval to assess its effect in the older group.
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Figure 6.5: Dependence on time of changes in breast composition between two sub-
sequent mammograms (N=332)
Figure 6.6: Dependence on time of changes in breast composition between two sub-
sequent mammograms, in women aged under 50 (N=231)
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Table 6.3 shows the results of regression analyses for the change in breast composition
factors by time between screens, both adjusted and unadjusted for age at baseline. Sig-
nificant associations were only observed for non-dense breast volume (p=.03 unadjusted;
p=.05 adjusted for age) and total breast volume (p=.02 unadjusted; p=.04 adjusted for
age). Age at baseline, on the other hand, seemed to have no effect on the changes,
indicating that the rates of change in breast composition were similar at all ages. This
can also be seen in Table 6.2.
Table 6.3: Linear dependance of changes in mammographic volumetric measures on
time between screens
Factor Coef. [95% Conf. Interval] p-value
Response: Difference in percent density
Interval between screenings .02 -1.00 1.04 .97
Interval between screenings -.08 -1.15 .99 .88
Age at baseline -.02 -.11 .06 .58
Response: Difference in absolute density
Interval between screenings 2.95 -1.74 7.63 .22
Interval between screenings 2.74 -2.16 7.63 .27
Age at baseline -.02 -.41 .38 .93
Response: Difference in non-dense volume
Interval between screenings 12.13 1.35 22.91 .03
Interval between screenings 11.28 -.02 22.58 .05
Age at baseline -.22 -1.13 .70 .64
Response: Difference in total volume
Interval between screenings 15.07 2.31 27.83 .02
Interval between screenings 14.01 .65 27.38 .04
Age at baseline -.23 -1.31 .85 .67
Scatter plots in Figure 6.7 illustrate the relationship between age and breast composi-
tion, i.e. (a) percent and (b) absolute density, (c) non-dense and (d) total breast volume,
at baseline. They suggest a steady increase of non-dense and total breast volume with
age, respectively +6.8 cm3/year (p<.01) and +6.3 cm3/year (p=<.01) and a consequent
constant decrease in percent density (-.41%/year, p<.01). The absolute amount of dense
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tissue did not change significantly (-.47 cm3/year, p=.26).
Figure 6.7: Relationship between breast composition and age at baseline
Table 6.4: Breast composition measures at first and second screen, stratified by resi-
dence
screen 1 screen 2
Variable Mean (SD) Mean (SD) p
London, N=213
Percent breast density (%) 26.1 (11.3) 25.3 (11.5) .01
Absolute breast density (cm3) 101.1 (67.9) 100.3 (70.7) .96
Non-dense breast volume (cm3) 341.4 (271.1) 351.3 (279.5) < .01
Total breast volume (cm3) 442.5 (319.2) 451.5 (328.0) .03
Other UK, N=83
Percent breast density (%) 21.3 (9.3) 22.2 (10.8) .51
Absolute breast density (cm3) 96.8 (60.1) 100.0 (65.4) .15
Non-dense breast volume (cm3) 401.9 (239.9) 402.3 (228.2) .30
Total breast volume (cm3) 498.7 (277.3) 502.3 (260.7) .21
Table 6.4 examines change in breast composition between successive screens according
to area of residence. UK residents living outside London seemed not to have experi-
enced any significant changes from screen 1 to screen 2, whereas in London residents,
on average, there was a significant decrease in percent density (-.71%, p=.01) because
of a substantial increase in non-dense tissue (+9.84 cm3, p<.01). It is possible that the
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absence of observed differences in the non-London residents is due to the smaller number
of subjects; however there are not even any suggestive differences in this group. Another
hypothesis to explain these differences between the two groups is a different age com-
position (Figure 6.1), but London residents are, on average, only slightly younger (46.7
years) than women living elsewhere in the UK (47.5 years). Furthermore a Wilcoxon
rank-sum test, comparing age distributions in the two groups, was unequivocally non-
significant (p=.81).
Studying Table 6.4 vertically between London and other UK locations, it appears that
at baseline all the subjects presented with similar volumes of fibroglandular tissue in vol-
umetric terms (Wilcoxon rank-sum test: p=.88), but that London residents had lesser
fatty (non-dense) tissue and smaller total breast size (p<.01 for non-dense breast vol-
ume, p=.02 for total breast volume) leading to a higher average percent density (p<.01).
Figure 6.8: Relationship between percent breast density and age at baseline, stratified
by residence
Figures 6.8, 6.9, 6.10 and 6.11 illustrate the correlations between breast composition
and age at baseline. The increase in non-dense volume per year of age was less steep in
London (+5.61 cm3/year, p=.01) than elsewhere in the UK (+8.51 cm3/year, p<.01),
likewise for the total breast volume (London: +4.69 cm3/year, p=.08; Other UK: +9.27
cm3/year, p<.01), arguably consistent with the smaller breast size and lower fatty tissue
volume in London.
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Figure 6.9: Relationship between absolute breast density and age at baseline, strati-
fied by residence
Figure 6.10: Relationship between non-dense breast volume and age at baseline,
stratified by residence
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Figure 6.11: Relationship between total breast volume and age at baseline, stratified
by residence
6.4 Discussion
In the present study we witnessed no significant change in absolute density with age at
baseline or between successive screens, indicating that the observed variations in breast
composition, and in particular the decrease in proportion of dense tissue, are to be
attributed to the growth in volume of non-dense tissue. Between screens percent den-
sity had, overall, a limited, but statistically significant, reduction of .27% because the
non-dense tissue was volumetrically increasing at a higher rate (+11 cm3/year, Table
6.3) than the dense tissue. This result is in agreement in McCormack’s and colleagues’s
study [91] where the growth in non-dense area was much larger in magnitude than the
decline in dense area.
However unlike in the previous literature, including McCormack et al.’s findings [91],
in our case, the dense tissue did not appear to vary in absolute size. This could be
due to lack of power investigating changes in fibroglandular tissue, but also the different
methods used for assessing density could have contributed: McCormack and colleagues
used interactive-thresholding, a computer-assisted technique that estimates breast com-
ponents in terms of areas [30], whereas the current data were assessed with Quantra, a
volumetric fully-automated system [51]. The estimates from Quantra were anticipated
to be more reliable because they are not affected by the rater subjectivity, unlike those
from interactive thresholding that depend on human input; nevertheless the Quantra
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method is still undergoing validation and currently there is no conclusive evidence of
its accuracy in measuring density. Another possible explanation for the disagreement
between the current findings and those of McCormack et al. is the different age com-
position of the samples: in the present study age at baseline ranged from 34 to 81, and
almost the 70% of subjects were aged under 50, whereas McCormack and colleagues in-
cluded in their study only women aged 50 to 65. In premenopausal women breast tissue
is known to be more susceptible to both endogenous and exogenous factors [12], and
this is reflected in a wider variability in breast composition at younger ages which was
also seen in our data. This variability could have been enhanced by the longer intervals
between screens, i.e. up to 5 years, in women aged under 50, but when we repeated the
analyses including only subjects screened one year apart the results were not affected.
Furthermore, analyses run separately in two age groups, “under 50” and “50 or more”,
did not report significant differences. Such findings could also indicate that longitudinal
changes in breast composition occur at similar rates at different ages. However this could
be due to lack of power, since these results are derived from relatively small subsets of
data.
Menopause affects the characteristics of mammographic appearance [21, 89, 90], promot-
ing the involution process and leading to an average further reduction in breast percent
density of 3.26%, over 5 years, due to a reduction in glandular, i.e. dense, tissue, and
an increase in connective tissue and fat, i.e. non-dense, tissue [90]. McCormack and
colleagues [91] observed this drop and consequently described as non-linear the trajec-
tory of reduction in absolute and percent dense area over time. In the current study,
by contrast, the rate of change in breast tissue components seemed to be unaffected
by age as a substitute for menopausal status. Moreover pre- and post-menopausal (age
50) mammographic appearances were significantly different in terms of percent density
because of non-dense volume. The volume of dense tissue appeared approximately con-
stant.
Since details on area of residence were available it was possible to verify the existence of
an “urban effect”. A previous study by Perry and colleagues [246] classified 962 women
(318 from London, 654 resident outside of London) according to BIRADS density cate-
gories and then compared the incidence of each category between subjects from London
or other UK areas. It was observed that women resident in London had significantly
higher Birads categories than women resident outside the capital, after adjusting for
age. Similarly, in the current data, percent density in London residents was substan-
tially higher (Table 6.4). Once more, we found that it was more attributable to larger
volumes of fatty tissue in women resident outside London, than to a difference in ab-
solute density. In the previous publication reporting higher percent density in London
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women [246], it was speculated that this was due to lower body mass in London women,
as evident from survey data [246, 249]. The results here support this speculation.
A limitation of this study is the fact that it only comprised two screens within a rela-
tively short interval. It is possible that with a longer interval between screens we might
have observed a reduction in absolute density, due to involution, within the subjects.
However the volume of dense tissue stayed constant across age even when we performed
a cross-sectional analysis of the data at baseline, supporting our longitudinal results.
Measurement error in Quantra estimates could be partially responsible for some of the
unexpected results. As noted above, the Quantra method is currently undergoing val-
idation to assess the extent to which it is correctly measuring mammographic density.
This issue will be further developed in Chapter 8.
The availability of details on only age and residence, besides volumetric estimates of
breast components, represents another limitation. Information on other factors, e.g. ex-
ogenous hormone use, potential pregnancies between the screens and menopausal status,
could have helped us explain more clearly the variations in breast composition.
In the current study, the volume of dense tissue seemed not to be susceptible to age and
time. It has been suggested that an absolute measure of density should be chosen over
a percent one in breast cancer risk prediction contexts [33, 226], since it is less affected
by BMI. Our results suggest that further study of the non-dense component might yield
further understanding of this.
In conclusions the main implications of this analysis are:
1. Absolute non-dense volume, as measured by Quantra, appears to be more sensitive
to temporal and age-related changes than percent or absolute dense volume.
2. Research in the future should focus on whether the previous implication is due
to the measurement qualities of Quantra or to a greater biological role for non-
dense tissue. If the latter, there may be major implications for prevention and for
monitoring of preventive interventions.
3. Assuming that the results are not primarily due to measurement properties of the
Quantra instrument, the results strongly support previous findings that percent
density is higher in London women, probably due to their lower body mass.
4. These results broadly support those of others using automated or semi-automated
methods, that absolute measures of breast composition are at least as important
as percentages (and probably more so).
Chapter 7
A case control evaluation of a
fully automated volumetric
density measure (Volpara) as a
predictor of breast cancer risk
7.1 Introduction
In Chapter 5, we examined the association of a fully-automated volumetric density mea-
sure, Quantra, with breast cancer risk in a case-control study. In that chapter we noted
that, whilst there is good evidence for density as a risk factor [6], there are practical diffi-
culties in its use at population level unless a reliable and fully-automated method is avail-
able. In the USA and in other countries, the visually assessed BIRADS categorisation is
in general use, and in parts of the USA it is mandated by statute [2, 3, 234, 235, 250–252].
Nevertheless, being based on human input, it is susceptible to subjectivity [28, 250] and
its reliability on digital mammograms still requires proper validation [32] [Chapter 5],
although Harvey and colleagues recently observed good agreement in reported BI-RADS
breast density categories according to acquisition method, i.e. film or digital [247]. As
already remarked, it is thought that a continuous density assessment could provide a
more informative and accurate measure [28].
In the late 1990s, technology advances led to the development of a computer-assisted
method for assessing density, based on interactive thresholding [30]. This technique,
available as the computer programme Cumulus, is considered by many in the field to
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be the gold-standard. It provides continuous information regarding both absolute and
percent dense area observed in mammograms. Not only does Cumulus record more
complete and comprehensive information regarding breast density, it has also been ob-
served to be very effective in breast cancer risk predictions [6, 26]. The drawbacks of
this technique are that it requires trained observers and digitized images, along with
being time- and labour-intensive. For these reasons, Cumulus is difficult to use in the
context of high-volume, population mammographic screening.
Automated approaches are expected to minimize or solve these limitations, by provid-
ing quick and non-subjective assessments with little or no call on human resources. In
particular, the newly developed methods have been focusing on volumetric assessments
[36–42, 51, 52, 178, 236], because it is anticipated that volumetric estimates of den-
sity may provide more precise information about the amount of fibroglandular tissue
[30, 201]. These methods are currently undergoing validation, however the results pre-
sented so far have suggested that volumetric estimates were no more predictive of risk
than bi-dimensional measures, assessed with interactive thresholding [8, 36, 201, 245].
Volpara [52] is one of these novel fully-automated volumetric methods. It is a soft-
ware package that analyses raw images from full-field digital mammograms (FFDM) to
quantify dense tissue. Despite the current scarcity of evidence in the public domain
supporting Volpara, its implementation has already spread internationally, e.g. in UK,
Netherlands, Korea and US [253], and made its evaluation and validation urgent and
necessary.
Here we report an evaluation of the association of Volpara with breast cancer risk in a
case-control dataset, using, largely but not entirely, the same cases and controls as in
the Quantra study reported in Chapter 5.
7.2 Materials and Methods
7.2.1 Data collection
For this study, we used mostly the same digital mammograms used in the Quantra case-
control study [Chapter 5], from women attending the Princess Grace Hospital, London,
who had full-field digital mammographic examinations between 2005-2009 . Originally,
two hundred cases were randomly selected from patients with histopathologically verified
breast cancer, along with two hundred controls. Due to missing raw digital information,
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124 (62 cases) subjects could not be assessed with Volpara. Consequently 90 new sub-
jects (43 cases) were recruited.
All mammograms were high quality two-view images, soft copy reported on high resolu-
tion monitors. Image quality was not a factor in case selection and none were rejected
on quality grounds during density estimation. Among cases, density was assessed on the
last mammogram of the contralateral breast before diagnosis; for controls, density was
estimated on the same side as the matched case, using mammograms dating as close as
possible to the matched case diagnosis. Estimation of density was based on an average
of the two-views, as it is known that the craniocaudal view tends to give higher density
estimates than the mediolateral oblique. The area-based density was estimated by one
of two experienced radiologists (Dr Nick Perry and Dr Katja Pinker Domenig), using the
standard density grades according to the American College of Radiology Breast Imaging
Reporting and Data System (BIRADS) [234], as described in Chapter 5.
Results regarding Quantra density estimates are given in Chapter 5. In this chapter, we
report the corresponding results using the Volpara software [52], acquired more recently.
As previous results suggested higher density in women residing in London [246], we also
recorded data on area of residence. Area of residence was classified as London, any other
region in the UK (based on the post-code of residence), or outside the UK, referred to as
“abroad” for brevity. In addition to age at mammogram (henceforth referred to simply
as age), area of residence, and density assessed with Volpara, Quantra and BIRADS, no
information on other breast cancer risk factors was available.
Volpara assessment was only available for 366 subjects (182 cases and 184 controls).
Table 7.1 shows the numbers of cases and controls used in both chapters.
Table 7.1: Data available for both measures
Density measure cases controls
Volpara only 43 47
Quantra only 61 63
Both 139 137
7.2.2 Statistical analyses
Demographic and other variables are summarised using percentages for categorical vari-
ables or medians and IQRs for continuous variables. As noted above, we had data on age,
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area of residence classified as “London”, “Other UK regions” and “Abroad”, Volpara
and Quantra estimates for total breast volume, dense volume and non-dense volume and
BIRADS classification. Total breast volume and non-dense volume were used as a proxy
for BMI, which was not available, and age under 50 versus greater than or equal to 50
was used as a surrogate for menopausal status.
The distributions of percent and absolute density, as well as non-dense and total breast
volume, were compared between cases and controls using the Wilcoxon rank-sum test.
Unconditional logistic regression was used to calculate odds ratios (OR) for risk of breast
cancer after adjustment for age and other potential confounding factors. Loss of infor-
mation at merging made conditional logistic regression analyses, used in Chapter 5, no
longer applicable to the data as this would have entailed loss of large numbers of matched
cases and controls. This analysis was repeated after log-transformation of Volpara esti-
mates. Secondary analyses were also performed stratified by age and area of residence
(London vs other UK).
The relationship between BIRADS and Volpara was investigated graphically and Cuz-
ick’s nonparametric test was used to evaluate differences for trend across ordered groups
[214].
The agreement between the two automated density measures was assessed using Pear-
son’s correlation coefficents and contingency tables of categorised measures. Finally the
associations of Volpara and Quantra density estimates with breast cancer risk were com-
pared using standardised odds ratios.
Quantra and BIRADS analyses are presented in Chapter 5. Henceforth, in this chapter,
Volpara density estimates are referred to simply as density, unless otherwise specified.
All analyses were performed using STATA, version 12.1.
7.3 Results
Characteristics of the 182 case subjects and 184 control subjects are presented in Table
7.2. Age at mammogram and areas of residence appeared equally distributed between
cases and controls. The distribution of percent and absolute density, as well as non-
dense and total breast volume, were compared between cases and controls using the
Wilcoxon-rank-sum test. There was no significant differences in these measures between
the two groups, but absolute density was borderline significantly higher among cases
than controls (p=.07).
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Table 7.2: Characteristics of the study samples
Cases Controls Total
N=182 N=184 N=366
Age at mammogram, No. (%)
<45 22 (15.8) 21 (15.3) 43 (15.6)
45-54 46 (33.1) 47 (34.3) 93 (33.7)
55-64 37 (26.6) 36 (26.3) 73 (26.4)
≥ 65 34 (24.5) 33 (24.1) 67 (26.3)
Area of residence, No. (%)
London 71 (51.1) 81 (59.1) 152 (55.1)
Other UK 53 (38.1) 46 (33.6) 99 (35.9)
Abroad 15 (10.8) 10 (7.3) 25 (9.0)
Measures of mammographic breast density assessed by Volpara, Median (IQR)
Percent breast density, in % 11.9 (7.2) 11.4 (7.0) 11.7 (7.1)
Absolute breast density, in cm3 66.4 (38.3) 58.7 (31.4) 62.5 (35.2)
Non-dense breast volume, in cm3 634.4 (416.3) 588.5 (372.5) 611.3 (395.0)
Total breast volume, in cm3 700.7 (428.2) 647.3 (382.3) 673.9 (406.1)
Table 7.3 summarises the distribution of BIRADS classification between cases and con-
trols. Overall, there was a smaller proportion of cases in the lowest density category,
and a greater proportion in the highest. These differences appeared stronger in the older
age group. Further results regarding BIRADS on this dataset are presented in Chapter
5.
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Table 7.3: Distribution of BIRADS in cases and controls (percentages)
BIRADS Cases (%) Controls (%)
N=139 N=137
Under 50
(A) <25% dense “almost entirely fatty” 11 (19.0) 11 (20.4)
(B) 25-50% dense “scattered fibroglandular density” 28 (48.3) 26 (48.1)
(C) 50-75% dense “hetereogeneously dense” 15 (25.8) 12 (22.2)
(D) >75% dense “extremely dense” 4 (6.9) 5 (9.3)
50 or more
(A) <25% dense “almost entirely fatty” 11 (13.6) 16 (19.3)
(B) 25-50% dense “scattered fibroglandular density” 50 (61.7) 40 (48.2)
(C) 50-75% dense “hetereogeneously dense” 6 (7.4) 19 (22.9)
(D) >75% dense “extremely dense” 14 (17.3) 8 (9.6)
Overall
(A) <25% dense “almost entirely fatty” 22 (15.8) 27 (19.7)
(B) 25-50% dense “scattered fibroglandular density” 78 (56.1) 66 (48.2)
(C) 50-75% dense “hetereogeneously dense” 21 (15.1) 31 (22.6)
(D) >75% dense “extremely dense” 18 (13.0) 13 (9.5)
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Figure 7.1: Distribution of (a) percent and (b) absolute breast density in cases and
controls
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Table 7.4: ORs for developing breast cancer from unconditional logistic regression
models using Volpara absolute density
Factor category obs OR [95% Conf. Interval] P>z
adjusted for age
absolute density per 10 cm3 366 1.07 1.00 1.13 .038
age per year 1.00 .98 1.02 .809
adjusted for age and non-dense volume
absolute density per 10 cm3 366 1.06 1.00 1.13 .069
age per year 1.00 .98 1.02 .914
non-dense volume per 10 cm3 1.00 1.00 1.01 .602
adjusted for age and London residence
absolute density per 10 cm3 251 1.06 .98 1.14 .123
age per year 1.00 .97 1.02 .754
area of residence Other UK 1.00 (referent) .309
London .77 .46 1.28
adjusted for age, non-dense volume and London residence
absolute density per 10 cm3 251 1.06 .98 1.15 .129
age per year 1.00 .97 1.02 .800
non-dense volume per 10 cm3 1.00 1.00 1.01 .841
area of residence Other UK 1.00 (referent) .302
London .76 .46 1.28
We also investigated the association of percent and absolute density assessed using Vol-
para with breast cancer risk (Figure 7.1). The odds ratios relating to absolute density
and non-dense volume are expressed per 10 cubic centimetre increase, whereas those re-
lating to percent density are per 10% increase. Comparing the performance in risk pre-
diction of the two density measures derived by the Volpara system (Tables 7.4 and 7.5),
the results suggested that only absolute density had a significant main effect (p=.04),
after age-adjustment. An increase of 10 cm3 1 in fibroglandular volume would lead to a
7% increase in the odds of breast cancer. The inclusion of non-dense volume to the model
did not substantially alter the result, whereas adjusting for area of residence weakened
it, possibly by causing a reduction in the number of observations (Table 7.4). Volpara
percent density, on the other hand, had a non-significant association with breast cancer
risk, even after adjustment for the other available risk factors (Table 7.5).
The introduction of the area of residence in the model (Table 7.4-7.5) caused a reduction
1the average absolue density is 62.5 cm3
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Table 7.5: ORs for developing breast cancer from unconditional logistic regression
models using Volpara percent density
Factor category obs OR [95% Conf. Interval] P>z
adjusted for age
% density per 10 % 366 1.11 .82 1.50 .513
age per year 1.00 .98 1.02 .886
adjusted for age and non-dense volume
% density per 10 % 366 1.37 .94 2.00 .105
age per year 1.00 .98 1.02 .872
non-dense volume per 10 cm3 1.01 1.00 1.01 .064
adjusted for age and London residence
% density per 10 % 251 1.20 .83 1.75 .335
age per year 1.00 .97 1.02 .823
area of residence Other UK 1.00 (referent) .247
London .74 .44 1.23
adjusted for age, non-dense volume and London residence
n=251
% density per 10 % 251 1.40 .88 2.22 .154
age per year 1.00 .97 1.02 .865
non-dense volume per 10 cm3 1.00 1.00 1.01 .267
area of residence Other UK 1.00 (referent) .273
London .75 .45 1.25
in sample size for two reasons: (a) 25 foreign women were excluded from the analysis, in
order to study the urban effect of London against other areas in the UK; (b) further 90
observations were dropped because of missing values. While it increases the standard
error and reduces significance, adjustment for area of residence does not notably change
the ORs for density, nor is area of residence significant. Therefore, adjustment for area
of residence is probably counter-productive, lowering precision of estimation with no
gain in validity.
Table 7.6 shows the ORs associated with quintiles of absolute dense volume, based on
the control distribution, in order to facilitate the understanding of the shape of the as-
sociation between Volpara absolute density and risk of developing breast cancer. There
was no significant difference in the odds across the quintiles (p=.12). This may suggest
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Table 7.6: ORs for developing breast cancer from an unconditional age-adjusted
logistic regression model using the quintiles of Quantra absolute density among controls,
N=366
OR [95% Conf. Interval] P>z
1st quintile (0− 34.75 cm3) 1.00 (referent) .119
2nd quintile (34.75− 43.58 cm3) .97 .49 1.92
3rd quintile (43.58− 59.15 cm3) 1.23 .63 2.41
4th quintile (59.15− 80.78 cm3) 1.43 .75 2.75
5th quintile (> 80.78 cm3) 1.35 .77 2.37
age 1.00 .98 1.02
that the association between breast cancer risk and density which we observed previ-
ously (Table 7.4) is substantially influenced by small numbers of extreme values among
cases, as Figure 7.1 also suggests. It may also suggest a threshold effect as the main
difference in Table 7.6 is between quintiles 1-2 combined and 3-5 combined.
Results of the analyses using Volpara measures after log-transformation are summarised
in Table 7.7. Evidence of an association between breast cancer risk and absolute density
appears weaker, i.e. only borderline significant (p=.06), in comparison with the results
obtained using the original measures. However, overall they led to similar conclusions
to those of Tables 7.4 and 7.5. We therefore returned to the original measures for subse-
quent analyses, to facilitate interpretation of results. In addition to this, in the analysis
based on the log-transformed densities, the χ2 statistics demonstrate that adjustment of
the percent density variable for non-dense or total breast volume is returning the same
information as absolute density but at the cost of adding a degree of freedom.
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Table 7.7: ORs for developing breast cancer risk from unconditional age-adjusted
logistic regression models using Volpara log-transformed measures
Factor obs OR [95% Conf. Interval] P>z model χ2 df
adjusted for age
log-absolute density 366 1.47 .98 2.19 .061 3.55 2
age 1.00 .98 1.02 .842
adjusted for age and log-non-dense volume
log-absolute density 366 1.45 .94 2.22 .091 3.59 3
age 1.00 .98 1.02 .890
log-non-dense volume 1.03 .74 1.45 .846
adjusted for age and log-total volume
log-absolute density 366 1.44 .92 2.24 .109 3.59 3
age 1.00 .98 1.02 .890
log-total volume 1.04 .71 1.53 .842
adjusted for age
log-% density 366 1.12 .79 1.58 .525 0.41 2
age 1.00 .98 1.02 .902
adjusted for age and log-non-dense volume
log-% density 366 1.51 .93 2.43 .094 3.55 3
age 1.00 .98 1.02 .904
log-non-dense volume 1.49 .96 2.32 .079
adjusted for age and log-total volume
log-% density 366 1.44 .92 2.24 .109 3.59 3
age 1.00 .98 1.02 .892
log- total volume 1.49 .96 2.33 .077
The logistic regression analyses were repeated in women aged under 50 and 50 or more
separately (Tables 7.8 and 7.9). Volpara absolute density was not significantly related
to risk in both groups, but there was a considerable loss of power as the sample size was
reduced from 366 to 130 and 236 respectively (Table 7.8). Also, the size of OR was the
same as the significant results for all ages combined. Similar results were obtained from
the analyses using percent density (Table 7.9).
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Table 7.8: ORs for developing breast cancer from unconditional age-adjusted logistic
regression models using Volpara absolute density, stratified by age
Factor category obs OR [95% Conf. Interval] P>z
adjusted for age
under 50
absolute density per 10 cm3 130 1.07 .98 1.17 .151
age per year .98 .93 1.04 .577
50 or more
absolute density per 10 cm3 236 1.07 .98 1.16 .123
age per year 1.01 .97 1.04 .735
adjusted for age and non-dense volume
under 50
absolute density per 10 cm3 130 1.08 .98 1.19 .132
age per year .99 .93 1.04 .604
non-dense volume per 10 cm3 1.00 .99 1.01 .643
50 or more
absolute density per 10 cm3 236 1.06 .97 1.15 .228
age per year 1.00 .97 1.04 .798
non-dense volume per 10 cm3 1.00 1.00 1.01 .393
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Table 7.9: ORs for developing breast cancer from unconditional age-adjusted logistic
regression models using Volpara percent density, stratified by age
Factor category obs OR [95 Conf. Interval] P>z
adjusted for age
under 50
% density per 10 % 130 1.16 .74 1.82 .505
age per year .99 .94 1.04 .686
50 or more
% density per 10 % 236 1.05 .68 1.62 .815
age per year 1.01 .97 1.04 .741
adjusted for age and non-dense volume
under 50
% density per 10 % 130 1.32 .73 2.39 .351
age per year .99 .94 1.04 .679
non-dense volume per 10 cm 3 1.00 .99 1.02 .511
50 or more
% density per 10 % 236 1.38 .81 2.35 .235
age per year 1.00 .97 1.04 .806
non-dense volume per 10 cm3 1.01 .99 1.01 .087
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Figure 7.2: Comparison of medians and inter-quartile ranges of Volpara (a) percent
density, (b) non-dense volume and (c) absolute density by age group, between cases
and controls
Figure 7.2 depicts the differences in breast composition between cases and controls ac-
cording to age group. Results showed no substantial difference at any age and in any
of the breast characteristics here presented, (a) percent density, (b) non-dense breast
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volume and (c) absolute density.
Table 7.10: ORs for developing breast cancer from unconditional age-adjusted logistic
regression models using Volpara absolute density, stratified by UK location of residence
Factor category obs OR [95% Conf. Interval] P>z
adjusted for age
London
absolute density per 10 cm3 152 1.10 .99 1.21 .069
age per year 1.01 .98 1.05 .374
other UK
absolute density per 10 cm3 99 1.02 .91 1.13 .768
age per year .98 .94 1.01 .162
adjusted for age and non-dense volume
London
absolute density per 10 cm3 152 1.08 .97 1.19 .163
age per year 1.01 .98 1.04 .546
non-dense volume per 10 cm3 1.01 1.00 1.02 .206
other UK
absolute density per 10 cm3 99 1.06 .94 1.20 .355
age per year .98 .95 1.02 .364
non-dense volume per 10 cm3 .99 .98 1.00 .121
In the analyses stratified by area of residence (Tables 7.10, 7.11 and 7.12) 25 women
living abroad were excluded to focus on the potential influence of urban and provincial
environment within the UK on breast density and its risk-predictive ability. A further
90 observations were dropped because of missing values resulting in a reduced sample
size which may affect the reliability of the results. Volpara absolute density seemed to
better discriminate cases from controls among London residents, although this was only
only borderline significant (p=.07), whereas Volpara percent density was borderline sig-
nificant (p=.08) in discriminating cases from controls among British women not living
in the capital.
According to Figure 7.3, cases residing in London or elsewhere in the UK have a very
similar pattern in absolute density (c) across ages, and have no significant differences
either in (a) percent density or (b) non-dense breast volume. Likewise, among controls
(Figure 7.4) we observed no difference among (a) percent density, (b) non-dense breast
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Table 7.11: ORs for developing breast cancer from unconditional age-adjusted logistic
regression models using Volpara percent density, stratified by UK location of residence
factor category obs OR [95% Conf. Interval] P>z
adjusted for age
London
% density per 10 % 152 .97 .61 1.55 .906
age per year 1.01 .98 1.04 .658
other UK
% density per 10 % 99 1.85 .93 3.67 .078
age per year .99 .95 1.03 .510
adjusted for age and non-dense volume
London
% density per 10 % 152 1.49 .81 2.76 .199
age per year 1.01 .98 1.04 .524
non-dense volume per 10 cm3 1.01 1.00 1.02 .035
other UK, n=99
% density per 10 % 99 1.68 .77 3.69 .196
age per year .99 .95 1.03 .506
non-dense volume per 10 cm3 1.00 .99 1.01 .639
Table 7.12: Distribution of cases and controls according to area of residence and age
at mammogram
controls (%) cases (%) Total (%)
London, n=152
Under 50 33 (40.7) 29 (40.8) 62 (40.8)
50 or more 48 (59.3) 42 (59.2) 90 (59.2)
Other UK, n=99
Under 50 15 (32.6) 23 (43.4) 38 (38.4)
50 or more 31 (67.4) 30 (56.6) 61 (61.6)
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Figure 7.3: Comparison of medians and inter-quartile ranges of Volpara (a) percent
density, (b) non-dense volume and (c) absolute density by age group, between UK
residents from London or other British regions, in cases
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Figure 7.4: Comparison of medians and inter-quartile ranges of Volpara (a) percent
density, (b) non-dense volume and (c) absolute density by age group, between UK
residents from London or other British regions, in controls
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volume and (c) absolute density comparing subjects living in London or in another UK
area. Nevertheless it can be observed that London control residents have consistently
higher median percent density than women resident elsewhere in the UK, despite the
fact that women with a different area of residence have mostly higher absolute dense
volume. This is observed because London residents had consistently lower non-dense
volume, according to Volpara estimates.
Figure 7.5: Boxplots of Volpara (a) percent and (b) absolute breast density stratified
by BIRADS categories and case-control status)
Figure 7.5 shows the relationship between BIRADS and Volpara density measures. These
boxplots represent the distribution of percent and absolute density in each BIRADS
category. Ideally, with increasing BIRADS category, we would expect to observe an in-
creasing trend, at least of Volpara percent density, as evidence of a positive association
A case control evaluation of Volpara 178
between the two methods. Results from tests for trend in Volpara percent density with
increasing BIRADS category suggest the absence of an overall association (p=.70), but a
positive association among controls (p=.05) and a negative trend among cases (p=.01).
However, there appears to be no association between BIRADS and Volpara absolute
density, and tests for trend confirm this lack of association between the two measures
(overall: p=.92, controls: p=.95 and cases: p=.99).
Figure 7.6: Boxplots of Volpara (a) non-dense and (b) total breast volume stratified
by BIRADS categories and case-control status)
Analyses of the other measures estimated by Volpara, non-dense and total breast volume
(Figure 7.6), help to explain these results. Overall no significant trend was observed for
either measure (non-dense breast volume: p=.59, total breast volume: p=.58), whereas
a significant declining trend for both was observed among controls (non-dense breast
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volume: p=.04, total breast volume: p=.04), and a significant increasing trend among
cases (non-dense breast volume: p<.01, total breast volume: p<.01).
Table 7.13: ORs for developing breast cancer risk from unconditional age-adjusted
logistic regression models using Volpara absolute density and adjusting for BIRADS
categories
Factor category obs OR [95% Conf. Interval] P>z
absolute density per 10 cm3 276 1.06 .99 1.14 .086
BIRADS 0-25% dense 1.00 (referent) .794
25-50% dense 1.51 .78 2.91
50-75% dense .80 .36 1.79
75-100% dense 1.73 .69 4.33
age per year 1.00 .97 1.02 .619
Given the lack of association between BIRADS and Volpara absolute density, we per-
formed an age-adjusted unconditional logistic regression including both measures, Table
7.13. These results provide further evidence of the lack of impact that BIRADS classifi-
cation has on Volpara absolute density and vice versa, as the values do not vary greatly
from those reported previously in Table 7.4. However, the association between Volpara
density and breast cancer risk was slightly weakened.
Further results regarding BIRADS on this dataset are presented in Chapter 5.
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Figure 7.7: Association between Volpara and Quantra estimates
Analyses of the association between Quantra and Volpara methods showed high and
significant correlations between all the breast composition characteristics estimated, (a)
percent and (b) absolute density, (c) non-dense and (d) total breast volume (Figure 7.7).
Volpara density measures were consistently lower than those estimated by Quantra, per-
haps because the former method does not treat skin as dense tissue. These plots also
highlighted a worse agreement between the two methods for higher values of Quantra.
As regards non-dense and total breast volumes, Volpara estimates were consistently
higher. Consequently standard deviations were higher for Volpara measures of non-dense
and total breast volume than those obtained by Quantra (395.0 vs 291.8 for non-dense
breast volume and 406.1 vs 334.3 for total breast volume). Conversely, Volpara density
estimates had a consistently lower standard deviations compared to Quantra density
measures (7.1 vs 9.7 for percent density and 35.2 vs 60.2 for absolute density).
The association between Quantra and Volpara estimates for absolute density was also in-
vestigated by comparing their quintile distributions in a contingency table (Table 7.14).
The cut-off points vary between the two methods, but because of the differences in the
two algorithms, standardised categories would lead to a poorer agreement, thus it was
preferred to compare Quantra and Volpara estimates on their own scales. Results indi-
cated an overall agreement of 54.7 %, with 26.5 % of subjects classified in higher quintiles
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by Volpara, and vice versa for the remaining 18.8%. The absence of observations in the
two most extreme cells (top right and bottom left) and low percent frequency in the
adjacent cells are also indicators of good agreement between the two measures.
Table 7.14: Absolute and relative (%) cell frequencies comparing Volpara and Quantra
quintile distributions for absolute density
Quantra
Volpara 0-46.6 cm3 46.6-68 cm3 68-91 cm3 91-125.4 cm3 >125.4 cm3 Total
0-34.8 cm3 32(11.6) 16(5.8) 1(.4) 0(.0) 0(.0) 49(17.8)
34.8-43.6 cm3 10(3.6) 18(6.5) 7(2.5) 5 (1.8) 1(.4) 41(14.9)
43.6-59.2 cm3 4(1.5) 8(2.9) 24(8.7) 9 (3.3) 7(2.5) 52(18.8)
59.2-80.8 cm3 2(.7) 5(1.8) 25(9.1) 29(10.5) 6(2.2) 67(24.3)
>80.8 cm3 0(.0) 4(1.5) 4(1.5) 11(4.0) 48(17.4) 67(24.3)
Total 48(17.4) 51(18.5) 61(22.1) 54(19.6) 62(22.4) 276(100.0)
Finally, we compared Volpara and Quantra with respect to their associations with breast
cancer risk (Table 7.15), in terms of the effect per 10 cm3 for absolute density and per
10% for percent density. We then report the standardised effects (i.e. OR per standard
deviation) to enable a scale-free comparison of the two methods. ORs and p-values were
very similar between the two methods for both absolute and percent density, and this
result is confirmed by the standardised ORs.
Further results assessing Quantra using this dataset are presented in Chapter 5.
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Table 7.15: ORs for developing breast cancer risk from age-adjusted unconditional
logistic regression using Volpara and Quantra density estimates
Factor obs OR [95% Conf. Interval] P>z
Absolute density
Volpara per 10 cm3 366 1.07 1.00 1.13 .038
age per year 1.00 .98 1.02 .809
Quantra per 10 cm3 400 1.04 1.00 1.07 .030
age per year 1.00 .98 1.02 .848
Percent density
Volpara per 10 % 366 1.11 .81 1.50 .513
age per year 1.00 .98 1.02 .886
Quantra per 10 % 400 1.15 .92 1.42 .221
age per year 1.00 .99 1.02 .679
Standardised OR
Volpara per 1 standard deviation 366 1.26 1.01 1.56 .038
age per year 1.00 .98 1.02 .809
Quantra per 1 standard deviation 400 1.25 1.02 1.53 .030
age per year 1.00 .98 1.02 .848
7.4 Discussion
The data support the hypothesis that absolute volume of dense tissue could be a bet-
ter predictor of breast cancer risk than percent density. This may be because absolute
density is a closer measure of the quantity of tissue at risk of malignant transformation.
However, despite being statistically significant, the ORs do not indicate a particularly
strong relationship, i.e. increases in absolute density do not reflect substantial increase
in risk. In fact, when comparing the extreme quintiles (Table 7.6), the odds of expected
cases and controls are not substantially different (OR: 1.35, 95% CI (.77-2.37)).
As noted in Chapter 5, the study population here is younger and likely to be of higher
socioeconomic status than generla population women in the UK screening programme.
However, one would expect case-control differences in breast density to prevail in our
population as in the general population.
The overall lack of association between Volpara and BIRADS is surprising and raises
questions about the validity of both measures. In particular, stratified analyses revealed
a positive association between BIRADS and Volpara percent density among controls and
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a negative one among cases. This was observed because Volpara non-dense and total
breast volume decreased with increasing BIRADS category among controls and increased
along with BIRADS categories among cases. Volpara absolute volume and BIRADS cat-
egories, on the other hand, appeared independent in both groups. Likewise, Quantra
measures of non-dense and absolute breast volume increased steadily with increasing
BIRADS categories [Chapter 5]. This leads to doubts about what the two volumetric
methods are actually assessing. Volpara percent density was non-significantly related to
breast cancer risk even after adjusting for age and non-dense volume. Also, the associa-
tion between BIRADS and risk of developing breast tumours was weaker than expected
[6] [Chapter 5]. This may be due to an inherent difficulty in visual estimation of density
from processed digital images. The use of processed images for visual assessment, and
raw data for automated assessment, may have implications for the association between
the two.
In 2013 Wang and colleagues [50] ran a study on 99 women comparing mammographic
measures of volumetric breast density, including Volpara, to MRI density [47]. They
found that average total breast volume was higher for Volpara than for MRI, probably
due to the fact that Volpara includes the edge in their estimates, a moderate correla-
tion and agreement were observed between the two methods measuring percent density
(squared Pearson’s correlation coefficient: .73, and kappa statistics: .68). These results
are encouraging, suggesting that Volpara is capturing the right amount of dense tissue,
nevertheless larger datasets are needed for validation.
Investigation of the relationship between the two volumetric methods suggest a strong
association and similarity. Pearson’s correlation coefficients showed an almost perfect
correlation (98%) for non-dense and total volume, and were lower, although still very
high (over 80%), in the density measures. This lower correlation is likely to be due to the
exclusion of skin tissue from Volpara dense estimates. Nevertheless, for the association
with breast cancer risk (Table 7.15), Volpara and Quantra density estimates were very
similar, both for ORs and p-values. The standardised ORs provide further support of
the hypothesis of equivalence between the two techniques, in terms of breast cancer risk
prediction.
In terms of costs, both Quantra and Volpara have multiple packages with diminishing
additional costs per additional unit, but both would cost approximately US $ 50,000 for
the software and hardware. On cost alone, it would be difficult to decide between the
two.
As in the Quantra study (Chapter 5), this dataset was comprised of symptomatic cases,
which may have affected our findings due to masking. Again, if this were the case, as in
Chapter 5, we would have expected a much stronger association between density and risk.
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Interestingly, for analysis of area of residence, the higher percent density among London
residents without breast cancer (Figure 7.4) was driven by a lower non-dense volume
rather than a higher dense volume. This is in agreement with the Quantra results
[Chapter 5] and is consistent with the hypothesis that a higher percent density in Lon-
don residents is largely due to lower BMI in London women [246, 249].
The main weakness of this study lies in the limited sample size, which suffered a fur-
ther loss of information during merging. The analyses may have also benefited from
additional details on other risk factors, which could have helped to explain and clarify
the unexpected results we observed. Thus these findings require further validation on a
richer and larger dataset.
In conclusion, Volpara absolute density is a breast cancer risk predictor of similar
strength to Quantra, and the two measures are strongly related. Validation in a larger
dataset with information on potential confounders would be useful.
Chapter 8
Measuring mammographic
density: results, issues and
potential implications
8.1 Introduction
In the review in Chapter 1, we described how the methods of measurement of mam-
mographic density have developed since 1976 [5] and discussed some of the outstanding
issues delaying a more extensive use of density in breast cancer screening.
Mammographic density is a strong risk factor for breast cancer. Evidence of this associa-
tion has been published in the past decades [15, 16, 254, 255] and a recent meta-analysis
[6] confirmed that a dense breast indicates a four- to six-fold increase of risk of devel-
oping a breast cancer compared to a non-dense. Nevertheless mammographic density is
underused as a means of assessing breast cancer risk. One explanation for this is that,
despite the wide availability of technology and the high attendance in breast screening
programs, how mammographic density should be assessed effectively and feasibly in rou-
tine screening has not been determined yet.
To date, the most commonly applied methods for measuring density are based on vi-
sual assessment (usually BIRADS), and interactive thresholding (Cumulus, a computer-
assisted technique), both of which have drawbacks. Firstly, visual assessments depend on
human judgement, and this introduces subjectivity in the form of inter- and intra-rater
variability, raising questions of reproducibility [27]. Advancements in technology led to
the introduction of interactive thresholding [256], arguably the current gold standard,
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which is less subjective, although it still relies on reader input, and has the advantage
of providing more comprehensive information about total breast area, dense area and
non-dense area [28, 30, 256]. However, the main barrier to density being routinely mea-
sured with this method lies in its time-consuming nature that makes it impractical for
density assessment in routine population screening. In addition, both methods reduce
a three-dimensional feature, the breast, to its bi-dimensional projection obtained on a
mammogram, and may lose accuracy by not taking into account the thickness of the
dense tissue of the breast. It is therefore anticipated that volumetric measures of dense
tissue will provide more precise estimates of the amount of fibroglandular tissue within
the breast and thus will be a better predictor of breast cancer risk [201]. For this reason,
recent years witnessed the development of several fully-automated volumetric methods
[36–42, 51, 52, 178, 236], that are undergoing validation.
In this chapter, we focus on some of these issues relating to variability, from both mea-
surement error and genuine population variation in breast composition, in measurement
of mammographic density and suggest possible solutions. Firstly, we analyse intra- and
inter-reader agreement in visual (21 categories) and Cumulus [256] assessments, using
data from the IBIS-I study [17]. Secondly, we investigate the potential effect of measuring
error on observed risk associations, in density assessed with the novel fully-automated
volumetric method Quantra [51, 178], using datasets introduced in chapters 5-6, and
applying a modification of Rosner’s and colleagues’s method [257–259] for correcting for
the measurement error. This method is based on the method of moments and requires
the estimates of the variability components from an external dataset with serial assess-
ments of the factor prone to measurement error, in this case Quantra absolute density
estimates. Then, we study the relationship between two- and three-dimensional density
assessments, focusing on their difference in variability, albeit in data from two different
population, with data from CADET1 [4] and the Quantra longitudinal study [Chapter
6]. Finally, we compare the association with breast cancer risk of most of the density
measures available for this project: visual (Chapter 2), Cumulus (Chapters 2 and 4),
Quantra (Chapter 5) and Volpara (Chapter 7). In this analysis, we use the exponential
of the standard logistic regression coefficient as the measure of association for each den-
sity method. Thus each measure of association is the odds ratio per standard deviation
of the density measure, so that all methods are assessed on a comparable scale.
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8.2 Inter- and intra-reader agreement (IBIS-I)
Cumulus is said to be preferable to visual assessment because it provides more complete
information regarding breast composition, thus leading to more accurate estimates of
breast cancer risk, and it is to some extent less subjective, because it is partially auto-
mated. However there is a scarcity of literature regarding reader reproducibility.
In this section we focus on quantifying variability in Cumulus estimates from the same
mammograms, and compare them with visual density assessment (to the nearest 5%).
We also evaluate both inter- and intra-reader agreement in visual assessment.
8.2.1 Materials and Methods
8.2.1.1 Data Collection
The IBIS-I chemoprevention study was an international trial designed to evaluate the
role of tamoxifen for breast cancer risk reduction in high-risk women. The study popu-
lation comprised a total of 7,152 women aged 30-70 years. A nested case-control study
was conducted to investigate relationships between treatment, change in mammographic
density and known breast cancer risk factors. It comprised data from 123 cases and 942
controls and some results were published in 2011 [17].
Mammographic density was assessed on these 1,065 subjects both at baseline and after
12-month follow-up. Three trained readers (J. Stone, J. Warwick and P. Allgood) used
Cumulus software to measure both absolute and percent dense area. The same read-
ers received training by one experienced radiologist (R.M.L. Warren) and classified the
proportion of dense tissue in the subjects visually on a 21-point scale (to the nearest
5%). Prof. Warren also performed visual density assessment on the whole sample, on
two separate occasions in order to allow analyses of intra-reader agreement. One reader
(PA) performed her assessment on only 56% of the sample. However most of the sub-
jects (98%) had density assessed with Cumulus by 2 readers (JS and JW) and visually
by 3 (JS, JW and RW). Note that there is a difference in the number of mammograms
read visually and using Cumulus by each reader.
Since Prof. Warren provided the training and was by far the most experienced reader,
we considered her as the referrent reader when comparing visual assessments.
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8.2.1.2 Statistical Analyses
The focus of the analyses reported here was the inter-reader agreement and not the
change in density between baseline and follow-up, hence each mammogram was counted
separately, allowing the size of the sample for the analyses to double. To verify that
the inclusion of two mammograms for each subject would not influence the results, we
repeated the analyses using only baseline mammograms. As we obtained very similar
outcomes (results not shown), we decided to keep all the mammograms available. Like-
wise the exclusion of the cancer cases gave similar results.
For an exploratory analysis, we compared the distributions in the readers’ assessments
using mean, SD and percentiles for Cumulus estimates, and histograms for visual.
We compared the readers in pairs using Bland-Altman limits of agreement plots [260]
and concordance correlation coefficients [261, 262] for Cumulus continuous estimates
and Cohen’s kappas for visual discrete measures, as well as average absolute differences.
Bland and Altman are sceptical about the intraclass correlation coefficient (ICC), as it
models measurements by different raters as replicates, whereas they may be systemati-
cally different due to individual rater tendencies. It has been noted, however, that the
ICC is a useful summary of the relative size of the between-subject variation (reader vari-
ation of the attribute from person to person) and the within-subject variation (variation
between measures on the same subject due to measurement error) [263]. We therefore
calculated ICCs as a secondary measure.
Prof. Warren repeated her readings in two occasions 6-month apart, and intrareader
agreement was also studied.
8.2.2 Results
The distributions of all the density measures considered are summarised in Table 8.1 and
Figure 8.1. Concerning Cumulus estimates, the two main readers (1 and 2) had similar
distributions (Wilcoxon rank-sum test: p=.12 for absolute density and p=.15 for percent
density), whereas assessments by the third reader appeared consistently lower, both for
absolute and percent density (Wilcoxon rank-sum test: p<.01 in each comparison). For
visual assessments (Figure 8.1), Prof. Warren is identified as “reader 0”, having trained
the other three. The distributions, in this case, appeared uneven but, overall, similar.
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Table 8.1: Summary statistics of Cumulus measures by reader
Reader obs Mean SD 1st quartile median 3rd quartile
Absolute density (cm2)
1 2084 24.62 15.54 13.75 23.29 33.33
2 2099 23.93 15.20 13.34 22.16 32.50
3 1192 21.08 14.64 10.33 18.77 28.85
Percent density (% )
1 2084 36.24 21.06 20.21 36.43 51.85
2 2099 37.25 21.37 20.71 36.83 53.16
3 1192 32.78 20.23 16.10 31.72 47.83
Figure 8.1: Distribution of visual density assessments according to reader
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Overall concordance coefficients (Figure 8.2) suggested about 80% concordance between
readers for both absolute and percent density estimated with Cumulus, with a peak of
85% between the two main readers. Bland-Altman limits of agreement plots allow to
evaluate how the agreement was affected by the level of density, in other words if the
mammograms were overall darker or whiter. The shapes of the scatter plots suggest a
better agreement for extremely low values, i.e. darker mammograms, then the variabil-
ity increased in an approximately linear fashion with increasing density estimates with a
peak at about 40% for percent dense area and between 30 and 50 cm2 for absolute mea-
sures. On the other hand, the width between the 95% limits of agreement line indicated
that the estimates were quite variable between readers, and also support the hypothesis
that readers 1 and 2 have the better agreement. Further evidence for this hypothesis
is the fact that the lines of observed average agreement between readers 1 and 2 are
close to the one of perfect agreement both for percent and absolute density estimates
(Figures 8.2.a and .b). Comparing these two readers with reader 3 (Figures 8.2.c-.f), it
appeared that this third reader would estimate density with on average lower values, as
suggested by the scatter plots and especially by the observed average agreement line.
It can be speculated that the better agreement between readers 1 and 2 is due to the
larger samples of mammograms used for the analyses. However repeating the analyses
on a reduced number of mammograms, including only those read also by reader 3, the
concordance correlation agreement between the first two readers remained the highest
(.86 (.85-.88) for both percent and absolute dense area, compared with .81 (.79-.83) for
percent and .80 (.78-.82) for absolute between readers 1 and 3, and .77 (.75-.79) for
percent and .77 (.75-.79) for absolute between readers 2 and 3).
In this comparison there was no reader known to be the referent as they all received
the same training. However, comparing the visual readings with reader 0 (our refer-
ent), reader 1 had the highest concordance correlation coefficient (.89 (.88-.89)), and
was therefore considered as referent for the Cumulus readings.
Note that readers 1-3 were abbreviated as r1-3.
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Figure 8.2: Bland-Altman’s limits of agreement plots and concordance correlation
coefficients between readers
y=0 is the line of perfect average agreement, the dotted line is the observed average
agreement and the two external lines are the 95% limits of agreement.
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Absolute differences between readers assessments are summarised in Table 8.2. Cumulus
density estimates were on average less than 8 cm2 apart, but for almost 120 mammo-
grams were over 15 cm2 when comparing reader 3 with the two other readers. Differences
were lower among the readers 1 and 2, and differences between assessments of at least 15
cm2 were recorded only on 8% of the mammograms. Cumulus percent dense estimates
were on average approximately 10 units apart between readers, with differences of over
20% for about 1 mammogram in 10. Again, readers 1 and 2 had the better agreement,
whereas reader 2 and reader 3 disagreed more often.
Table 8.2: Absolute differences in Cumulus density estimates between readers
Readers Obs. Mean SD Min Max 1st decile 9th decile
Absolute density (cm2)
r1-r2 2073 5.86 6.33 .00 53.09 .651 13.65
r1-r3 1172 6.90 6.90 .00 52.63 .744 15.65
r2-r3 1181 7.51 7.34 .00 59.97 .831 17.03
Percent density (% )
r1-r2 2073 8.39 7.83 .00 56.94 1.11 18.48
r1-r3 1172 9.45 8.61 .00 57.48 1.01 20.91
r2-r3 1181 11.05 9.38 .00 57.20 1.34 23.62
The ICC was 82% (95% CI (81%, 83%)) for both absolute and percent dense area, indi-
cating considerably more variance between subjects than between measures on the same
subjects, and suggesting reproducibility of density assessed with Cumulus by trained
readers, both in absolute and percent terms.
Table 8.3: Weighted Cohen’s kappas for visual density estimates between readers
Expected
Readers Agreement Agreement Kappa Std. Err. Z Prob>Z
r0-r1 90.19% 67.95% .69 .014 50.77 <.001
r0-r2 86.14% 67.87% .57 .014 41.51 <.001
r0-r3 87.15% 66.86% .61 .019 32.8 <.001
r1-r2 88.74% 70.30% .62 .013 46.32 <.001
r1-r3 88.76% 68.88% .64 .018 35.5 <.001
r2-r3 87.15% 69.87% .57 .018 31.22 <.001
Measuring mammographic density: results, issues and potential implications 193
Table 8.4: Absolute differences in visual percent (to the nearest 5%) density estimates
between readers
Readers Obs. Mean SD Min Max 1st decile 9th decile
r0-r1 2090 9.81 9.06 0 80 0 20
r0-r2 2090 13.86 12.89 0 95 0 30
r0-r3 1180 12.85 12.44 0 75 0 30
r1-r2 2090 11.26 12.26 0 85 0 25
r1-r3 1180 11.24 11.06 0 65 0 25
r2-r3 1180 12.85 12.14 0 80 0 25
Visual classification (21 categories) showed excellent inter-rater agreement between read-
ers, between 86% and 90% (Table 8.3). There was on average a distance of 2 categories
(over 10%) for every pair of readers (Table 8.4), except for the pair composed by reader0
and reader 1 who had an average smaller distance (9.8%), that suggests a better agree-
ment. In around 10% of cases, two readers would classify the mammograms at least
four units apart (a difference of 20% or more). In particular, reader 2’s assessments
were the furthest from reader 0’s, who was considered as the gold standard because of
her experience.
The intraclass correlation coefficient, calculated over all four readers, was 81% (80%,
82%), supporting the reliability of visual density assessments.
Figure 8.3: Correlation in visually assessed percent density between first and second
reading by reader 0
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Figure 8.4: Absolute differences in visually assessed percent density between first and
second reading by reader 0
Intra-reader agreement was assessed on reader 0 repeated assessments (Figure 8.3), and
appeared especially strong (weighted Cohen’s kappa: 90.2%, p<.01). In particular first
and second assessments differed on average by less than 10%, and in 70% of cases the
mammograms would be reclassified either in the same category or in 1 or 2 categories
apart (Figure 8.4). The intraclass correlation coefficient also suggests the high reliability
in intra-reader visual assessment, being 89% (88%, 90%).
8.2.3 Discussion
There are differences in Cumulus estimates according to reader, however the overall re-
producibility of this method was high for both absolute and percent estimates. Likewise
visual assessments appeared reliable, with good agreement both inter- and intra-reader.
Although we had good agreement on average, the fact that there were a few mammo-
grams for which the readings differed of up to 60 cm2 or 60% in Cumulus absolute and
percent density respectively, and even 80% or more in visual assessments, suggests that
these methods are still subjective and have room for improvement in reproducibility, if
they are to be used for individual risk prediction and management.
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8.3 Adjusting for measurement error in estimating odds
ratios associated with volumetric density measures from
Quantra
Fully-automated volumetric methods are anticipated to resolve issues regarding repro-
ducibility of measurements and to provide a more precise estimate of the amount of
fibroglandular tissue; for this reason several have been or are being developed [36–
42, 236]. However the results so far suggest that volumetric methods provide similar
or weaker risk prediction than the area-based measures [201]. Recent evidence suggests
that this problem in volumetric breast density estimation may be due to inaccuracy
in assessing the thickness of the breast, as an effect of compression when performing a
mammogram [264, 265]. A particular challenge, “paddle tilt”, which occurs when com-
pression is applied with a flexible compression paddle, allowing the upper plate to tilt,
results in variation in breast thickness from the chest wall to the outer side of the breast
[265].
Our case-control study of the fully automated Quantra volumetric density measures
[Chapter 5] found only moderate association with risk. Since fully automated density
analysis is still very much in development, it is reasonable to hypothesise that measure-
ment error is at least partially responsible for the weakness of Quantra’s risk predictions.
In this section we attempt to correct the risk estimates for random measurement error
using established statistical methods in our case-control study [Chapter 5]. More specif-
ically we apply a modification of Rosner’s and colleagues’s method [257–259] to the
case-control data, estimating the necessary components of the variance from our longi-
tudinal dataset of repeated Quantra measurements on a similar population [Chapter 6].
In addition, since for Quantra we observed a weaker association with risk than was shown
in previous studies using Cumulus, we estimated how substantial the measurement error
in Quantra estimates would need to be in order to have a strength in the association
with risk similar to the that of Cumulus in Stone et al.’s study [266].
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8.3.1 Materials and Methods
8.3.1.1 Data Collection
We used the two datasets [Chapters 5 and 6] collected from women attending breast
cancer screening at Princess Grace Hospital. All the subjects underwent digital mam-
mography and their breast density was assessed using Quantra software, as described in
[Chapter 5], providing estimates in cubic centimetres for total breast volume and dense
breast tissue volume (absolute density). Percent density (%) and non-dense volume
(cm3) were computed by division and subtraction respectively.
The first dataset is described in Chapter 5 and was used to evaluate the association
between density estimates and risk. The second dataset had a longitudinal structure
with repeated measurement [Chapter 6] and thus allowed us to estimate the variance
components. In the case-control study [Chapter 5] details were recorded of 200 cases,
female patients with histopathologically verified breast cancer, and 200 matched con-
trols. The longitudinal dataset [Chapter 6] comprised information on 332 women, (231
younger than 50 years and 101 aged 50 or more years) undergoing two mammographic
examinations, typically 12-24 months apart. See Chapter 6 for further details.
8.3.1.2 Statistical Analyses
We used the method of Rosner and colleagues, based on the method of moments, to
correct for measurement error [257–259].
Suppose the model relating our true amount of fibroglandular tissue (mammographic
density) X, the probability (risk) of developing breast cancer B and the probability of
not developing breast cancer B¯ is of logistic form, whereby
ln
(
Pr(B|X)
Pr(B¯|X)
)
= α+ βX (8.1)
where ln(·) is the natural logarithmic function, α and β are unknown parameters. From
now on we refer to ln
(
Pr(B|X)
Pr(B¯|X)
)
simply as Y .
Furthermore, suppose that a linear relationship is assumed to exist between true density
X and observed, error-prone, density Z that is of the form
Z = X +  (8.2)
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where  is the random error and has a standardised Normal distribution (N(0, σ2)).
Note that in equation (8.2) there is no fixed intercept or coefficient for X because that
would indicate the presence of a systematic error whereas in this case we suppose that
the measurement error is random (unbiased) and distributed as normal with mean 0.
In the empirical application, the assumption of random error is an approximation, but it
is a reasonable one. While it is known that density reduces with age, in the longitudinal
dataset, the average values of the two consecutive density measures did not differ signif-
icantly. It is thus reasonable to assume that the differences between the two consecutive
measures on the same subjects are mainly due to random variation and that the time
between masurement is not sufficient for changes in density with age to contribute ma-
terially to the differences. We refer to this as measurement error, although it may come
from two sources: (1) random error of determination of density by the measurement tool
(including position of the subject); and (2) fluctuation of the breast composition over
time, around a central “average” or typical composition.
Since the true density X is mistakenly observed as Z, the relationship between density
and breast cancer risk which we estimate is not equation (8.1), but as follows
Y = α+ β˜Z. (8.3)
Hence we focus on the relationship between β and β˜.
In a linear regression equation (8.1) with true density X, β is commonly estimated as
β =
σxy
σ2x
(8.4)
where σxy is the covariance between X and Y , and σ
2
x the variance of X. However, in
our observed data (8.3) Z is replacing X, therefore
β˜ =
σzy
σ2z
. (8.5)
where σzy is the covariance between Z and Y and σ
2
z the variance of Z. Since the
measurement error here is assumed independent from Y and X we can conclude that
equation (8.5) resolves as follows
β˜ =
σxy
σ2x + σ
2

. (8.6)
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Consequently, a corrected estimate β∗ is
β∗ =
σ2x + σ
2

σ2x
β˜ =
β˜
λ
where λ =
σ2x
σ2x + σ
2

. (8.7)
In a longitudinal dataset, where no significant change in density is observed over time,
we could estimate σ2 as the variance of measurements within the same subject (vari-
ance WITHIN ), whereas σ2x represents the variance between the subjects (variance BE-
TWEEN ). Therefore λ represents an estimate of the reliability of Z and is also called
the intraclass correlation coefficient (ICC).
Since we have a logistic link, the exact correction would not be in closed form. However,
Rosner et al. [257] show that the above formula (8.7) is a second order Taylor approxi-
mation to the true value β∗.
The variance of the new adjusted β∗ is then computed and the confidence interval varies
accordingly, following the next formulas [257]:
var(β∗) = var(
β˜
λ
) =
1
λ2
var(β˜) +
β˜2
λ4
var(λ) (8.8)
CI95%(β
∗) = [β∗ ∓ 1.96SE(β∗)] =
[
β˜
λ
∓ 1.96SE( β˜
λ
)
]
. (8.9)
The confidence limits for the associated odds ratio exp(β∗) are given by
CI95%(OR) = exp[β
∗ ∓ 1.96SE(β∗)]. (8.10)
After verifying and justifying the comparability of the population in the two datasets,
i.e. that it is reasonable to use the estimates of ICC from the longitudinal study to
correct estimates in the case-control study, we applied this method empirically. The
case-control dataset was used to estimate the association of the observed density with
risk (β˜), and then the longitudinal study provided the data necessary to compute λ, that
is the ICC. The variance of β˜ was calculated by logistic regression, and the variance of
λ was estimated using Smith’s method [267].
Menopause affects the characteristics of mammographic appearance [21, 89, 90], and
therefore the variance of density. For this reason the different age composition in the
two datasets may lead to different variances. Thus analyses were run separating the
subjects into those aged less than 50 and those aged 50 or more, considering baseline
age in the longitudinal study.
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The focus of the analyses here is on the absolute density, because not only was its asso-
ciation with breast cancer risk in our case-control study stronger, it is also less affected
by confounding with BMI [33, 226] [Chapter 5].
For the second part of our investigation, we compared the odds ratios estimating breast
cancer risk associated with increasing quintiles from our case-control data, with those
of Stone and colleagues’ [266] which used the Cumulus interactive thresholding method
to assess breast dense area. To promote a more direct comparison between the two
assessing techniques, we considered whether to transform the volumetric measures into
areas, by the approximating assumption that volumes are spherical, using the following
formulas:
V =
4
3
pir3 ⇒ r =
(
3V
4pi
) 1
3
Therefore: A = pi
(
3V
4pi
) 2
3
where V is volume, A is area and r stands for radius. However, Stone et al. presented
the ORs per quintile and, since the transformation of volumes into areas is monotonic,
it would not affect the ranking of the measures and, consequently, the ORs per quintile.
In view of this, we retained the volumetric estimates.
We also used equation (8.7), to obtain the λ, or ICC, which would be required to give a
corrected association of the same strength as that of Stone and colleagues. In this case
there was no age-stratification, since only overall results were available [266].
All analyses were performed with STATA software version 12.1.
8.3.2 Results
Previous Chapters 5 and 6 reported the analysis of these two datasets from the Princess
Grace Hospital in more detail. The longitudinal data [Chapter 6] was used to investigate
both the change in breast composition by time and age, and the relationship between
breast components, i.e. density and non-dense volume, and age. In the case-control
study [Chapter 5], we examined the relationship between risk of breast cancer and
mammographic density measures. According to the results, absolute density had a
stronger association with breast cancer risk than percent density and the final OR per
10 extra cm3 of dense tissue was 1.04 (95% CI(1.00 , 1.08)).
Descriptive statistics for absolute density in the two studies are summarised in Table
8.5. The means and standard deviations obtained among controls and in the longitudi-
nal study were similar in the younger group (Wilcoxon rank-sum test: p=.85). Women
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Table 8.5: Characteristics of the study samples in the two datasets
Case-control study Longitudinal study
cases controls at baseline
N=200 N=200 N=332
mean (SD) mean (SD) mean (SD)
Under 50
Absolute density (cm2) 111.38 (59.76) 104.17 (71.49) 102.91 (72.11)
50 or more
Absolute density (cm2) 99.18 (60.54) 82.33 (49.11) 96.48 (52.02)
Overall
Absolute density (cm2) 103.88 (60.39) 90.74 (59.53) 100.96 (66.63)
in the older groups of the two studies had significantly different means (p=.02), possibly
due to a different age composition (mean age: 62 years in the case-control study and 58
in the longitudinal study). Consequently we performed a linear regression of absolute
density on a categorical variable identifying the two studies, in order to explain absolute
density differences due to the two studies after age-adjustment. Results would suggest
that subjects in the longitudinal study would have higher absolute density (linear re-
gression coefficient β=+ 12.6 cm3), yet not significant (p=.07). In any case, we require
the two studies to be comparable mainly in terms of variability rather than absolute av-
erage, as the longitudinal study is used to estimate the variance components. Standard
deviations were similar in both groups (controls from the case-control study and subjects
in the longitudinal study), suggesting that the two samples can be used together. This
is as we would expect since the subjects were both selected from the same population,
the Princess Grace Hospital breast surveillance service.
Step 1: Estimate β. Coefficients for association between breast cancer risk and the
observed absolute density were obtained from the case-control study (Table 8.6) using
conditional logistic regression.
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Table 8.6: Coefficients from the conditional logistic regression models using Quantra
absolute density
Coefficient SE [95% Confidence Interval] P> |z|
Under 50, N=154
.0017 .0025 -.0032 .0066 .493
50 or more, N=246
.0056 .0024 .0008 .0104 .022
Step 2: Compute the intraclass correlation coefficient. Table 8.7 displays the
ICCs obtained in the longitudinal study. These values are the estimates of λ in the two
age groups.
Table 8.7: Intraclass correlation coefficients, for absolute density, estimated in the
longitudinal study
ICC SE [95% Confidence Interval ]
Under 50, N=231
.887 .014 .859 .914
50 or more, N=101
.930 .013 .904 .956
Step 3: Compute the adjusted β∗. Following equations (8.7), (8.8) and (8.9) we ob-
tained the adjusted coefficient for absolute density and relative variance and confidence
intervals.
For women aged under 50:
β∗ =
β˜
λ
=
.0017
.887
= .0019
var(β∗) = var(
β˜
λ
) =
1
.8872
(
.0025 ∗
√
154
)2
+
.00172
.8874
(
.0141 ∗
√
231
)2
= .0012
CI95%(β
∗) = [β∗ ∓ 1.96SE(β∗)] =
[
.0019∓
√
.0012
154
]
= [−.0036, .0075]
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Similarly for the subjects 50 or more:
β∗ = .0060, var(β∗) = .0017 CI95%(β∗) = [.0009, .0112].
Step 4: Obtain the ORs and 95% CIs. Finally, from equation (8.10), among
younger women (Under 50) an extra 10 cm3 of fibroglandular tissue would lead to an
OR of 1.020 (.965, 1.078), whereas in the 50 or more group it would be 1.062 (1.009,
1.118), Figure 8.5. The original ORs per 10 cm3 were 1.017 (.968, 1.069) in the group
aged under 50 and 1.058 (1.008, 1.110) for the women 50 or more.
Figure 8.5: Comparison of the ORs before and after adjustment
Table 8.8 compares the association of Quantra density estimates with breast cancer risk
[Chapter 5] with that of dense area assessed with interactive thresholding by Stone et
al. [266].
From equation (8.7), we obtained that an ICC in Quantra density estimates of .83 (.30,
1) would be needed to give an adjusted association with breast cancer risk similar to
Stone et al.’s findings, whereas in our data the ICC was .89 (.87, .92).
ICC = λ =
β˜
β∗
=
log(1.18)
log(1.22)
=
.1653
.1989
= .8315
That is, the correction for measurement error, as estimated from repeat Quantra mea-
sures, is not sufficient to give results compatible with Stone’s area based estimates. In
other words we would need a more substantial measurement error in our data for the
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Table 8.8: ORs estimating breast cancer risk associated with increasing quintiles of
mammographic density
Measuring method Odds Ratio [95% Conf. Interval] P>z
Quantra case-control data [Chapter 5], unadjusted
dense volume 1.18 1.03 1.36 .020
Stone’s and colleagues’ data (interactive thresholding) [266]
dense area 1.22 1.11 1.33 <.001
adjusted estimates to replicate Stone and colleagues’s findings. However, the difference
in coefficients per quintile is modest, and it might be due to variation in the population,
rather than a truly poorer risk association for Quantra.
8.3.3 Discussion
Estimates of association between risk and Quantra absolute density did not change sig-
nificantly after correction per measurement error. ORs per 10 cm3 of dense tissue went
from 1.017 to 1.020 in the under 50 group and from 1.058 to 1.062 in those aged 50
or more. There is an important qualification to interpretation of these results. The
relatively high ICC’s, 89% and 93% in subjects aged respectively under 50 and 50 or
more, suggests that there is strong repeatability and reliability, and, therefore, low mea-
surement error. However, it may not be error around the quantity at which it is aimed,
that is to say, although we get very similar measurements when we repeat the method
on the same individual, it may not be measuring density, or the aspect of density which
is relevant to breast cancer risk. Thus both before and after correction for measurement
error, we still have a relatively weak relationship of the measure with breast cancer risk.
There are very strong correlations between density for left and right breast, and between
density measures for the same breast from two different views, and as we have seen here,
between successive measures taken a year or so apart. All this is evidence that Quantra
is measuring some aspect of breast appearance with considerable precision, but it might
not be capturing the aspect which most strongly relates to breast cancer risk. In this
case, help from statistical methods is limited and it is the density estimation algorithm
that needs further correction. Studies [48, 50, 248] comparing Quantra volumetric as-
sessments to MRI breast density [47] observed a low correlation between measures of
absolute density [50, 248] and also suggested that Quantra significantly overestimates
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density in low dense breasts, in comparison to MRI [48]. These findings give us a bet-
ter understanding of the accuracy of Quantra density estimates, nevertheless should be
validated in a larger datasets.
The comparison with Stone’s and colleagues’ findings also highlighted that measurement
error is lower than one would expect in order to observe an association between den-
sity and breast cancer risk as strong as recorded in literature [6]. This should further
encourage improvement to the algorithm for breast density assessment. That said, the
risk of breast cancer assessed by quintile is not radically different between Stone et al.’s
area based estimate and our Quantra volume estimate.
From this, doubts arise again as to whether a single radiological view of the breast could
be sufficient to construct a volumetric measure of density, since it seems to be a very
ambitious aim. The use of breast MRI and the development of breast tomosynthesis and
automated tomosonography [268–270] could lead to opportunities for volumetric density
estimation which uses more complete three-dimensional information in construction of
the density measure.
There is another possible explanation for the slightly poorer risk prediction than area-
based measures even after correction for measurement error. The correction method
assumes random, non-differential measurement error acting in an additive manner. If
the measurement error is systematically related to the true value (for example, overesti-
mated at low values, underestimated at high), our correction would be inadequate [271].
However, the relatively low variation within persons and between occasions suggests that
it is not so much measurement error that is the problem, rather it is the phenomenon
being measured.
Currently, several other novel fully-automated volumetric approaches [36–42, 236] have
been or are undergoing validation. When evaluating them it is important to consider
the potential measurement error and take action to adjust for it. In particular in re-
gression analysis, regression coefficients of error-prone variables are usually attenuated,
and treatment effects are potentially estimated with bias in either direction when we in-
clude error-prone covariates [272]. We used the method of moment correction [257], but
other methods are available, for instance regression calibration [273] that estimates the
unknown true value X by developing and fitting a calibration model for on the observed
covariates. It was not possible to apply regression calibration to our data because it
requires an external dataset comprising details on the true, or gold standard, measures
of dense volume, and not only there was no such dataset available for this analysis, but
also to date there is no agreement on what is the most reliable measure of fibroglandular
volume.
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8.4 Relationship between two- and three-dimensional den-
sity measures
The high intraclass correlations and the surprisingly low within-screenee variation in
Quantra measures observed in the previous section, suggest that classical random mea-
surement error is not responsible for the relatively modest associations with breast cancer
risk.
The range of Quantra measures between screenees also seems small, but of course this
will depend on the population under study, in particular the age range, as well as on the
properties of the measurement method. If there really is considerably lower variability
between women’s Quantra densities than between their densities as measured by other
methods, this may indicate that an aspect of individual breast composition which re-
flects individual risk of breast cancer is not captured by the Quantra measure.
In our data the Quantra and BIRADS assessments were not strongly related [Chapter 5].
Given the processing of the digital mammography, visual assessment of these mammo-
grams for density is fraught with difficulties of interpretation. We can, however, obtain
some indirect evidence, by comparing the average and variation of Quantra densities in
our population with visual density assessment from film mammography by individual
year of age. The conditioning on individual year of age renders the populations more
comparable.
Percent breast density was visually assessed on 10,046 women aged 50 and over, in the
CADET1 study of computer aided detection in breast screening. The subjects attended
breast screening in Aberdeen and Manchester in the late 1990’s [274]. Breast density was
assessed by each of the eight radiologists involved in the study using a linear analogue
scale. For further details of the density component of the study see Duffy et al. [4].
Since the visual assessment is based on area, and Quantra on volume, we need to trans-
form one of these. As in the previous section, we adopt the approximating assumption
that volumes are spherical. In particular if the dense portion of the breast were spherical
with radius r1 and the total breast volume were spherical with radius r2, the percentage
area and volume are
A =
r21
r22
and
V =
r31
r32
.
From this
V = A
3
2 .
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Table 8.9: Characteristics of percent density in the two studies [Chapter 6] [4], ac-
cording to age
Visually assessed Transformed Automated
Age percent dense area percent dense area percent dense volume
Obs. Mean (SD) Range Mean (SD) Range Obs. Mean (SD) Range
50 736 39 (22) 0-96 27 (21) 0-94 13 25 (14) 10-62
51 845 40 (23) 0-98 28 (22) 0-97 6 28 (8) 17-42
52 706 38 (22) 0-96 26 (21) 0-94 6 19 (6) 12-29
53 581 37 (21) 0-96 25 (20) 0-94 6 25 (7) 15-32
54 577 35 (21) 0-96 24 (19) 0-94 3 15 (2) 13-16
55 516 33 (22) 0-98 22 (20) 0-97 4 19 (6) 12-24
56 508 33 (21) 0-98 22 (19) 0-97 10 16 (6) 11-31
57 541 32 (21) 2-94 21 (20) 0.3-91 7 16 (8) 10-33
58 595 31 (19) 0-96 19 (17) 0-94 3 17 (4) 14-21
59 681 32 (20) 0-90 20 (18) 0-85 8 22 (16) 9-55
60 681 30 (19) 0-90 19 (17) 0-85 8 23 (9) 11-39
61 674 30 (18) 0-96 18 (16) 0-94 4 20 (7) 12-29
62 682 30 (19) 0-92 19 (17) 0-88 4 20 (7) 13-27
63 660 29 (19) 0-92 18 (17) 0-88 3 17 (4) 14-21
64 689 30 (19) 0-96 19 (17) 0-94 2 22 (5) 18-25
Overall 9672 33 (21) 0-98 22 (19) 0-97 86 21 (10) 9-62
The situation is complicated by the fact that neither the breast nor the dense portion of
the breast are spherical. However, since one measure is in two dimensions and the other
in three, one might expect to achieve a comparison approximately on the same scale by
first expressing the visual percent dense area as a proportion (between 0 and 1 rather
than 0 and 100), raising it to the power of 32 and converting back to a percentage.
Table 8.9 shows the mean, SD and absolute range of densities in the two populations by
individual year of age, for the visual percent area density, the volumetric percent density
and the former transformed as noted above. Because the CADET1 mammograms were
taken within the UK National Breast Screening Programme, which at the time had a
policy of inviting ages 50-64, very few mammograms for individual years of age greater
than 64 were available. We therefore show results for ages 50-64 only.
The numbers of subjects in each age group are small in the Quantra dataset. However,
certain observations are clear: first, the average transformed percent areas are similar
in absolute size to the average Quantra volumes; second, that all three measures de-
cline in mean value with age; and third, that both overall and for each year of age, the
transformed area-based measures are considerably more variable between subjects than
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the Quantra volumetric estimates. Overall, the coefficients of variation were 0.64 for
visual percent density, 0.86 for transformed visual percent density and 0.48 for Quantra
volumetric percent density. In the Quantra case-control dataset [Chapter 5], breast den-
sity in absolute terms (cm3) showed a stronger association with breast cancer risk than
percent breast density, therefore it could be interesting to explore also the relationship
between absolute dense volume and absolute dense area. Unfortunately these data were
not available in the CADET1 study. Another observation is that spherical approxima-
tion may not be the most appropriate solution to transform dense volume into dense
areas.
While not conclusive, these observations are consistent with the visual percent dense
area representing a wider variability among women, and this may contain significant
individual risk information, in addition to an inevitable quantity of purely random er-
ror. Further support for this comes from a study which calculated area and volumetric
densities on the same subjects, using a different volumetric measurement tool, the Stan-
dard Mammographic Form [275]. In this study in 1,830 women without breast cancer
the mean percent dense area using the Cumulus interactive threshold method [256] was
24 with an SD of 18. The average percent volume using the Standard Mammographic
Form was 24 again, but with an SD of 7.
8.5 Comparison of density measures in their association
with breast cancer risk
In this thesis we had the opportunity of analysing the association of breast density and
breast cancer risk using a variety of measures (visual and Cumulus assessments in Chap-
ter 2, Cumulus percent and absolute estimates in Chapter 4, Quantra and BIRADS in
Chapter 5 and Volpara in Chapter 7) in a number of studies. In the present section, we
investigate their performances in terms of association with breast cancer risk.
In order to promote a more straight-forward interpretation of the results we used stan-
dardised ORs. In other words, every measure of density was divided by its standard
deviation so that all the density estimates and ORs were expressed on the same scale, i.e.
per unit of standard deviation. BIRADS was excluded from this analyses because of its
categorical nature. The standardised ORs presented in Table 8.10 are all age-adjusted
(either by analysis or matching). In case of percent density in IBIS-I we also adjusted for
BMI, as BMI confounding effect may lead to underestimating the association between
percent density and breast cancer risk [12, 25]. Absolute density estimates instead do
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not require this adjustment, being less affected by changes in BMI [33, 75] [Chapters
4, 5 and 7]. We included Kallemberg et al.’s results for an external comparison of our
results with a more extensive dataset (N=53,975) [276].
We also compared the ability of the density measures to discriminate cases from controls,
using the areas under the ROC curve (AUCs).
Table 8.10: Standardised measure ORs for developing breast cancer after age-
adjustment
Density measure OR [95% Conf. Interval] P>z AUC
IBIS-I case-control study, N=1065 (case=123) [Chapter 2]
Visual assessment (21-category) 1.32 1.08 1.61 .006 .58
Visual assessment (21-category)* 1.49 1.20 1.86 <.001 .60
Cumulus percent dense area 1.23 1.01 1.51 .043 .57
Cumulus percent dense area* 1.35 1.08 1.69 .009 .58
FH01 case-control study, N=292 (cases=101) [Chapter 4]
Cumulus absolute dense area 1.24 .99 1.57 .064 .56
Quantra, N=400 (cases=200) [Chapter 5]
Automated absolute dense volume 1.26 1.02 1.55 .030 .57
Volpara, N=366 (cases=182) [Chapter 7]
Automated absolute dense volume 1.26 1.01 1.56 .038 .55
Kallenberg et al.’s Volpara study, N=53,975 [276]
Automated absolute dense volume† 1.25 1.17 1.33 not available -
Notes: ORs are expressed per unit of standard deviation;
(*) adjusted for age and BMI;
(†) adjusted for age and total breast volume;
Table 8.10 reports the results of this comparison. Similarities, both in terms of stan-
dardised ORs and AUCs, among the different methods are noticeable, especially among
the automated volumetric measures and the computer-assisted Cumulus. All the AUCs
have low values indicating an overall poor discriminatory ability of the methods here
compared. It should be noted though that in general predictive models for breast cancer
struggle to get near 1 [167], and also there has been discussion on whether the AUC is
the most appropriate statistic to evaluate the predictive ability of a model [172, 173].
Nevertheless in our analyses, visual classification appeared as the best predictor, both
in terms of standardised OR and AUC, especially when adjusting also for BMI.
This finding would suggest that there is still something in the parenchymal patterns
that is missed by computerised techniques, but that appears more obvious to a trained
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eye. It could be speculated that the risk factor is not just pure dense tissue but it
depends also on the texture or other aspects of pattern on the mammogram. Never-
theless there is no doubt that, for a better use of information on density in a clinical
setting, an automated measure would be preferable and more practical. For this reason
several alternative automated methods have been proposed. Nielsen et al. developed
a software that extracts textural information from all pixels of segmented breast im-
ages, yielding a mammographic texture resemblance marker which was strongly related
to breast cancer risk [56]. Their findings showed that this measure of mammographic
texture was independent of mammographic density and that it may provide additional
information on breast cancer risk. Likewise Schmidt and colleagues designed CIRRUS,
a fully-automated predictor of breast cancer risk, that tries to identify the features in
a mammographic image that best predict breast cancer risk [57]. Heine et al. had a
simpler but still effective approach [58]. They worked on an algorithm for estimating
the “variation measure”, i.e. the standard deviation of calibrated pixel values, that
appeared to have an association with breast cancer risk at least as strong as percent
density assessed with Cumulus [58]. That is, the more variable the pixels values, the
higher the risk.
8.6 Conclusions
In this chapter we have discussed inter- and intra-reader agreement in visual and computer-
assisted density assessments. We evaluated the measurement error in a fully-automated
volumetric density assessment software tool and attempted to address this issue math-
ematically with Rosner’s method [257–259]. Then, we studied the relationship between
two- and three-dimensional density estimates. Finally, we compared different methods
for assessing density according to their association with breast cancer risk, on an equiv-
alent scale, and their accuracy in discriminating cases from controls.
In conclusion we observed ICCs in excess of 80% in both visual and Cumulus density
estimates when performed by trained readers, which gives some confidence in the re-
producibility of results in studies based on film mammograms. Secondly, according to
our results, Quantra estimates have a limited measurement error, and they suggest that
it might be productive to revise the algorithm, as it may not be measuring the tissue
component most relevant to breast cancer risk. Volumetric estimates appeared to have a
much lower variability than two-dimensional estimates, and this is expected to affect the
discriminatory power of density in risk prediction contexts. Finally, in our comparison,
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visual density estimates resulted the method more strongly associated with breast can-
cer risk, suggesting that there are some aspects of mammographic appearance relevant
for breast cancer development, that are missed by computerised methods.
Further, all these assessments are based on mammography which is designed to detect
tumours, not to measure density. For instance, during mammographic examinations we
compress the breast and consequently the dense tissue is also compressed, possibly mak-
ing its measurement more difficult. Hence, it may be that a tool specifically designed
to measure the amount of fibroglandular tissue in the breast would improve noticeably
both the density and the risk-prediction estimates. Also alternatives to mammography
examinations, such as MRI, automated ultrasound, electrical impedance or tomosyn-
thesis, should also be considered for deriving density indicators [43–50, 54, 59–61, 248].
Although these examinations are often more time and resource consuming, they could
provide more accurate 3D estimates of breast composition. It may be that dual MRI
measures of fibroglandular volume and background parenchymal enhancement have com-
plementary relationships to breast cancer risk. Both are positively associated with risk
[49]. The effect of background parenchymal enhancement on risk was observed to re-
main significant after adjustment for fibroglandular tissue volume but not vice versa
in a study with 39 breast cancer cases and 116 controls [54]. However, the ORs for
fibroglandular tissue volume remained substantially higher than unity, and it may be
that larger numbers of cases would show independent effects of both measures. If this
were the case, MRI-based risk determination from breast composition might well be a
major improvement upon mammographic measures.
As a matter of fact, methods for density estimation from these new 3D breast imaging
systems, in particular tomosynthesis, are currently being developed. The research on
this topic has just started moving its first steps and currently there is scarce published
evidence of their association to risk, which is the ultimate validation of their usefulness
in clinical practice.
An important implication of Table 8.10 is that the automated and semi-automated meth-
ods all seem to have similar propensity for risk prediction. Thus, if they were to be used
as part of individual risk prediction management or surveillance planning, it would be
reasonable to use any of the measures. For example, the fully automated methods are
almost as strongly associated with risk as the more labour-intensive semi-automated
methods. It is desirable, however, to identify the additional risk information picked up
by expert visual assessment and incorporate this into the automated methods.
Conclusions
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Chapter 9
Conclusions
9.1 Introduction
Mammographic density has been known as a risk factor for breast cancer since 1976,
when Wolfe first suggested an association between parenchymal patterns and risk of de-
veloping a tumour in the breast [5]. In the past decades mammographic density has been
the object of many studies that have enriched our knowledge on the subject, although
the causal pathway linking enhanced fibroglandular tissue and risk of breast cancer has
not yet been fully explained. As summarised in the literature review in Chapter 1,
mammographic density is a strong independent risk factor for breast density in terms of
both relative and attributable risk and appears to have potential for improving not only
screening and risk management programs, but also selection for chemoprevention trials
and other disease-control policies. Despite this, its use is still currently limited mainly
because of a lack of a practical standardised method of measuring density.
Hence, this research project focused on providing further insights of mammographic
density as a biomarker of breast cancer risk, its potential in risk-prevention and disease-
control trials, and its association with tumour sub-types and other risk factors. Ad-
ditionally, the project investigated the two main automated volumetric methods for
assessing density on the market (Quantra and Volpara).
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9.2 Part I: Mammographic density as a biomarker for breast
cancer risk
In Chapter 2 we investigated whether mammographic density reduction is a valid sur-
rogate marker, including whether it fulfilled Prentice’s criteria [185], in the IBIS-I risk-
prevention trial, using a nested case-control dataset. The results (PIG=89%) suggested
that a reduction in density of at least 10% could be an effective indicator of the success
of tamoxifen chemoprevention.
Chapter 3 presents the results of analyses on 601 post-menopausal women enrolled in
the ATAC study. On these data we observed that higher levels of mammographic den-
sity were not associated with enhanced risk of recurrence. Similarly, and in contrast to
the IBIS results, change in the proportion of dense tissue, over 1, 2 or 5 years, did not
predict the outcome of the treatment. We also investigated the relationship between
density and tumour characteristics, and found that the associations were mostly not
significant. However results suggested that subjects with poorly differentiated primary
invasive breast cancer experienced smaller density reductions in the years following di-
agnosis. Furthermore, higher baseline levels of cell proliferation, indicated by levels of
Ki-67, were associated with lesser significant changes in breast composition.
Chapter 4 focused on a different population, that of a case-control study of 298 women
aged between 40 and 49 enrolled in the FH01 study because of their enhanced familial
risk of breast cancer. In this dataset absolute density (cm2) was more effective than
percent density in discriminating cases and controls. In addition, absolute dense area
was not associated with most of the risk factors, such as age at menarche or parity,
that percent dense area was, making it a simpler risk-predictor and less affected by
confounding factors. Moreover, the association between breast cancer risk and absolute
density was not altered after adjusting for Tyrer-Cuzick 10-year risk estimates. This
result supports the belief that mammographic density could add information to the ex-
isting risk-prediction models for breast cancer even in populations already known to be
at increased risk and should be useful in the design of more tailored screening programs.
The studies analysed in this part of the thesis differ significantly from one another
because of design, purpose and population. Mammographic density at baseline was a
strong predictor for risk of developing breast cancer in both IBIS-I and FH01 case-control
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studies. Eligible subjects for both studies were at enhanced familial risk, and FH01 fo-
cused on women aged 40-49. Our findings suggest that breast density has the potential
to provide an additional discriminatory power in the standard risk-prediction models
for breast cancer, and thus support the belief that density should be introduced in such
models to improve the identification of subjects at enhanced risk, who could benefit
from preventive interventions or extra screening examinations (e.g. magnetic resonance
imaging or MRI, digital breast tomosynthesis and ultrasound). A possible future tactic
might be to use a woman’s first mammogram in the programme (at age 47-52 in the UK
programme) to provide risk information, contribute to individual surveillance planning,
and possibly inform primary prevention intervention.
Our findings from the IBIS-I study indicate that mammographic density reduction is a
good predictor of the efficacy of tamoxifen therapy. In practical terms, mammographic
examination, including density assessment, should be carried out at baseline, then re-
peated regularly from a year after beginning the treatment, so that changes in density
can be assessed and incorporated into the decision making process for continuing this
therapy or switching to a different treatment. For instance, a woman might switch to
an aromatase inhibitor in order to achieve a better outcome, if density indicated non-
response to tamoxifen.
There was no association between density and risk of recurrence in the ATAC data.
This could be evidence of the fact that breast density may not be an important factor
once the neoplastic process has started [63, 82]. In addition to this, most of the sub-
jects involved in the study underwent treatments such as chemotherapy or radiotherapy
which are known to influence breast composition, not only in terms of appearance but
also of susceptibility to recurrence. Moreover these treatments may modify response of
the breast radiological appearance to hormonal treatment, since mammographic density
reduction was not an indicator of the success or failure of the tamoxifen therapy, unlike
in the IBIS-I and other studies [17–19].
These possibilities for using density in surveillance, prevention and disease-control pro-
grams are contingent on an accepted and practicable, in terms of resource use, method
for assessing density. Most popular techniques currently in use present limitations and
are often too resource-intensive for routine population-based programmes. For this rea-
son automated methods of density measurement were evaluated in the second part of
this thesis.
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9.3 Part II: Automated volumetric assessment of mammo-
graphic density
Chapter 5 describes the findings from a study on 400 age-matched cases and controls,
evaluating the risk-predictive potential of density assessed with Quantra, a novel auto-
mated volumetric method, and comparing it with BIRADS, a well-established method
based on visual classification. The main result is that absolute density (cm3) was the
most promising predictor for breast cancer, performing better than percent density.
Surprisingly, there was no overall association between Quantra measures and BIRADS.
Among cases, unexpectedly, BIRADS category increased with increase in non-dense and
total breast volume, and as percent density correspondingly declined. Since in this study
the association between BIRADS and breast cancer risk was weaker than in previous
literature [6], we speculated that visual classification might be affected by the use of
processed digital mammograms, that have already been altered to lesser the effect of
density on diagnostic accuracy.
In Chapter 6 the analyses involved 332 healthy women, aged 34-81, who underwent two
mammographic examinations, 1 to 5 years apart. On both occasions density was assessed
with Quantra, and we investigated the change in breast composition between screens
and according to age at baseline. The main findings suggested that the effect of time
and age was especially evident on non-dense volume (cm3), which increased steadily,
whereas no substantial change was seen in percent and absolute density. These results
within subject may be partly due to the limited time interval between screens, but they
support the hypothesis that for risk assessment, absolute density should be preferred
to percent density because it appears more stable. The lack of substantial change in
absolute density across ages (cross-sectional analysis) is in contrast to previous literature
[88] and may indicate an area where the Quantra algorithm could be improved.
Most of the mammograms from the Quantra case-control study were reassessed using
Volpara, another novel fully-automated volumetric measure. These data were then anal-
ysed focusing on the relationship between Volpara density measures and breast cancer
risk, on their association with BIRADS classification and on a comparison with Quantra
measures. Results are reported in Chapter 7. In brief, findings from this dataset were
very similar to those from the previous Quantra case-control study. Volpara absolute
density was a strong breast cancer risk predictor, that should be preferred to percent
density, and there was no strong relationship between Volpara and BIRADS measures.
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In addition to this, the association between breast cancer risk and Volpara absolute
density was similar in strength to that observed for Quantra absolute density, as the
analyses with standardised odds ratios highlighted. In general the two measures ap-
peared strongly related.
In both Quantra datasets and in the one including Volpara assessments we also consid-
ered the relationship between breast composition and area of residence to verify the hy-
pothesis of an “urban effect”. Results showed no significant difference, between women
living in London or in other UK regions, in terms of amount of fibroglandular tissue
(cm3), but London residents had consistently lower amounts of fatty tissue (non-dense
breast volume). This suggests a lower body mass index in London residents when com-
pared to subjects from another UK region, confirming previous findings [249].
As it was highlighted previously, it is crucial for introducing density assessment for risk-
prediction in routine population-based screening that we have a standardised, reliable
and precise measuring method, feasible to be performed in such a context, i.e. one that
is not onerous in terms of time, labour and costs. For this reason, Chapter 8 addresses
some of the measurement and risk prediction issues raised regarding both visual assess-
ments and volumetric measures.
In this chapter we estimated inter- and intra-reader agreement in visual and computer-
assisted density assessments, observing over 80% reliability in both visual and Cumulus
density estimates, when performed by trained readers, that is reassuring about the re-
producibility of data in studies based only on film mammograms.
We, then, evaluated measurement error in Quantra fully-automated volumetric density
assessments. Our findings indicated that Quantra estimates have limited measurement
error, although it is not clear what they are measuring; thus our results might suggest
further development of the algorithm. Then, we studied the relationship between two-
and three-dimensional density estimates. Results showed that volumetric estimates ap-
peared to have a much lower variability than bi-dimensional estimates, and this may
affect the discriminatory power of density in risk prediction contexts. Finally, in our
comparison of different density measuring methods, visual assessment appeared as the
strongest predictor of breast cancer risk. This suggests that there are aspects of the
mammographic appearance relevant to breast cancer risk that are missed by the comput-
erised methods but not by a trained eye. For this reason, several alternative automated
methods [56–58], that have recently been proposed, consider features of mammographic
appearance other than density, for instance textural information or variation in pixel
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values.
The comparison of risk prediction propensities was based on standardised odds ratios,
that computed all the methods “fairly”, on the same scale, and AUCs. One notable
finding was that the association of the volumetric density measures with risk was only
slightly weaker than that of the more resource-intensive interactive thresholding method,
Cumulus. Since the latter is considered the gold standard by many researchers, the im-
plication of this is that for only a small loss in predictive potential, a significant gain in
resources could be achieved by use of the fully automated volumetric methods. With the
growing prevalence of digital mammography, it would appear reasonable, if density is to
be measured routinely in the screening programme, to use one of the fully automated
methods.
That said, the notably better prediction from visual assessment suggests that there is
room for improvement in automated assessment. Also a phenomenon we observed in
both volumetric automated methods, Quantra and Volpara, is the limited variability in
their density estimates [Chapter 8]. Further analyses on the correlation between non-
dense and total breast volume revealed that between these two measures exists an almost
deterministic relationship (Pearson’s correlation coefficient: .99 for Quantra and 1.00 for
Volpara). This result adds further incentive for continuing evolution of the automated
algorithms.
9.4 Implications and policy for future research
In the 1980s, the American Cancer Society recommended a baseline mammogram for
women at average risk who were aged 35-40 years to provide a comparison image that
would be available when regular screening began at age 40 or older. This recommenda-
tion was dropped in 1992 after a consensus meeting reviewed the evidence on screening
recommendations and agreed that there was little evidence to support a benefit of the
baseline screening before age 40 years [277]. Since the harms of such a strategy might
exceed the benefits, instead we suggest to exploit the potential for density assessed at
the first available mammogram (around age 50 in the UK). Over the past two decades
research has led to more detailed and accurate information on predictors of breast cancer
risk, and made them available more easily and at a lower cost. Hence now we should
probably reconsider the idea of a baseline risk-assessment for breast cancer, based on
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known risk factors, such as age at menarche, parity and family history, as well as mam-
mographic density and possibly SNPs, when a women is invited for her first screen
examination at around age 50. This could help design optimal tailored screening plans,
varying starting age, interval and possibly adopting new methods of examination, such
as MRI and tomosynthesis [150], as supplementary or alternative investigations. This
could also contribute to decisions in relation to primary prevention. A reasonable ap-
proach might be to pilot such an early risk assessment including mammographic density,
in an experimental design similar to the introduction of the breast screening age exten-
sion in the UK.
The results from the standardised odds ratio analysis suggest that it would be safe to
use one of the fully automated methods in the first instance. However, evaluation of
this should be built into such a pilot, and in parallel research should continue on further
development of fully automated methods.
A risk assessment, based on density, would also facilitate decision making when consid-
ering primary prevention treatments, such as tamoxifen. In this case a mammographic
density assessment, a year into the treatment, is recommended to compare with baseline
and verify whether the subject is responding positively to the therapy or would benefit
more from a different prevention regimen, e.g. anastrozole. On the basis of results here
and elsewhere, mammographic density reduction does not seem to be useful as a sur-
rogate marker in case of treatment of existing breast cancer with aromatase inhibitors,
however it has been suggested that a measure of the amount of fibroglandular tissue
obtained from breast MRI may be more sensitive to treatment-induced changes in this
case [200]. Although MRI is unlikely to be used in general population surveillance in the
near future, there is no reason why its use should not be expanded in follow-up of cases
of breast cancer. Whether density might be a marker of primary prevention effective-
ness with aromatase inhibitors should be investigated in the IBIS-2 study in the future.
Findings from the ATAC trial [278] revealed that another useful biomarker suggesting a
positive response to anastrozole therapy might be the appearance of new vasomotor or
joint symptoms within the first three months of treatment. Further studies are needed
to confirm or dismiss these hypotheses.
In any case, these tailored strategies for breast screening and disease-control can be
rendered more attractive by improving the methods of measuring density. Quantra and
Volpara absolute dense volume estimates appear promising for predicting risk, without
being significantly affected by measurement error; nevertheless both algorithms would
benefit from further improvement. Automated approaches considering textural features
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could also represent a valid alternative. Further studies with richer and larger datasets
are needed.
A fully validated objective means of assessing density and an agreed and clear policy
regarding how to use this detail in clinical practice should be the primary goals of re-
search in this field. Without this knowledge informing of their density women undergoing
screening could cause more harm than good, thus the introduction of Breast Density
Inform Law, which is currently spreading across the US, may be premature. Firstly,
a standardised automated density assessment tool is essential in order to ensure that
all women access the same information. Secondly, an accurate risk predicting system,
incorporating density, is required to be able to discuss effectively with the subject about
their risk and evaluate their options, avoiding unnecessary anxiety, especially until there
is an established health policy strategy comprising additional examinations or preven-
tive treatments.
Although other technologies such as MRI clearly have great potential in breast compo-
sition determination, resources arguably prohibit their use in mass screening, although
this may not always be the case. Also, their use in high risk groups means that such
populations might have individual risk more accurately predicted by incorporation of
MRI-based measures of breast composition in risk assessment. As noted in Chapter 8,
it may be that the dual effect of background parenchymal enhancement and fibroglan-
dular tissue volume can substantially improve our current mammographic density as a
risk predictor. Confirming or refuting this should be a target for future studies.
One technology which has potential to radically improve automated volumetric density
is digital breast tomosynthesis [279, 280]. Unlike MRI, the incorporation of tomosynthe-
sis into mass screening is feasible, and the technology can in principle provide much more
three-dimensional information on breast composition than two-view mammography. It
would therefore seem timely to develop and evaluate methods of density measurement
from three-dimensional tomosynthesis data.
As stated above, the priority in research on breast density and its clinical applications
should be to identify the most appropriate standardised method to assess it. For this
reason in Chapter 8 we presented a comparison of the methods available in this thesis
and their association to risk, bearing in mind that this analyses had the major weakness
of not being performed on the same dataset. Thus an ideal future study would require
a case-control dataset, where cases are screen-detected, to limit potential masking bias,
and density is assessed using several methods, primarily: visual classification (21 cate-
gories), Cumulus that would be used as current reference, secondly automated methods
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such as Quantra and Volpara, and, possibly, the newly presented methods based on
pattern or variation measures. It would be interesting also to have data for at least
a portion of these women on fibroglandular volume and background parenchymal en-
hancement measured with MRI, in order to see which of the afore-mentioned methods is
the more accurate, to clarify what each method is actually measuring and to understand
how they differ. Nevertheless, for practical reasons, the priority must be to identify the
density measure with the strongest association with risk, as there is still an ongoing de-
bate about the measure of breast composition in terms of risk prediction and association
with pathology. Such a study should be feasible in the near future as there are currently
really large studies, such as PROCAS and TOMMY, collecting multiple density mea-
sures using different tools. These have great promise in terms of answering this question.
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